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Abstract
HIV-Associated Neurocognitive Disorders (HAND) continue to afflict approximately half of HIV-infected
patients, despite effective viral suppression through antiretroviral therapy (ART). Synaptodendritic
damage and white matter pathologies persist; suggesting that toxicities from antiretroviral drugs
combined with viral protein effects from CNS reservoirs may be at fault. We hypothesized that ART
compounds activate cellular stress pathways leading to dysfunction of neuroglial cells, and that
attenuating this stress could ameliorate the dysfunction. Previous studies have demonstrated abundant
oxidative stress in HAND
patients, and antiretroviral compounds are capable of generating reactive oxygen species (ROS) to invoke
this stress in peripheral cell populations. Here we have established that antiretroviral compounds produce
robust levels of oxidative stress in neurons and oligodendrocytes in vitro. In neurons, increased ROS leads
to mitochondrial depolarization and apoptotic cell death, which was successfully rescued by treatment
with fumaric acid ester monomethyl fumarate (MMF) through activation of the endogenous antioxidant
response (EAR). Oligodendrocytes were also negatively affected by specific antiretroviral agents. While
not directly toxic, protease inhibitors invoked dose-dependent, reversible decreases in the differentiation
from oligodendrocyte precursor to mature oligodendrocytes. ROS were produced, but MMF did not rescue
the maturation deficit. Further investigation concluded that MMF, the active metabolite of the drug
Tecfidera, which is approved for treatment of Multiple Sclerosis, does not activate the EAR in
oligodendrocytes. In fact, the EAR was also not activated by any oxidant compound tested, suggesting
that precursor cells which
are known to have low levels of antioxidant/detoxifying enzymes may also be susceptible to oxidative
stress because they cannot appropriately activate this response. In vivo, both synaptodendritic damage
and myelin loss were observed in rodent models of antiretroviral administration. In higher primates,
synaptodendritic damage was evident in SIV-infected pigtail macaques that had received an ART regimen,
and myelin basic protein levels were reduced in human HIV patients with HAND who had been ARTmedicated for at least one year. Together these results strongly implicate antiretroviral compounds as a
contributing factor for the persistence of HAND, and necessitate the development of less toxic
antiretroviral therapeutics and adjunctive therapies which can minimize the CNS side-effects of currently
utilized compounds.
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ABSTRACT
ANALYSIS OF THE EFFECTS OF THERAPEUTIC COMPOUNDS FOR THE TREATMENT OF
HIV INFECTION AND MULTIPLE SCLEROSIS IN NEUROGLIAL CELLS

Brigid Kathleen Jensen
Kelly L. Jordan-Sciutto
Judith B. Grinspan

HIV-Associated Neurocognitive Disorders (HAND) continue to afflict approximately half of HIV-infected
patients, despite effective viral suppression through antiretroviral therapy (ART). Synaptodendritic damage
and white matter pathologies persist; suggesting that toxicities from antiretroviral drugs combined with
viral protein effects from CNS reservoirs may be at fault. We hypothesized that ART compounds activate
cellular stress pathways leading to dysfunction of neuroglial cells, and that attenuating this stress could
ameliorate the dysfunction. Previous studies have demonstrated abundant oxidative stress in HAND
patients, and antiretroviral compounds are capable of generating reactive oxygen species (ROS) to invoke
this stress in peripheral cell populations. Here we have established that antiretroviral compounds produce
robust levels of oxidative stress in neurons and oligodendrocytes in vitro. In neurons, increased ROS leads
to mitochondrial depolarization and apoptotic cell death, which was successfully rescued by treatment with
fumaric acid ester monomethyl fumarate (MMF) through activation of the endogenous antioxidant response
(EAR). Oligodendrocytes were also negatively affected by specific antiretroviral agents. While not directly
toxic, protease inhibitors invoked dose-dependent, reversible decreases in the differentiation from
oligodendrocyte precursor to mature oligodendrocytes. ROS were produced, but MMF did not rescue the
maturation deficit. Further investigation concluded that MMF, the active metabolite of the drug Tecfidera,
which is approved for treatment of Multiple Sclerosis, does not activate the EAR in oligodendrocytes. In
fact, the EAR was also not activated by any oxidant compound tested, suggesting that precursor cells which
are known to have low levels of antioxidant/detoxifying enzymes may also be susceptible to oxidative
stress because they cannot appropriately activate this response. In vivo, both synaptodendritic damage and
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myelin loss were observed in rodent models of antiretroviral administration. In higher primates,
synaptodendritic damage was evident in SIV-infected pigtail macaques that had received an ART regimen,
and myelin basic protein levels were reduced in human HIV patients with HAND who had been ARTmedicated for at least one year. Together these results strongly implicate antiretroviral compounds as a
contributing factor for the persistence of HAND, and necessitate the development of less toxic
antiretroviral therapeutics and adjunctive therapies which can minimize the CNS side-effects of currently
utilized compounds.
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CHAPTER 1
	
  

Introduction
	
  
1.1 OVERVIEW
In addition to effects from HIV infection and viral proteins, the antiretroviral compounds used to treat HIV
have major implications for cell populations of the central nervous system (CNS) which likely contribute to
the continued prevalence of HIV-Associated Neurocognitive Disorders (HAND) in roughly half of infected
individuals. In addition to studying the effects of these compounds in neurons and astrocytes, the work
presented here is novel in that it also focuses heavily on oligodendrocytes and a potential adjunctive
therapy that may help to ameliorate antiretroviral-mediated side-effects in the CNS. This introduction will
therefore provide the background for our studies on the effects of ART on these cell populations.

We will begin with an introduction of HAND, mechanisms of CNS neuropathology, and the persistence of
neurological dysfunction despite therapeutic intervention (1.2). We will then proceed to review
antiretroviral therapies: their development, suggested regimens, and side-effects (1.3). From this
knowledge, we hypothesized that ART compounds activate cellular stress pathways in neuroglial cells
leading to dysfunction, and that attenuating this stress could ameliorate these effects. One prominent
cellular stress found in HAND is oxidative stress, which is generated by viral infection, viral proteins, and
antiretroviral agents. This is presented next, as it is a likely mechanism for much of the neuroglial damage
observed in patients (1.4). While our preliminary experimental endeavor is in neurons, a majority of the
investigations and implications presented in this body of work regard oligodendrocytes. As such, the
specific pathologies observed in HAND and susceptibility of oligodendrocytes to oxidative stress are also
presented, and are followed by a detailed introduction to oligodendrocyte differentiation and myelin
maintenance (1.5, 1.6). Due to the potential for oxidative stress operating as a mechanism for dysfunction
in HAND and oligodendrocyte dysfunction, the cellular stress response pathway of the endogenous
antioxidant response is summarized, and is followed by the consequences of dysfunction of this pathway in
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disease (1.7, 1.8). Potential avenues for countering oxidative stress in HAND are then described (1.9).
Finally, taking all of these areas into consideration our rationale and objectives are outlined (1.10).

1.2 HIV-ASSOCIATED NEUROCOGNITIVE DISORDERS (HAND)
According to the most recent reporting in 2014, approximately 36.9 million people worldwide are infected
with human immunodeficiency virus-1 (HIV-1) (UNAIDS, 2014). This disease, which is characterized by
depletion of CD4+ T-cells and progression into acquired immunodeficiency syndrome (AIDS), also
frequently leads to behavioral, cognitive, and motor disturbances collectively termed HIV-Associated
Neurocognitive Disorders (HAND) (Kaul, 2005, Ozdener, 2005, UNAIDS/WHO, 2009). Before the advent
of combined antiretroviral therapy (cART) in the late 1990s, approximately 25% of HIV-infected
individuals were afflicted by a severe neurocognitive dysfunction termed HIV-Associated Dementia
(HAD), with rampant neuronal death observed in frontal lobes, hippocampi, and basal ganglia (Navia,
1986, McArthur, 1987, 1994, Glass, 1995).

Neuroinvasion occurs early in the course of HIV infection, and likely enters the central nervous system
(CNS) within 1-2 weeks post-infection during the time of peak viremia (Chakrabarti et al., 1991, Williams
et al., 2001). The mechanism by which this occurs is still under some speculation, as this requires viral
migration across the blood brain barrier (BBB) and blood cerebral spinal fluid barrier, which are normally
non-permissive to invading pathogens (Atluri et al., 2015). There is accumulating evidence that the virus
can cross into the CNS within infected monocytes traversing the barrier, as well as through direct
transcytosis across the endothelial cell barrier (Roberts et al., 2010, Dohgu et al., 2012, Williams et al.,
2012). The “Trojan Horse” model, originally proposed by Haase and colleagues for the spread of visna
virus, and which has been supported by many in vitro and in vivo studies for other lentiviruses, proposes
that neuroinvasion and establishment of CNS viral reservoirs occurs as infected monocytes transmigrate
across the BBB, and subsequently differentiate into macrophages. This pool of infected macrophages can
then spread infection to neighboring brain-resident microglia, perivascular macrophages, and astrocytes,
quickly establishing a viral reservoir in this compartment (Peluso et al., 1985, Haase, 1986, Gendelman et
al., 1994, Liu et al., 2002, Gonzalez-Scarano, 2005, Kaul, 2005). Importantly, neurons themselves are not
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able to be infected by HIV, as they lack the CD4 receptor required for viral entry (Kaul, 2005). With this in
mind, several factors play a role in the neuronal damage occurring in those individuals with HAND. The
first proposed mechanism holds that direct injury occurs from HIV proteins gp120, Tat, and Vpr, which are
released from infected macrophages and microglia, and interact with receptors on neurons. The second,
termed the “bystander effect”, suggests that the damage is instead caused by the immune response mounted
by infected cells. These macrophages, microglia, and astrocytes release a myriad of cytotoxic molecules,
including reactive oxygen species, nitric oxide, glutamate, and pro-inflammatory cytokines and chemokines
which culminate in neuronal damage and dysfunction in addition to activation of neighboring uninfected
immune cells which further secrete toxic factors (Gonzalez-Scarano, 2005). Classic cellular hallmarks in
response to a neuroinflammatory environment were readily apparent in HAND patients prior to therapeutic
interventions, including multinucleated giant cells, microglial nodules, astrogliosis, and myelin pallor
(McArthur et al., 2003). Elevated levels of inflammation can also lead to an excitotoxic state, where excess
extracellular glutamate chronically activates N-methyl-D-aspartate (NMDA) receptors on neurons, raising
intracellular calcium levels and causing the activation of calcium-dependent proteases calpains and
caspases, ultimately leading to apoptotic death. This mechanism of HIV-mediated neuronal toxicity has
been well documented and characterized (O'Donnell et al., 2006). Both direct viral protein effects and
indirect bystander effects of viral infection have been demonstrated, with the observed changes in patients
likely resulting from a combination of the two mechanisms.

Since the introduction of cART, there has been a dramatic reduction in HAD from 25% to only 2% of
patients (Heaton, 2010). While this was a promising and hopeful development, unfortunately there is now
an increased prevalence of a broader spectrum of dysfunction in HAND, which includes categories of
asymptomatic neurocognitive impairment, and mild neurocognitive disorder. Current estimates based on
clinical findings suggest that approximately half of infected individuals suffer from some level of HAND
(Gray, 2003, Brew, 2004, Heaton, 2010, 2011). Additionally, a recent study has reported that HIV-positive
individuals aged 50 years or older with undetectable viral loads were greater than seven times more likely
to have mild cognitive impairment than age-matched seronegative controls (Sheppard et al., 2015).
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Changes in pathology have also been discovered following widespread access to antiretroviral therapy,
with the subcortical pathology evident in untreated individuals shifting to cortical manifestations in treated
patients (Gray, 2003, Brew, 2004, Gonzalez-Scarano, 2005, Heaton, 2011). While drastic cellular responses
to neuroinflammation are no longer commonly discovered in cART-mediated HAND patients, abundant
clinical and pathological studies have demonstrated that synaptodendritic damage and white matter
pathologies persist (Masliah et al., 1997, Everall et al., 1999, Zheng et al., 2001, Langford et al., 2003, Ellis
et al., 2007, Everall et al., 2009, Muller-Oehring et al., 2010, Tate et al., 2010). Additionally, while
extensive neuronal death is no longer observed, evidence for continued neuronal damage in the form of
dendritic pruning and reduction in synaptic density remain (Everall et al., 2005). Finally, over the course of
lifetime infection, HIV severely disrupts the integrity of the BBB through a variety of mechanisms,
including reducing the expression of structural components required for intercellular junctions, transporters,
and metabolizing enzymes in endothelial cells (Atluri et al., 2015, Shawahna, 2015). Therefore in addition
to early CNS viral entry, over the lifetime of infected individuals, continuing effects resulting from the
escape of drug resistant viral species and direct antiretroviral toxicities also need to be considered.

Finally, another critically important area to highlight is the pediatric HIV-infected population. In infected
children neurological complications are common, with pathologies including progressive multifocal
leukoencephalopathy, encephalopathy, and cerebrovascular events (Wilmshurst et al., 2006). Additionally,
there is increasing documentation of neurocognitive deficits, developmental delays, and emerging motor,
cognitive, and behavioral deficits in young patients (Crowell et al., 2014, Whitehead et al., 2014,
Wilmshurst et al., 2014). It is urged by the World Health Organization that all infected children under the
age of 5 receive antiretroviral therapy (WHO, 2013). Despite this mandate for treatment, very little is
known about the effects of HIV and antiretrovirals on the developing brain. As these children will have
lifelong effects of both virus and therapy, it is crucial to understand the cellular ramifications of these
xenobiotic insults during the critical periods for neurological development and cortical myelination.

Through suppression of plasma viremia and reconstitution of immune system function, cART was
anticipated to resolve HIV-mediated neurological pathologies. While explicit mechanisms remain unclear,
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it is thought that the early CNS invasion and establishment of a persistent viral reservoir which perpetuates
an inflammatory and excitotoxic environment underlies continuing neurocognitive deficits despite effective
peripheral viral suppression in HIV patients, at least in part (Anthony, 2005, Gonzalez-Scarano, 2005).
Another area of interest, which is the prominent focus of this work, is the potential for CNS side-effects of
antiretroviral compounds to also play a significant contributing role to the persistence of neurocognitive
impairment in the ART-era. As it is undeniable that neurologic deficits remain in treated patients, further
investigation into mechanisms underlying dysfunction is imperative (Palella, 1998, Antinori, 2007, Broder,
2010, Heaton, 2010, 2011).

1.3 ANTIRETROVIRAL THERAPY
Due to the error-prone process of reverse transcription during replication, HIV-1 is highly susceptible to
mutations. This feature of the virus underlies the emergence of drug resistant mutations in patients over
time, leading to viral resurgence and the ultimate failure of single drug antiretroviral therapy as introduced
in the early 1990s to combat progression to AIDS. This led to the revision of antiretroviral therapy to a
multiple drug treatment approach termed ART, which was implemented to simultaneously target multiple
stages of replication, employing knowledge of HIV replication and its ability to undergo RNA mutational
selection (Broder, 2010, NIH, 2011). As of March 2015, of the nearly 37 million individuals globally
infected with HIV, approximately 15 million were currently accessing antiretroviral therapy translating to
41% of HIV-positive adults, 32% of HIV-positive children, and 73% of HIV-positive pregnant women
which serves to prevent vertical transmission to their babies (UNAIDS, 2014).

Currently recommended ART regimens include a cocktail of nucleoside/nucleotide reverse-transcriptase
inhibitors (NRTIs), non-nucleoside reverse-transcriptase inhibitors (nNRTIs), protease inhibitors (PIs), and
the more recently developed entry and integrase inhibitors (NIH, 2011, AIDSTAR-One, 2012, AIDSInfo,
2015). These most recent guidelines recommend treatment of all infected children under the age of 5 years,
irrespective of CD4+ T-cell count. For adults, it is urged that all individuals with severe or advanced HIV
disease corresponding to clinical stage 3 (advanced) or stage 4 (severe) and those with a CD4 count ≤350
cells/mm3 to immediately initiate ART (see Table 1.1 for full HIV clinical staging details). It is also
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suggested for all individuals with a CD4 count between 350 and 500 cells/mm3, and is strongly
recommended for those with active tuberculosis, those with HBV co-infection with evidence of chronic
liver disease, as well as those with serodiscordant partners to reduce transmission to the uninfected
individual (AIDSInfo, 2015).

Components of suggested ART regimens vary according to age of the patient, previous antiretroviral
experience, and co-morbidities for which treatment produces drug interactions with certain classes of ART
compounds. For adults and adolescents 10yrs and older weighing more than 35kg, first-line ART should
consist of two NRTIs supplemented with a nNRTI to inhibit viral reverse transcriptase, thereby suppressing
pro-viral DNA generation from viral RNA. When second-line ART is necessary due to acquired drug
resistance, the primary recommendation is two NRTIs + a Ritonavir-boosted PI, which bind the active site
of HIV-aspartyl protease and prevent maturation of viral gag-pol precursor proteins (Broder, 2010, NIH,
2011, WHO, 2013). While the NRTIs that make up this secondary regimen differ based on the makeup of
the original regimen, Darunavir/ritonavir and Lopinavir/ritonavir are the preferred boosted PI options
(AIDSInfo, 2015). Currently, all infected children under 3 years of age should receive a Lopinavir/ritonavir
based regimen for first-line ART (WHO, 2013).

This multi-drug approach has led to long-term viral suppression and restoration of immune system
function, which underlies the reduction in morbidity and mortality caused by HIV-infection since the
introduction of ART (Heaton, 2010, McArthur et al., 2010, Sacktor and Robertson, 2014). Unfortunately,
despite undetectable viral load in the periphery, latent viral reservoirs and persistent inflammation exist in
the CNS of infected individuals (Chun, 1997, Finzi, 1997, Wong, 1997, Li, 1998, Anthony, 2005,
Persidsky, 2006).

While the criteria for ART initiation have now been made clear based on patient CD4 counts, AIDSdefining illnesses, and specific co-morbidities, strategies for eradication of CNS viral reservoirs and for
decreasing the risk of developing HAND have not yet been well-refined. A likely cause for the persistence
of CNS viral effects is due to limited penetration of ART compounds into brain tissue through actions of
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the blood brain barrier (BBB). The major proposed method to eliminate viral reservoirs and reduce
inflammation is to implement therapies with drugs that would attain therapeutic concentrations in the CNS
of patients. While HIV can circumvent the BBB, the actions of efficient drug efflux and transport proteins
in the endothelial cells comprising this structure results in reduced levels of ART concentrations in cerebral
spinal fluid (CSF) and brain parenchyma as compared with blood plasma (Berger, 2004, Letendre, 2008,
Varatharajan, 2009). To address this issue, researchers have established the CNS penetrance effectiveness
(CPE) score, which gives a numerical value following an algorithm which takes into account the chemical
structures, pharmacokinetic, and pharmacodynamic data of antiretroviral compounds (Letendre, 2008,
Tozzi et al., 2009, Letendre et al., 2010). Unfortunately results of clinical studies incorporating predicted
highly CNS penetrant regimens utilizing these CPE scores have not yielded consistent results in terms of
neurological function. Several studies yielded inconclusive outcomes, others reported a positive correlation
between higher CPE and better neurocognitive outcome, and the study undertaken by Marra and colleagues
revealed that regimens containing compounds with higher CPE scores may in contrast be associated with
worse neurocognitive performance (Letendre, 2008, Cysique and Brew, 2009, Marra, 2009, Tozzi et al.,
2009, Garvey et al., 2011, Lanoy et al., 2011, Smurzynski, 2011, Baker et al., 2015).

While these studies were well designed, investigating the effects of CPE scores on neurological outcomes
in human patients comes with inherent caveats. Due to technical and ethical limitations, in living patients
clinical studies cannot directly assess brain parenchymal drug concentrations, and rely instead on drug
levels found in the CSF, usually after a single-dose administration. CSF and parenchyma have very
different hydrophobic/hydrophilic compositions, which will greatly impact drug solubility and binding to
cellular proteins and result in dissimilar concentration readings. In addition, other drug-related factors such
as poor ART adherence or the impact of additional medications taken by the patient can alter the
concentrations obtained by clinicians and confound the measured outcomes. Efforts to assess the impact of
high CPE on neurological outcomes is also hindered by CNS reservoirs established early in infection with
viral species harboring many iterations of rapidly acquired mutations, as well as later escape of drugresistant viral species to the protected CNS environment (Chakrabarti et al., 1991, Gonzalez-Scarano,
2005). Moreover, comorbidities such as drug and alcohol abuse and infections should be considered when
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assessing CNS drug availability and establishing and evaluating CPE scores, as all of these factors have
been demonstrated to alter BBB integrity independent of HIV infection (Shiu et al., 2007, Ramirez et al.,
2009). Another crucial factor to consider given the interest of implementing high CNS-penetrant ART
regimens long-term in patients is the potential for direct toxicities of antiretroviral drugs in the CNS, as
side-effects in the rest of the body are pervasive.

Unfortunately, peripheral side-effects of antiretroviral compounds are widespread and include metabolic
syndrome, lipodystrophy, atherosclerosis and peripheral neuropathy (Carr, 1998a, Dalakas, 2001, Cohen,
2005, Parker, 2005, Ellis et al., 2008, Vidal et al., 2010). These functional deficits have been linked to
various cellular effects of ART compounds of multiple drug classes. Through careful study in hepatocytes,
T-cells, macrophages, adipocytes, lymphocytes, a cell line derived from a human laryngeal cancer, and
purified human proteasomes, activation of ER stress, the unfolded protein response, and proteasome
inhibition have been documented following PI exposure (Andre, 1998, Carr, 1998b, Piccinini M, 2002,
Parker, 2005, Zhou, 2005, 2006, Gupta et al., 2007). Dysfunction through these mechanisms leads to
pathologies culminating in atherosclerosis, hypercholesterolemia, lipodystrophy, and insulin resistance
(Carr, 1998a, b, Cohen, 2005, Parker, 2005, Zhou, 2005). While not yet studied in the CNS, side-effects of
antiretrovirals have been demonstrated in the peripheral nervous system (PNS). A debilitating peripheral
neuropathy has been described in patients, stemming from NRTI and to a lesser extent PI usage (Dalakas,
2001, Ellis, 2008). Toxicity caused by compounds of the NRTI class arises by competition with cellular
thymidine triphosphate for DNA pol-γ, resulting in the termination of mitochondrial DNA synthesis
(Dalakas, 2001). Ensuing decreases in mitochondria number and oxidative phosphorylation enzymes leads
to electron transport chain uncoupling and an increase in mitochondrially-derived intracellular reactive
oxygen species (ROS) resulting in mitochondrial depolarization, and ultimately culminates in activation of
the apoptotic cascade and neuronal death (Dalakas, 2001).

An interesting development was the finding that ART compounds themselves produce oxidative stress,
even in the absence of virus (Mondal et al., 2004, Blas-Garcia et al., 2011). It has also recently been
reported that AZT can modulate gene expression through ROS produced in the mitochondria in
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cardiomyocytes. This study showed that the ROS diminished DNA methylation, which altered gene
expression and promoted the pathophysiological changes associated with cardiomyopathy (Koczor et al.,
2015). ART may therefore also be a contributing factor to the persistence of chronic oxidative stress
observed in patients with well-controlled viral titers, and this stress may cause not only direct cellular
toxicity but also changes in gene expression resulting in alterations of cellular function.

Toxic effects of ART in the CNS have not been rigorously studied, however as antiretroviral-associated
toxicities are well documented in the periphery, these observations suggest that it is plausible that these
compounds may contribute to cellular damage and death leading to continued manifestations of HAND in
the ART-era. In the past several years the idea of direct ART toxicity has begun to be appreciated, as both
we and others have demonstrated neurotoxic effects in primary neuronal cultures in response to ART
compounds (Chapter 3) (Robertson et al., 2012).

1.4 OXIDATIVE STRESS IN HAND
Chronic oxidative stress is thought to play a significant role in the cellular damage resulting in the
manifestation of HAND, as has also been suggested for many other neurodegenerative diseases (Mariani,
2005, Romano, 2010). Even in HIV-positive patients with well-controlled viral infection, evidence for
persistence of oxidative stress is profound (Blas-Garcia et al., 2011). This topic has been thoroughly
explored in Chapter 2, which has been excerpted from a book chapter we published reviewing the
Persistence of HAND in the Era of ART. Key evidence demonstrating persistence of oxidative stress in
patients, and oxidative stress induced by viral infection, viral proteins and antiretroviral therapy have been
summarized and included here.

Despite effective viral control, lipid peroxidation remains pervasive in HIV-infected individuals, with
persistently elevated levels of hydroperoxides, isoprostanes, and malondialdehyde detected in ART-treated
patients compared with seronegative controls (Jareno et al., 1998, Hulgan et al., 2003, Ngondi et al., 2006,
Masia et al., 2007, Wanchu et al., 2009). Levels of peroxide species were more highly elevated in patients
on PI-based regimens compared with those on nNRTI-based regimens, suggesting that the PI class may
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induce or enhance levels of oxidative stress (Hurwitz et al., 2004, Masia et al., 2007). Additionally, through
chemical-shift magnetic resonance spectroscopy and careful analysis of lipids, lactate, and creatine levels
derived from patients, it was determined that the inflammation and oxidative stress initiated by HIVinfection was not ameliorated by suppressive ART (Roc et al., 2007). Through nuclear and mitochondrial
staining, the oxidized DNA product 8-hydroxy-2’-deoxyguanosine (8-oxoG) was shown to be significantly
elevated in autopsy tissue from frontal cortex of HAND patients, suggesting that ongoing infection and/or
ART promote oxidative modification of DNA (Zhang et al., 2012). Furthermore, clastogenic factors, which
cause chromosomal breaks and DNA damage and may be released from cells undergoing oxidative stress,
were present in plasma of all HIV-infected individuals regardless of ART status (Edeas et al., 1997).
Finally, circulating levels of glutathione are markedly reduced in ART-medicated HIV patients, with the
ratio of oxidized to reduced glutathione also remaining out of balance (Walmsley et al., 1997, Wanchu et
al., 2009, Gil et al., 2010). Glutathione is a critically important antioxidant molecule in the cell, which acts
as a reducing agent through its thiol groups and is able to donate an electron to unstable molecules such as
reactive oxygen and nitrogen species (Espinosa-Diez et al., 2015). Once oxidized, it reacts with another
similarly oxidized glutathione molecules to become glutathione disulfide, and then is converted back to its
reduced state by glutathione reductase (Espinosa-Diez et al., 2015). In cells, this enables glutathione to act
as an efficient buffer for reactive oxygen species produced by normal cellular activity, with homeostatic
conditions normally supporting a ratio of 1:9 oxidized to reduced glutathione (Halprin and Ohkawara,
1967). An increase in this ratio, such as is seen in ART-medicated patients described above, is indicative of
oxidative stress, with buildup of cellular ROS contributing to activation of signaling molecules responsible
for triggering the endogenous antioxidant response as will be discussed in Section 1.7 (Halprin and
Ohkawara, 1967).	
  	
  

Therefore, while patients have effective viral suppression to undetectable levels, evidence for persistently
robust levels of oxidative stress is abundant. Contributing factors to this chronic stress include
consequences of viral infection, direct effects of viral proteins from brain-resident reservoirs, and sideeffects of antiretroviral therapies, each of which will be discussed in further detail below. 	
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1.4a: OXIDATIVE STRESS BY HIV INFECTION
In the decades since the discovery of HIV, extensive research has been conducted to determine the effects
of the virus on infected cells and cytotoxic factors released by these cells. Infected macrophages secrete a
variety of neurotoxic oxidative stress inducing compounds including glutamate, nitric oxide, and
superoxide (Lipton, 1994, Bukrinsky et al., 1995, Jiang et al., 2001, Mollace et al., 2002, O'Donnell et al.,
2006). In addition, activation and degranulation of macrophages by viral infection leads to release of
enzymes that further produce free radicals, such as myeloperoxidase. This protein is released as a cellular
response to infection as it behaves as a viricidal and inactivates HIV, but it also produces oxidative damage
to surrounding cells through production of hypocholorous acid and oxidation of tyrosine residues causing
protein cross-linking (Chase and Klebanoff, 1992, Heinecke et al., 1993, Hong and Banks, 2015).
Furthermore, HIV infection of macrophages and microglia also results in deficiency of intracellular
glutathione, and imbalance of the oxidized to reduced glutathione ratio (Lipton, 1994, Zhao et al., 2004,
Erdmann et al., 2007, Huang et al., 2011). Increased malondialdehyde levels in astrocytes treated with
supernatants from infected macrophages validated that secreted factors have negative oxidative stressmediated consequences on neuroglial cells (Mollace et al., 2002). In addition to the oxidative consequences
as a result of infection, viral proteins found on the HIV envelope or secreted from infected cells also need
to be considered independently from their roles in viral entry and replication, as they too produce oxidative
effects in brain resident cells.

1.4b: OXIDATIVE STRESS BY HIV PROTEINS
When HIV proteins gp120 and Tat were examined in vivo and in vitro in the absence of whole virus, both
induced glutathione depletion, lipid peroxidation, and increase in malondialdehyde (Banerjee et al., 2010).
Additionally, both gp120 and Tat alter lipid metabolism in primary cultured neurons, increasing levels of
hydroxynoneal, sphingomyelin, and ceramide (Haughey et al., 2004). Independent studies investigating
gp120 effects on astrocytes revealed an accumulation of ROS and activation of the antioxidant response
(Viviani et al., 2001, Reddy et al., 2011). Studies investigating the oxidant species produced following
gp120 application determined that production of both nitric oxide and superoxide ions contribute to
neuronal toxicity (Dawson et al., 1993, Walsh et al., 2004). Exogenously applied Tat protein also triggers
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the accumulation of ROS in a variety of cell types including microglia, brain microvascular endothelial
cells, and neurons (Flores et al., 1993, Kruman et al., 1998, Toborek et al., 2003). Tat protein directly
injected into rat striatum also significantly increases levels of both oxidative modifications and carbonyl
additions to proteins (Aksenov et al., 2001). Finally, microglia expressing viral protein R (Vpr) have been
demonstrated to have activated oxidative stress pathways (Deshmane et al., 2009). Studies investigating
Vpr have shown that exogenous application to human fetal astrocytes resulted in decreased intracellular
glutathione and ATP levels, and skewed the balance of the remaining glutathione towards the oxidized
rather than reduced form (Ferrucci et al., 2012).

It has been well documented through these in vivo and in vitro studies that viral proteins can generate
oxidative stress in multiple cell populations from the periphery and CNS. These findings highlight the
importance for effective suppression of viral replication via ART to minimize the oxidative damage caused
by infection. Emerging evidence also suggests that an additional source of oxidative stress includes the
antiretroviral compounds themselves, which will be discussed in the next section.

1.4c: OXIDATIVE STRESS BY ART
Through a combined effort of many laboratories, it has been clearly demonstrated that a variety of drugs
from the PI and NRTI drug families alone or in combination result in accumulation of ROS, hydrogen
peroxide, and factors promoting the recruitment of monocytes in a wide range of cell populations. The
compounds shown to cause these effects in human adipocytes, monocytes, aortic endothelial cells, and
myeloid cell lines included the PIs: Ritonavir, Saquinavir, Lopinavir, Indinavir, Nelfinavir, and Atazanavir,
as well as the NRTIs: Zidovudine (AZT), Stavudine (d4T), and Didanosine (Mondal et al., 2004, Ferraresi
et al., 2006, Lagathu et al., 2007, Chandra et al., 2009, Touzet and Philips, 2010, Manda, 2011, Brandmann
et al., 2012). Combined antiretroviral treatment also led to increased oxidative stress and mitochondrial
dysfunction in BBB endothelial cells (Manda, 2011). Thus, in many cell populations antiretroviral drugs of
varying classes show evidence for generation of oxidative stress. The individual effects of specific drug
classes will be discussed in more detail below.
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The NRTI AZT has been extensively studied, as it was the first available antiretroviral drug. Within five
years of clinical approval, AZT-induced deficits in mitochondrial enzymes and electron transport chain
(ETC) uncoupling had been reported (Lewis et al., 1992). ETC disruption causes the accumulation of
intracellular ROS and mitochondrial DNA oxidation, which has been demonstrated following AZT
exposure in both acute and chronic experimental paradigms (de la Asuncion et al., 1999, Bialkowska et al.,
2000, de la Asuncion et al., 2004, Gao et al., 2011). Subsequently, AZT has also been shown to deplete
intracellular glutathione, increase mitochondrial lipid peroxidation, and ultimately induce caspase-3
dependent apoptotic cell death (Yamaguchi et al., 2002, de la Asuncion et al., 2004, Gao et al., 2011).
Another NRTI, d4T, behaves very similarly to AZT. d4T also causes ROS accumulation, mitochondrial
stress and oxidized DNA, and altered activity of mitochondrial oxidative phosphorylation enzymes
(Gerschenson et al., 2001, Velsor et al., 2004). The nNRTI drug class includes the compounds Efavirenz,
Nevirapine, and Rilpivirine, and has also been implicated in the production of oxidative stress in cells.
Application of Efavrienz to a human hepatoblastoma cell line resulted in superoxide generation, depletion
of cellular glutathione, and loss of mitochondrial function and membrane potential (Apostolova et al.,
2010). Efavirenz has been linked to neuropsychological side effects, and has since been removed from
treatment recommendations (Decloedt and Maartens, 2013). It is widely held that the oxidative stress
effects described above play a role in the neurotoxicity of this compound (Apostolova et al., 2010,
Ciccarelli et al., 2011). Within the PI drug class, Ritonavir has been demonstrated to increase nitrotyrosine
levels, and both Ritonavir and Amprenavir invoke noted increases in superoxide anion production in
porcine coronary arteries (Chai et al., 2005). In astrocytes and pancreatic beta cells, both Indinavir and
Nelfinavir induce time- and concentration- dependent depletion of intracellular glutathione (Chandra et al.,
2009, Brandmann et al., 2012). Currently, potential oxidative effects of the entry and integrase inhibitor
antiretroviral drug classes have not been explored. Similarly the lack of studies investigating the effects of
antiretroviral compounds on the neuroglial cell populations affected in HAND is surprising, despite the
abundant evidence which supports a role for antiretroviral compounds in oxidative stress-induced cellular
dysfunction and damage.
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As has been summarized here, it is clear that pervasive oxidative damage occurs in HIV patients despite
effective viral control. Therefore it is of upmost importance to recognize the cellular effects of viral
enclaves and antiretroviral drugs, and how they may be perpetuating these effects.

1.5 OLIGODENDROCYTES IN HAND
Prior to the introduction of antiretroviral therapy, alterations in white matter including myelin pallor,
gliosis, and leukoencephalopathy were prominent in HIV-infected patients (Gray et al., 1996, Everall et al.,
2005). Now even with effective viral suppression in the ART-era, while severe forms of
leukoencephalopathy have been diminished, the prevalence of white matter pathologies in patients has
increased, with amount of white matter damage positively correlated with the degree of neurocognitive
impairment observed (Langford et al., 2003, Everall et al., 2005, Muller-Oehring et al., 2010, Tate et al.,
2010). MRI and diffusion tensor imaging studies have revealed that these effects include dramatic thinning
of the corpus callosum, reduction in blood flow to white matter, and loss of both structural integrity and
volume from white matter structures including: the superior longitudinal fasciculus, superior corona
radiata, and the internal capsule (Pomara et al., 2001, Ragin et al., 2004, Gongvatana et al., 2009,
Wohlschlaeger et al., 2009, Hoare et al., 2010, Tate et al., 2011, Kelly et al., 2014). A transcriptome
analysis determined genes which were altered following HIV-infection and which remained dysregulated in
individuals who attained successful viral suppression through ART but were diagnosed with HAND
(Borjabad et al., 2011). Among the persistently altered transcripts were myelin transcription factor 1,
myelin basic protein, and myelin-associated oligodendrocyte basic protein, which are critical for
oligodendrocyte maturation, myelination, and maintenance (Borjabad et al., 2011). Thus, white matter
pathologies remain prevalent in HIV-infected patients despite viral suppression through ART, with
dysregulation of myelin mRNAs and loss of structural integrity of myelin evident by imaging technologies.

Similar to their neuronal counterparts, oligodendrocytes lack the CD4 receptor required for HIV entry, and
thus, changes in these two cell populations must be caused by indirect effects of viral infection of other cell
populations, rather than direct consequences of infection of neurons or oligodendrocytes (Sattentau et al.,
1986, Wiley et al., 1986). While molecular mechanisms have not yet been investigated, oligodendrocytes
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exhibit elevated p53 and BAX levels in postmortem brain samples from frontal cortex of HIV-infected
individuals who had progressed to AIDS, indicating the activation of apoptotic cell death pathways
(Jayadev et al., 2007). However, in patients with end stage disease of fully developed AIDS, many of
whom suffered from HIV-Associated Dementia and HIV-encephalitis, it is difficult to attribute specific
mechanisms leading to neuronal or oligodendrocyte death.

As was discussed in section 1.4, chronically high burdens of oxidative stress are abundant in HIV patients
even following suppression of viral replication. Oligodendrocytes are exceptionally susceptible to oxidative
stress-mediated cell death due to low glutathione and antioxidant levels, coupled with high energy demands
required to efficiently produce and maintain myelin to insulate surrounding neurons (Back et al., 1998,
Back et al., 2002, Folkerth et al., 2004, Jana and Pahan, 2007). In rodent models of hypoxia/ischemia,
oxidative stress generated by the insult led not only to immediate death of oligodendrocyte precursor cells
(OPCs), but also to a subsequent reduction in number of mature oligodendrocytes and hypomyelination of
white matter (Levison et al., 2001, Reid et al., 2012). In addition to direct OPC dropout due to oxidative
stress-mediated toxicity, we found in vitro that at sub-toxic doses, oxidative stress caused by oxidant insult
halts oligodendrocyte differentiation (French et al., 2009). In vitro studies have also demonstrated a
maturation-stage specific vulnerability of this cell population, as mature oligodendrocytes are far more
resilient than OPCs and immature oligodendrocytes due to higher glutathione and antioxidant enzyme
levels (Halliwell, 1992, Back et al., 1998, Fern and Moller, 2000, Baud et al., 2004). Several demyelinating
disorders including MS and periventricular leukomalacia involve oxidative stress as a contributing factor to
pathology (Haynes et al., 2003, Gilgun-Sherki et al., 2004, van Horssen et al., 2008). With this in mind, it is
likely that the chronically high-levels of oxidative stress still observed in ART-medicated HAND patients
also contributes to the persistence of white matter pathologies in this population.

Despite these striking pathological findings in HIV-infected individuals, there is a notable lack of
molecular studies detailing the cellular effects of secreted factors from HIV-infected macrophages or direct
effects of ART on oligodendrocyte precursors or mature oligodendrocytes. However, the laboratory of
Pamela Knapp has recently published an article investigating the effects on oligodendrocytes in a rodent
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model of inducible astrocyte-driven Tat expression. After 3 months of Tat-transgene expression, animals
displayed disruption of myelin in the caudate-putamen, aberrant oligodendrocyte morphology in corpus
callosum and anterior commissure, and significantly decreased levels of myelin basic protein and myelinassociated glycoprotein in striatum (Zou et al., 2015). Additionally, when cells in vitro were exposed to
exogenously applied Tat protein, viability of immature oligodendrocytes was significantly decreased and
surviving cells displayed significant deficits in maturation as evidenced by decreased branching processes
and myelin membrane extensions (Zou et al., 2015). This pioneering study has provided the groundwork
that viral proteins can affect oligodendrocyte survival and extent of myelination. It is of crucial importance
now to further understand the effects of HIV on oligodendrocytes in the context of the entire virus and in
infection. This is extremely challenging due to imperfect animal systems that do not fully recapitulate
human cellular attributes. In addition to direct effects of viral proteins, evidence has suggested that factors
secreted by macrophages and astroglia, both which are infected or non-infected but activated due to the
presence of viral infection, may also contribute to negative neuroglial effects. Therefore the model of
human macrophage infection and application of supernatants to cells in culture may be utilized to provide
insight into additional aspects of neuropathology. Furthermore, effects of antiretroviral compounds on
oligodendrocytes have not been considered in the context of chronic HIV infection. As this cell population
is vitally important to ensure proper neuronal signaling and cognition, effects of viral infection,
inflammation, oxidative stress, and antiretrovirals on this cell population need further consideration.
Oligodendrocytes are frequently overlooked in the study of diseases; however, because myelin formation
and maintenance occur both during human development and adulthood, the consequences are profound
when these processes are disrupted.

1.6

THE

IMPORTANCE

OF

OLIGODENDROCYTE

DEVELOPMENT

AND

MYELIN

MAINTENANCE
Myelin, produced by oligodendrocytes in the CNS and Schwann cells in the PNS, provides the basis for the
propagation of rapid neuronal impulses, which is required for proper functioning of the human nervous
system. This process, known as salutatory conduction, is facilitated by the ensheathment of axons by
multiple layers of specialized glial membrane, which insulates the neuronal axonal plasma membrane by

16	
  

reducing the transverse capacitance and increasing the resistance. By effectively restricting action
potentials to small unmyelinated axon segments known as nodes of Ranvier, velocity of signal conduction
is accelerated up to 100-fold when compared with an unmyelinated axon of the same diameter (Landahl
and Podolsky, 1949, Frankenhaeuser, 1952, Nave and Werner, 2014). In addition to their function in
insulating axons, oligodendrocytes also provide trophic support to the axons their myelin membranes
surround, which is crucially important for maintaining cellular functioning and signaling at long extended
distances from the neuronal soma (Lappe-Siefke et al., 2003, Edgar and Garbern, 2004). In contrast, loss of
myelin integrity can disrupt proper signaling, resulting in neuronal degeneration and neurological
dysfunctions (Criste et al., 2014, Mighdoll et al., 2015).

Mature oligodendrocytes are generated from oligodendrocyte precursors cells (OPCs) according to a wellcharacterized progression, allowing for assessment according to stage-specific antigens (Figure 1.1)
(Miller, 2002). In rodents, at embryonic day 12.5, OPCs originate in ventricular zones and migrate both
dorsally and radially, expressing markers such as A2B5, platelet-derived growth factor receptor A (PDGFA), and NG2. OPCs transition to immature oligodendrocytes expressing galactocerebroside (GalC) and
begin to extend actin filaments to elaborate processes and adopt the morphology of mature
oligodendrocytes. During this period, oligodendrocyte precursor cells (OPCs) decrease levels of Inhibitor
of DNA binding (ID) transcription factors, allowing the pro-differentiation transcription factors Olig1 and
Olig2 to promote upregulation of proteins required for maturation into oligodendrocytes, as well as myelin
component mRNAs (Miller, 2002, Chen et al., 2012). Following contact with neurons, these maturing cells
continue to extend processes, upregulate expression of myelin proteins, and ultimately ensheath neuronal
axons with the lipid- and protein-based myelin membrane (Grinspan, 2002, Miller, 2002). A majority of
myelin proteins are translated in the perinuclear endoplasmic reticulum and trafficked via the secretory
pathway for ultimate insertion into the forming myelin membrane (Colman et al., 1982). In contrast,
mRNA for myelin basic protein is trafficked intracellularly via microtubules to sites proximal to membrane
insertion. Translation into protein then occurs on free-ribosomes and is quickly followed by insertion into
the nearby developing myelin membrane (Colman et al., 1982, Carson et al., 1997). In vivo, myelin is
highly enriched in lipids, which constitute approximately 75% of membrane constituents, with the
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remaining 25% being myelin proteins. Chief among the protein components are proteolipid protein (17%),
myelin basic protein (8%), cyclic nucleoside phosphodiesterase (CNPase, 4%), myelin oligodendrocyte
glycoprotein (MOG, 1%), and myelin-associated glycoprotein (MAG, 1%) (Jahn et al., 2009).

Myelin maintenance and replacement is a continually ongoing process over the course of an individual’s
lifetime, which is essential for optimal neuronal functioning and survival (McLaurin and Yong, 1995). In
addition to baseline myelin maintenance, remyelination of axons from which damaged myelin has been
stripped off has been extensively documented, primarily through clinical and molecular studies
investigating the pathology of Multiple Sclerosis (Hartley et al., 2014, Kutzelnigg and Lassmann, 2014). In
notable recent studies, while myelination was previously viewed solely as an early life event, it has been
shown that active synthesis and formation of new myelin is required for motor learning in adulthood (Long
and Corfas, 2014, McKenzie et al., 2014).

Myelin is damaged or improperly formed in a variety of conditions, which primarily result in motor
dysfunction. Factors contributing to these diseases include genetic mutations of myelin components termed
leukodystrophies, demyelinating diseases caused by inflammation such as Multiple Sclerosis, and
hypomyelination or myelin damage caused by injury such as in perinatal white matter injury in preterm
infants (Volpe, 2001, Garbern, 2007, Lee et al., 2010, Markowitz, 2013). Myelin deficits have now also
been implicated in neurodegenerative diseases such as ALS, and neurological diseases with cognitive and
behavioral consequences such as autism and schizophrenia (Kang et al., 2013, Chavarria-Siles et al., 2015,
Libero et al., 2015). While OPCs persist in the CNS in most of these diseases, they are unable to
differentiate and effectively form new myelin.

Two of these disorders highlight the contribution of oxidative stress to myelin dysfunction. In Multiple
Sclerosis, while the mechanism driving initial autoimmune targeting of myelin is not understood,
inflammation and oxidative stress are thought to drive much of the continuing pathology (Friese et al.,
2014, Mahad et al., 2015). Symptoms arise from disruption of myelin integrity in white matter tracts within
the brain, resulting in improper transmission of neuronal impulses (Markowitz, 2013, National Multiple
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Sclerosis Society, 2015). In addition to destruction of myelin sheaths and death of associated
oligodendrocytes, cellular pathology also includes axonal damage and subsequent cell death of the
demyelinated neuron (Criste et al., 2014, Mallucci et al., 2015). As was mentioned previously, impaired
myelination can hasten neuronal axonal degeneration by altering trophic support provided by the
ensheathing oligodendrocytes (Lappe-Siefke et al., 2003, Edgar and Garbern, 2004, Criste et al., 2014).
Oxidative stress negatively impacts oligodendrocytes on multiple levels, as it can perturb myelination in
mature oligodendrocytes, and concomitantly both depletes the OPC pool and prevents effective
differentiation of the remaining OPCs for replacement of the damaged mature oligodendrocytes to
remyelinate affected areas (Levison et al., 2001, French et al., 2009, Reid et al., 2012). A devastating loss
of myelination also occurs in pre-term infants who suffer from perinatal white matter injury (PWMI),
which frequently results in considerable neurologic dysfunction and diagnosis of cerebral palsy (Volpe,
1981, 2001). This brain damage targets white matter specifically, and while it can be triggered by several
independent events, one of the leading causes is lack of cerebral oxygenation (Back and Rosenberg, 2014).
This causes the generation of robust levels of oxidative stress, and cell death of the particularly vulnerable
OPC pool as discussed in section 1.5, ultimately resulting in hypomyelination of the cortex in the
developing child (Volpe, 2001, Back and Rosenberg, 2014). The evidence of oxidative stress-mediated
damage to oligodendrocytes in these conditions highlights the necessity for reduction of this stress in order
to facilitate recovery or attenuate dysfunction in demyelinating disorders.

1.7 THE ENDOGENOUS ANTIOXIDANT RESPONSE (EAR)
In response to an imbalance of redox homeostasis, cells activate a cellular stress pathway known as the
endogenous antioxidant response (EAR) in order to reduce levels of oxidative stress. This response is
mediated by the activity of a ubiquitously expressed transcription factor of the Cap’n’Collar family, NF-E2
(nuclear factor (erythroid-derived 2))-related factor-2 (Nrf2) (Motohashi, 2004b). Nrf2 has been
demonstrated to be essential for a transcriptional response to oxidative stress (Chan, 1999, Leung, 2003).
Under homeostatic conditions, Nrf2 is sequestered in the cytoplasm by a Kelch-like ECH-associated
protein-1 (Keap1) dimer, in complex with Cul3/Rbx/E3 ligase which facilitates constitutive ubiquitination
and proteasomal protein degradation (Figure 1.2A) (Itoh, 1999, Zipper, 2002, Zhang DD, 2003, Zhang,
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2004). Cytoplasmic retention of Keap1/Nrf2 complexes are ensured by dual actions of Keap1 through its
nuclear export signal and actin binding via its Kelch repeat domain (Kang, 2004, Velichkova, 2005).

Under pathway activating conditions, the interaction between Nrf2 and Keap1 is altered, with release from
Keap1-mediated repression allowing for Nrf2 nuclear translocation (Li, 2009). Two methods of pathway
activation occur, through either modification of Keap1 cysteines or Nrf2 phosphorylation (Figure 1.2B).
Several cysteine residues on Keap1 are critically responsible for effective basal ubiquitination of Nrf2,
which targets the protein for proteasomal degradation (Dinkova-Kostova, 2002, Zhang DD, 2003). During
pathway activation, modification of these residues results in a conformational change of the Keap1 homodimer sequestering Nrf2 in the cytoplasm (Wakabayashi, 2004, Eggler, 2005, Tong, 2007). In this way, the
altered Keap1 dimer retains the Nrf2 molecule bound in complex, but ubiquitin transfer to Nrf2 is
disrupted, no longer successfully targeting it for degradation. As a result, there is an accumulation of
unbound de novo translated Nrf2 which can enter the nucleus and activate transcription (Zhang DD, 2003,
Wakabayashi, 2004, Eggler, 2005, Kobayashi, 2006, Purdom-Dickinson, 2007, Tong, 2007). Pathway
activation by this method also switches the ubiquitin transfer to the Keap1 molecules, instead targeting
Keap1 for degradation and further enhancing the available Nrf2 pool (Hong, 2005, Zhang, 2005).
Alternatively, Nrf2 can be phosphorylated by Protein Kinase C or PKR-like ER kinase, which directly
disrupts the association of Keap1 and Nrf2 (Huang, 2000, 2002, Bloom, 2003, Cullinan, 2003).

Once nuclear translocation has occurred, Nrf2 dimerizes with small musculoaponeurotic fibrosarcoma
oncogene (sMaf) proteins, conferring binding specificity to the antioxidant response element (ARE) DNA
motif (Rushmoore, 1991, Itoh, 1997, Nguyen, 2003, Motohashi, 2004a, Kobayashi, 2005, Li, 2009).
Following assembly of this heterodimer at the ARE, Nrf2 domains then recruit CREB (cAMP Responsive
Element Binding protein) Binding Protein (CBP), inducing acetylation of Nrf2 and allowing for initiation
of transcription and translation of a battery of cytoprotective genes (Rushmore, 1990, Rushmoore, 1991,
Katoh, 2001, Zhu, 2001, Lee, 2003, Shen, 2004, Kobayashi, 2005, Li, 2009, Kawai, 2010). Antioxidant
response genes driven by this Nrf2-mediated transcription include the antioxidant proteins: heme
oxygenase 1 (HO-1), peroxiredoxins, thioredoxins, and superoxide dismutase, phase II detoxifying
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enzymes: NAD(P)H:quinone oxidoreductase (NQO1), glutathione S-transferase, and the xCT subunit of the
cystine/glutamate exchange transporter, as well as stress response chaperones, transcriptional regulators,
proteasome components, and phase III detoxifying enzymes (Itoh, 1997, Alam, 1999, Ishii, 2000, Kwak,
2001, McMahon, 2001, Lee, 2003, Shih, 2003). Additional regulation occurs through competitive ARE
binding, through both positive (Nrf1), and negative (c-fos, Fra1, Bach1/2) transcriptional modifiers
(Venugopal, 1996, Muto, 2002, Dhakshinamoorthy, 2005, Sun, 2009, Kaspar, 2010).

While still incompletely understood, two mechanisms have been proposed for cessation of the antioxidant
response. In the absence of Nrf2, the Keap1 complex can bind prothymosin-α, driving nuclear import
(Figure 1.2Ci) (Karapetian, 2005, Padmanabhan, 2008, Niture, 2009). Once nuclear, Keap1 switches
prothymosin-α for Nrf2 binding (Niture, 2009). This nuclear Keap1-Nrf2 complex can either be directed to
Crm-1 mediated export to resume normal cytoplasmic repression activity, or alternatively can remain
nuclear and target Nrf2 for internuclear proteasomal degradation (Nguyen, 2005, Velichkova, 2005, Sun,
2007, Niture, 2009). The second proposed mechanism involves glycogen synthase kinase 3β (GSK3β)
(Figure 1.2Cii). Free cytoplasmic Nrf2 can be phosphorylated by active GSK3β, which prevents nuclear
import and targets for Keap1-independent ubiquitination by the SCF/β-TrCP/Cul1/Rbx/E3 ubiquitin ligase
complex leading to subsequent proteasomal degradation (Salazar, 2006, Rada, 2011). Activated GSK3β can
also phosphorylate cytoplasmic Fyn kinase, causing its translocation and phosphorylation of nuclear Nrf2,
which once modified in this manner becomes fated for nuclear export and degradation (Jain, 2006, 2007).

While this pathway has been well described in many cell populations, investigation into EAR activity has
been somewhat limited in lineages of the central nervous system (Li, 2009). Through many elegant studies
the laboratory of Johnson and colleagues has demonstrated Nrf2-mediated EAR activity in astrocytes
(Kraft, 2004) and reviewed in (Vargas and Johnson, 2009). Similarly, it has been well documented that
upregulation of Nrf2-mediated antioxidant response proteins can occur in macrophages (Itoh et al., 2003, Li
et al., 2004). Through these studies, it has been shown that activating the EAR in both astrocytes or
macrophages can provide protection to neurons (Kraft, 2004, Li et al., 2004). Neurons are particularly
susceptible to toxicity from oxidative stress, with many findings concretely demonstrating that in an in vivo
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context other cell populations likely provide a supportive buffer (Bell, 2013). In contrast to other cell
populations, very little is known about the EAR in oligodendrocytes. Studies using OLN-98 cells and
primary rat oligodendrocytes showed HO-1 protein upregulation following hydrogen peroxide exposure
(Goldbaum and Richter-Landsberg, 2001, Stahnke et al., 2007). While this suggested EAR pathway
activation, this insult also culminated in loss of mitochondrial function and apoptosis, suggesting an
ineffective or incomplete response which was insufficient to protect the cells (Goldbaum and RichterLandsberg, 2001). In summary, little is known about the EAR pathway in neurons and oligodendrocytes,
two cell populations that have been suspected to primarily draw on macrophages and astrocytes for
cytoprotective support. In support of this, both macrophages and astrocytes have been demonstrated to
robustly activate the EAR pathway.

1.8 NRF2 PATHWAY DYSFUNCTION IN DISEASE
Given the pervasive oxidative stress found in many neurodegenerative diseases, better understanding of the
EAR pathway in CNS cell populations is of vital importance (Gilgun-Sherki et al., 2004, Mariani, 2005,
Ramsey, 2007, Romano, 2010). In the absence of Nrf2 activity there is heightened susceptibility not only to
direct oxidative stress, but also to acetaminophen hepatotoxicity, carcinogens, ischemia, and hyperoxic
lung injury, as well as a general suppression of immune responses (Chan, 2001, Enomoto, 2001, RamosGomez, 2001, Cho, 2002, Shih, 2005, Thimmulappa, 2006). Postnatal lethality occurs under conditions of
Keap1 deletion in knockout mice, resulting from Nrf2 pathway dysregulation (Wakabayashi, 2003). As
these studies indicate, balance of Nrf2 and Keap1 functions are critical for maintaining cellular redox
homeostasis, with alterations in either component resulting in drastic cellular consequences. Additionally,
changes in subcellular localization of these proteins can also impact function, as Nrf2 activity is highly
dependent on its ability to activate transcription of EAR targets.

In many neurodegenerative pathologies, Nrf2 and other transcription factors undergo aberrant cellular
localization, precluding appropriate transcriptional regulation in response to activation of their respective
signaling pathways (Chu, 2007, Patel, 2011). Several lines of evidence suggest that dysregulation of the
EAR through inappropriate localization of Nrf2 may contribute to disease progression. In Alzheimer

22	
  

Disease (AD), levels of nuclear Nrf2 are significantly reduced in affected patients compared to agematched controls, even in neurons displaying abundant oxidative damage, suggesting a defect in nuclear
Nrf2 translocation (Ramsey, 2007). Nrf2 is highly enriched in the nucleus of affected neuronal cell
populations in Parkinson Disease (PD), suggesting that the EAR has been activated but the response is not
capable of overcoming the levels of oxidative stress to provide cellular protection (Ramsey, 2007).
Recently, high levels of nuclear expression of Nrf2 and downstream target HO-1 were found in
oligodendrocytes in active demyelinating regions from Multiple Sclerosis (MS) patients (Licht-Mayer et
al., 2015). However, in a similar finding to cells in PD, the highest enrichment of nuclear Nrf2 was found
in degenerating oligodendrocytes in the MS lesions (Licht-Mayer et al., 2015). Preliminary evidence from
our laboratory has suggested that Nrf2 localization may also be affected in individuals with HAND. In
comparison to ART-treated, HIV-positive neurocognitively normal individuals, ART-treated individuals
with HAND have elevated cytoplasmic Nrf2 levels. This abnormal elevation does not indicate a productive
antioxidant response, as nuclear Nrf2 is required for EAR-based gene upregulation. Increased evidence of
oxidative damage (4-HNE) is also seen in the HAND patients compared to seronegative age-matched
neurocognitively normal controls, supporting the notion that while oxidative stress is accumulating with
HIV and ART, an effective protective response is not mounted. However, it is challenging to draw
conclusions regarding stress response proteins in post-mortem tissue derived from patients with a chronic
degenerative condition. Cells frozen in time at the point of autopsy which display highly enriched levels of
a particular response protein could be chronically and effectively combatting a stressor, or conversely could
be ineffectively attempting to overcome a non-survivable level of stress and are instead fated for cell death.

1.9 COUNTERING OXIDATIVE STRESS IN HAND
Nrf2 pathway upregulation has been suggested as a potential avenue for therapy in ALS, Alzheimer
Disease, and Parkinson disease (Calkins, 2009, Tufekci, 2011, Kumar et al., 2012, Petri et al., 2012). In
MS, where oxidative stress is a key pathological feature of the disease, therapies aimed at reducing this
stress burden have been approved and are used currently in the clinical setting (FDA, 2013, Friese et al.,
2014, Dubey et al., 2015, English and Aloi, 2015, Mahad et al., 2015). Due to the vast amount of
experimental evidence demonstrating that both HIV and ART induce oxidative stress, it has also been
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proposed that boosting the EAR through promoting Nrf2 pathway activity may be an effective adjunctive
therapeutic option for all individuals living with HIV, not only those already affected by HAND.

Encouragingly, multiple compounds activating the Nrf2 pathway have proven effective in preventing
oxidative consequences of viral infection, viral proteins, and antiretroviral compounds in vitro. Chief
among these compounds are dimethyl fumarate, resveratrol, and curcurmin (Chai et al., 2005, Touzet and
Philips, 2010, Cross et al., 2011, Gao et al., 2011). Other antioxidants also show promise in preventing
oxidative stress invoked by exposure to antiretroviral drugs in vitro, but their actions have not been
confirmed to be Nrf2-pathway dependent. These compounds include: acetyl-L-carnitine, dihydroxybenzyl
alcohol, and glutathione mimetic tricyclodecan-9-yl-xanthogenat (D609) (Ferraresi et al., 2006, Opii et al.,
2007, Weakley et al., 2011). In a slightly different approach, the compound diphenylene iodonium was
used to specifically inhibit NADPH oxidase in adipocytes. Through the action of this compound, the
generation of oxidative stress was prevented for the PI drug class, but not for the NRTIs (Lagathu et al.,
2007). This finding suggests that different classes of antiretroviral agents may lead to the generation of
ROS through different mechanisms, requiring adjunctive therapeutics that target these specific cellular
pathways.

Of the currently proposed potential adjunctive options, dimethyl fumarate is of particular interest, due to its
dual functionality of activating the Nrf2-mediated EAR, as well as suppressing levels of HIV-replication in
macrophages (Cross et al., 2011). This compound could potentially become a vital adjunctive therapy for
HIV, which would lower viral titers in addition to lowering oxidative stress generated by viral proteins and
co-administered antiretrovirals. DMF has recently been FDA approved for the treatment of MS under the
trade name Tecfidera and successfully reduces relapse rates (FDA, 2013, Limmroth, 2013, English and
Aloi, 2015). Surprisingly, while suspected to act as an antioxidant on the basis of previous reports
demonstrating activation of the Nrf2-pathway, the mechanism of action by which Tecfidera is effective in
MS has not yet been elucidated. In the body, DMF is rapidly converted to monomethyl fumarate (MMF),
so that in blood plasma only MMF is ever detected (Litjens et al., 2004, Fox et al., 2014). While the effects
of MMF on oligodendrocytes, the primary cell population affected in MS pathology currently remains
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unexplored, antioxidant effects of MMF have been reported in neurons and macrophages through
upregulation of Nrf2-mediated EAR target genes, similar to findings using the parent compound DMF
(Cross et al., 2011, Linker et al., 2011, Albrecht et al., 2012, Scannevin et al., 2012).

A second alternative approach to combatting oxidative stress is direct scavenging of reactive oxygen and
nitrogen species through dietary supplementation of antioxidants such as Vitamin C (ascorbate). This has
been demonstrated to have beneficial outcomes in patients when supplemented to their ART regimens, and
has protected against effects of HIV protein gp120, PI Nelfinavir, and NRTI AZT in vitro (de la Asuncion
et al., 2004, Vincent et al., 2004, Walsh et al., 2004). Supplementation with a variety of other antioxidants
and micronutrients such as vitamins A and E, selenium, coenzyme Q10, and alpha-lipoic acid have also
demonstrated partial protection from oxidative stress induced by HIV/SIV and ART in vivo, through
assessment of restored blood glutathione levels (Delmas-Beauvieux et al., 1996, Batterham et al., 2001, de
la Asuncion et al., 2004, Jariwalla et al., 2008). While still in early stages of determining their efficacy,
both the NMDA-receptor blocker memantine and monoamide oxidase type B inhibitor selegiline have been
proposed as potential adjunctive therapeutics for the treatment of HAND (Lindl et al., 2010, Zhao et al.,
2010). Memantine, which is currently approved for Alzheimer Disease, may benefit patients by reducing
glutamate-mediated excitoxicity (Kutzing et al., 2012). Selegiline, which is utilized for treatment of
Parkinson Disease, may aid in reducing the oxidative stress burden in HAND through direct reduction of
oxygen-based free radicals (Nagatsu and Sawada, 2006). Going forward, it is imperative to identify and
develop adjunctive therapies that can effectively attenuate the oxidative stress caused by HIV infection and
antiretroviral therapy. Until antiretroviral compounds with less toxic side effects can be designed and
successfully targeted to all areas of established viral enclaves, oxidative stress will continue to be a
persistent burden in this patient population who are now living with their infection long-term, over greatly
enhanced life expectancies.

1.10 RATIONALE AND OBJECTIVES
Antiretroviral compounds are quite successful at attenuating HIV-replication, yet despite peripheral viral
titers below the limit of detection, approximately half of infected individuals suffer from some level of
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impairment within the spectrum of dysfunction characterized as HIV-Associated Neurocognitive Disorders
(HAND) (Gray, 2003, Brew, 2004, Heaton, 2010, 2011). Peripheral toxicities of these compounds have
been well characterized, yet the toxic effects of these compounds on the major cell types of the CNS, which
have potential implications for the persistence of HAND, have been overlooked (Carr, 1998a, Dalakas,
2001, Cohen, 2005, Parker, 2005, Ellis et al., 2008, Vidal et al., 2010). We anticipated that antiretroviral
compounds, which activate several cellular stress pathways in the periphery, are likely to affect cell
populations within the brain, which may contribute to loss of cognitive function (Parker, 2005, Zhou, 2005,
2006, Gupta et al., 2007). In chapter 2, we extensively review the evidence for oxidative stress in HIVinfected individuals both before and after the development and widespread use of therapy, the contributions
of the virus and of antiretrovirals to this continued stress, and potential adjunctive therapeutic interventions
to combat these effects.

In chapter 3, we then test the hypothesis that antiretroviral compounds negatively impact neuronal function
in vivo and in vitro. We found that in both pigtail macaques and rats, in vivo antiretroviral administration
resulted in synaptodendritic damage. In vitro studies demonstrated that exposure to antiretrovirals led to
accumulation of ROS and slight activation of the EAR, yet culminated in neuronal damage and death. Use
of the fumaric acid ester monomethyl fumarate (MMF) to potently upregulate the cellular antioxidant
response prevented both the accumulation of ROS and subsequent neuronal toxicity. These findings
suggest that oxidative stress is a major contributor underlying neuronal toxicity following antiretroviral
treatment, and could inform potential adjunctive therapies to ameliorate cellular damage caused by these
compounds.

In chapter 4, we explore the white matter loss prevalent in HIV patients on ART by directly testing the
effect of antiretroviral compounds on the survival, maturation, and maintenance of the myelin-producing
cells of the CNS, oligodendrocytes. We discovered that compounds in the PI drug class invoked reversible
dose-dependent decreases in the maturation of oligodendrocyte precursor cells. No deficits were noted
following NRTI treatment. Unlike the rescue from toxicity found in neuronal cultures, MMF was unable to
restore maturation to normal levels when co-administered with PIs. In vivo administration of Ritonavir
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resulted in reduced myelin protein levels in frontal cortex. Similarly, prefrontal cortex from HIV-positive
individuals with HAND who had received antiretroviral therapy displayed a significant decrease in myelin
basic protein levels compared to HAND individuals who had not received treatment, as well as HIVnegative control individuals. These findings demonstrate that antiretrovirals in the PI class have damaging
effects in oligodendrocytes, and have clinical implications for treatment regimen recommendations both in
juvenile HIV patients who are in the process of initial cortical myelination, as well as maintenance of
myelin in adults on longitudinal lifelong therapy.

Intrigued by our finding that MMF failed to rescue oligodendrocyte maturation in the presence of
antiretrovirals where it had succeeded in rescuing neuronal toxicity, we next pursued a thorough
investigation into the activity of the EAR in oligodendrocytes following oxidant and antioxidant treatment
(Chapter 5). In vitro application of oxidant tBHP to mouse oligodendrocyte precursors and mature
oligodendrocytes resulted in robust accumulation of ROS, yet target genes of the antioxidant response were
not upregulated. As we noted in previous studies (French et al., 2009, Reid et al., 2012), oxidant treatment
also resulted in a significant reduction in maturation of precursors into maturing oligodendrocytes.
Application of MMF successfully reduced ROS accumulation induced by multiple oxidants, but also did
not activate the EAR or rescue maturation deficits in oligodendrocytes. Quite surprisingly,
oligodendrocytes did not activate the EAR under conditions of oxidative stress to restore homeostasis, even
after treatment with MMF. In addition to these implications in HAND, this study also aids in explaining the
mechanism behind the recently FDA-approved drug Tecfidera (DMF), which has proven to be effective in
reducing relapse rates in Multiple Sclerosis. Based on our findings, the therapeutic effect of the primary
metabolite MMF in MS patients is not likely a direct antioxidant effect on oligodendrocytes, but rather an
indirect effect by promoting this response in other CNS cell types, or through anti-inflammatory actions
that we have not yet investigated.

Finally, we incorporate our findings into the context of previous studies (Chapter 6). We provide a
summary of this body of work, an interpretation of the significance of our findings, and considerations for
both clinical ramifications as well as potential future avenues of investigation.
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Clinical
Stage:

HIV-Associated
Symptoms

1

Asymptomatic

2

3

4

Mild

Advanced

Severe

Clinical Event

No HIV-related symptoms
Painless enlarged lymph nodes persisting 3+ months
Involuntary loss of body weight (<10%)
Recurrent upper respiratory tract infections
Herpes zoster (Shingles)
Recurrent oral ulceration
Papular pruritic lesions
Seborrhoeic dermatitis
Involuntary loss of body weight (>10%)
Chronic diarrhea persisting 1+ months
Persistent fever-intermittent or constant for 1+ months
Persistent oral candidiasis, Oral hairy leukoplakia
Pulmonary tuberculosis
Severe bacterial infection (pneumonia, meningitis, etc)
Acute necrotizing ulcerative gingivitis or necrotizing
ulcerative periodontitis
Unexplained anaemia, neutropaenia
or chronic thrombocytopaenia
HIV wasting syndrome
Pneumocystis pneumonia
Recurrent bacterial pneumonia
Chronic or disseminated- herpes simplex virus
infection, mycobacteria infection, cytomegalovirus,
isosporiasis. mycosis, cryptosporidiosis,
CNS toxoplasmosis, or atypical leishmaniasis.
Extrapulmonary cryptococcosis (including meningitis)
Extrapulmonary tuberculosis
Recurrent non-typhoid Salmonella bacteraemia
Lymphoma (cerebral or B-cell non-Hodgkin)
Invasive cervical carcinoma
Kaposi sarcoma
Progressive multifocal leukoencephalopathy
HIV encephalopathy
HIV-Associated nephropathy
HIV-Associated cardiomyopathy

Table 1.1 HIV Clinical Staging
Adapted From “Criteria for HIV Staging Events”, and “WHO clinical staging of HIV/AIDS for adults and
adolescents with confirmed HIV infection” (WHO, 2007). Clinical staging score is determined by level of
HIV-Associated symptoms according to occurrence of specific clinical events in patients.
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Adapted from oligodendrocyte differentiation figures (Grinspan JNEN 2002, See et al. JNEN 2009)
Figure 1.1 Oligodendrocyte Lineage Progression

Oligodendrocyte maturation stage can be assessed through expression of stage-specific protein markers.
The top panel shows immunofluorescent images of typical cells in each of the three identified
oligodendrocyte lineage stages. These cells, isolated from newborn rat pups, were labeled with antibody to
the ganglioside marker A2B5 for precursors, galactocerebroside (GalC) for immature oligodendrocytes,
and proteolipid protein (PLP) for mature oligodendrocytes. In the lower panel are illustrations denoting
process length and complexity with maturation. Under these drawings are the typical markers found at each
stage in the lineage progression. In addition to PLP, myelin protein components: 2’,3’-cyclic nucleotide
phosphodiesterase (CNP), myelin-associated glycoprotein (MAG), myelin basic protein (MBP), and myelin
oligodendrocyte glycoprotein (MOG) begin to be expressed where indicated.

Adapted from oligodendrocyte differentiation figures (Grinspan, 2002, See, 2009).
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Figure 1.2 Complex Nrf2 Regulation Occurs Under Varying Cellular Conditions
A model of Nrf2 pathway regulation is presented as described in the text. A) Basal conditions, B) Pathway
activation, C) Pathway attenuation with two proposed mechanisms Ci) Keap1 shuttling and Cii) Fyn
shuttling and Nrf2 phosphorylation.
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2.1 OXIDATIVE STRESS IN NEURODEGENERATIVE DISEASES
Oxidative stress is a shared pathological finding in a myriad of neurodegenerative diseases including
Alzheimer Disease, Parkinson Disease, Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), and
HIV-Associated Neurocognitive Disorder (HAND) (Reynolds et al., 2007, Shukla et al., 2011). While it is
clear that chronic levels of oxidative stress which will overwhelm the protective capacities of the cellular
endogenous antioxidant responses may be responsible in part for the neuronal death occurring in these
conditions, in many neurodegenerative diseases it is difficult to ascertain whether oxidative stress is the
causative factor for disease pathology and progression or rather a resultant downstream event of other
cellular dysfunctions (Ramsey, 2007, Reynolds et al., 2007, Melo et al., 2011, Shukla et al., 2011).
Nonetheless, in HAND several lines of evidence suggest that both HIV and antiretroviral compounds may
result in oxidative and nitrosative stress in the periphery and in the CNS (Lipton, 1994, Mondal et al., 2004,
Walsh et al., 2004, Lagathu et al., 2007, Li et al., 2008, Chandra et al., 2009, Blas-Garcia et al., 2011).
Deficits in total antioxidant levels and increases in the markers for oxidative stress are still observed in
individuals on stable ART regimens with undetectable viral titers, necessitating the need for adjunctive
therapies to ameliorate this imbalance (Hulgan et al., 2003, Mandas et al., 2009). As has been suggested in
a variety of neurodegenerative conditions, antioxidant supplementation or upregulation of the endogenous
antioxidant response in cells of the CNS may ameliorate the neuronal damage and death contributing to
HAND (Reynolds et al., 2007, Calkins, 2009, Lindl et al., 2010, Melo et al., 2011).

2.2 OXIDATIVE STRESS IN THE ERA OF ART
The evidence of disrupted antioxidant balance and oxidative stress represent a continued concern for HIVinfected individuals even when virus is successfully controlled by ART (Blas-Garcia et al., 2011). To
understand the magnitude and implications of this problem, it is important to understand the initial
disruptions to the antioxidant system that were observed in infected individuals, and determine whether
ART contributed to the resolution or the exacerbation of these problems.

2.2a Oxidative stress prior to ART: As early as 1988, while researchers were just beginning to
understand the HIV virus, Sönnerborg and colleagues determined that plasma levels of malondialdehyde in
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adults with HIV infection were elevated up to 30% when compared with controls (Sonnerborg et al., 1988).
Malondialdehyde is the breakdown product of polyunsaturated lipids by reactive oxygen species, and is a
mainstay in terms of a biological marker for measuring the relative levels of lipid peroxidation and
oxidative stress in individuals (Moore and Roberts, 1998). A multitude of studies followed, showing
significant increases in the levels of free radicals, hydroperoxides, hydroxynoneal, and oxidation of thiols
in infected individuals, and confirming that malondialdehyde is increased significantly in infected adults, as
well as children (Favier et al., 1994, Malvy et al., 1994, Repetto et al., 1996, Walmsley et al., 1997, Allard
et al., 1998, Jareno et al., 1998, McLemore et al., 1998, Turchan, 2003, Haughey et al., 2004, Sacktor,
2004, Suresh et al., 2009). The metabolic synthesis of lipids is closely tied to the oxidative state of the cell
and the lipids residing in the cell membrane, as certain enzymes such as sphingomyelinase, are sensitive to
the oxidative status of the cell and regulate their activity based on cellular need (Haughey et al., 2008).
Studies looking into the production of sphingolipids illustrated an overproduction of both sphingomyelin
and ceramides with HIV-infection, suggesting a lipid imbalance caused by the virus (Haughey et al., 2004,
Sacktor, 2004, Haughey et al., 2008). Additionally, studies showed remarkable deficiencies in antioxidant
micronutrients including zinc, selenium, Vitamin C, Vitamin D, Vitamin E and beta-carotene (Vitamin A)
(Dworkin et al., 1986, Droge et al., 1994, Favier et al., 1994, Allard et al., 1998, Ogunro et al., 2006,
Srinivas and Dias, 2008, Suresh et al., 2009, Bilbis et al., 2010, Oliveira et al., 2011, Sudfeld et al., 2012).
Conflicting reports exist on perturbation of total antioxidant status prior to ART, with several clinical
studies reporting decreased total antioxidant capacity (Jareno et al., 1998, McLemore et al., 1998, Suresh et
al., 2009), while Repetto et al. described an increase in the overall antioxidant capacity as individuals
progressed to AIDS (Repetto et al., 1996). The discrepancies between these findings are likely based on the
assays utilized to determine “total antioxidant capacity”, as different enzymatic approaches target different
portions of the antioxidant system.

Activity levels of superoxide dismutase (SOD), which catalyzes the detoxification of the oxidant
superoxide into hydrogen peroxide and water, were assessed by a variety of laboratories. Elevated SOD
activity was observed in all evaluated HIV-infected individuals, with further increases occurring with
disease progression to AIDS. In addition, increases in SOD mRNA levels were reported in individuals with
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HAD, as compared to those who were neurocognitively normal (Delmas-Beauvieux et al., 1996, Repetto et
al., 1996, Boven et al., 1999). These changes in SOD were observed in microglial cells, as well as in HIVinfected macrophages, suggesting a virus-triggered induction (Boven et al., 1999). An essential antioxidant
found in the brain which buffers many reactive oxygen species is glutathione. In HIV-infected patients,
overall glutathione levels were found to be reduced, and the remaining glutathione was greatly skewed to
the oxidized versus reduced form (Buhl et al., 1989, Aukrust et al., 1995, Delmas-Beauvieux et al., 1996,
Repetto et al., 1996). The enzyme glutathione peroxidase, which promotes the conversion of hydrogen
peroxide to water through the use of glutathione, was also decreased, illustrating a severe imbalance in this
system whose goal is to maintain cellular redox homeostasis (Ogunro et al., 2006). Another deleterious
consequence of rampant pro-oxidants within cells is oxidative modification of DNA bases. Increased levels
of 5-hydroxyuracil, 5-hydroxycytosine, 8-hydroxyadenine and 8-hydroxyguanine were found when
comparing DNA isolated from lymphocytes of HIV-infected individuals versus uninfected controls (Jaruga
et al., 1999). One other common product of an imbalanced oxidative state which is beginning to gain more
interest and research focus is peroxynitrite. This compound, which is formed when superoxide reacts with
nitric oxide, is detectable through its nitrotyrosine moiety, and is found at higher levels and with more
frequency in the brains of patients with HAD, compared with those who are neurocognitively normal
(Boven et al., 1999). In addition to the generation of superoxide as a direct result of HIV infection, the virus
also increases mRNA expression of inducible nitric oxide synthase (iNOS), which enables a precipitous
accumulation of this deleterious oxidation product (Boven et al., 1999). Further research in the Nath
laboratory has illustrated that thirteen proteins with nitrotyrosine modifications are present in the CSF of
individuals with HIV-infection. Individuals with dementia had the highest levels of these nitrites and
nitrates. Importantly, three of these proteins were significantly elevated in individuals who showed declines
in neurocognitive assessment over a period of 6 months (Li et al., 2008).

While it appears that there is not an all-or-nothing increase or decrease in antioxidant capacity, the evidence
is clear that the components of the antioxidant defense system prior to ART were greatly affected by HIVinfection, and that the capabilities of endogenous antioxidant response were not able to alleviate damaging
oxidative alterations to proteins and DNA.
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2.2b Persistence of oxidative stress in the era of ART: In the ART era, oxidative stress is still pervasive
in individuals living with well-controlled HIV-infection (Blas-Garcia et al., 2011). In 2007, a group at the
University of Pennsylvania sought to ascertain whether ART had an effect on inflammation and oxidative
stress in the brains of HIV-infected individuals through utilization of chemical-shift magnetic resonance
spectroscopy. Through careful analysis of lipid, lactate, and creatine levels, they determined that the
inflammation and oxidative stress initiated by the HIV infection was not ameliorated in ART-treated
individuals, compared to seronegative controls (Roc et al., 2007). While these effects were observed in all
HAND patients, the levels of oxidative stress markers were higher in those with more severe cognitive
deficits (Roc et al., 2007).

Lipid peroxidation is still rampant despite effective viral control. While a couple of studies report decreased
levels in markers of lipid peroxidation in ART-medicated patients, as compared with those not receiving
ART, multiple studies have shown persistent statistically significant increases in hydroperoxides,
isoprostanes, and malondialdehyde in ART-treated HIV-infected individuals, compared to seronegative
controls (Jareno et al., 1998, Hulgan et al., 2003, Flourie et al., 2004, Ngondi et al., 2006, Masia et al.,
2007, Wanchu et al., 2009, Gil et al., 2010, Ibeh et al., 2011, Ibeh and Emeka-Nwabunnia, 2012).
Interestingly, two independent groups have determined in patient blood samples that the levels of peroxide
species and oxidative stress are higher in patients on protease inhibitor (PI) based regimens, as compared
with those in individuals on non-nucleoside reverse transcriptase inhibitor (nNRTI) based regimens,
implicating a role for the protease inhibitor class in induction or exacerbation of oxidative stress (Hurwitz
et al., 2004, Masia et al., 2007).

Micronutrient deficiencies are still problematic with ART, and while most patients have adequate plasma
concentrations of vitamins C, D, and E, reported levels are still considered sub-optimal and lower than
seronegative patients (Stephensen et al., 2006, Sudfeld et al., 2012). While subsequent reports have
indicated that zinc and selenium deficits are no longer observed in individuals on ART, further definitive
confirmation of these findings is necessary (Stephensen et al., 2007, Sundaram et al., 2008). Additionally,
in studies which evaluated the serum of adults and the saliva of children, the total antioxidant status was
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found to be decreased in ART treated HIV-patients when compared to HIV-negative controls, mirroring
findings in studies conducted in the pre-ART era (Mandas et al., 2009, Padmanabhan et al., 2010).

While several studies have indicated that introduction of ART has been accompanied by an improvement in
overall glutathione status, this effect is not totally rectified and imbalances still occur (Aukrust et al., 1995).
In particular, numerous groups have shown that circulating glutathione levels are still markedly reduced in
HIV-infected individuals, when compared with age-matched controls, with the ratio of oxidized to reduced
glutathione remaining out of balance (Walmsley et al., 1997, Flourie et al., 2004, Wanchu et al., 2009, Gil
et al., 2010, Awodele et al., 2012). Unfortunately, studies investigating nitrosative stress and nitrosylated
proteins in HIV-infected individuals on ART are still lacking; however, the Nath, Hammond, and Sutliff
laboratories have been investigating nitrosative stress in HIV, and it is likely that such reports are
forthcoming.

It has been reported that HIV-positive individuals do not have altered levels of 8-hydroxy-2’deoxyguanosine [8-oxoG) in their urine regardless of ART or lipodystrophy status (Paul et al., 2003).
While these findings appear to be promising, in a recent study, autopsy tissue from frontal cortex was
stained for both nuclear and mitochondrial 8-oxoG. The levels of this oxidized DNA product were
significantly increased in cases of HAND, suggesting that ART, or ART in combination with ongoing
infection may promote DNA oxidative modification, cellular dysfunction damage and death (Zhang et al.,
2012). Additionally, the presence of clastogenic factors, which cause chromosomal breaks and DNA
damage and which may be released from cells under conditions of oxidative stress, was observed in the
plasma of all HIV-patients tested by Edeas et al.. This was true of patients that were both asymptomatic and
symptomatic for AIDS-defining pathologies, and was independent of ART status (Edeas et al., 1997). The
effects of these clastogenic factors appear to persist in multiple cell populations implicated in HAND
pathogenesis. For example, in leukocytes obtained from HIV-infected individuals, the percentage of cells
exhibiting DNA fragmentation was increased in individuals on ART, as compared with those who were
ART-naïve (Gil et al., 2010). However, the results of this study have not addressed the possible
contribution of latent or low level of infection to the findings.
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Due to pervasive oxidative damage and antioxidant imbalance despite effective long-term viral control in
patients, it is now imperative to recognize the direct effects that viral enclaves and antiretroviral drugs
themselves may have on perpetuating these effects. Further studies are needed to investigate the
independent effects of ART and the virus on oxidative damage in the CNS, as well as in the periphery in
order to better determine therapeutic interventions to resolve these dysfunctions.

2.3: OXIDATIVE STRESS BY HIV
Exhaustive research has been conducted in order to determine the effects of the HIV on infected cells and
the cytotoxic factors released from these cells. As addressed earlier, it is now clear that HIV-infected
macrophages secrete a variety of neurotoxic substances including glutamate, nitric oxide, and superoxide
(Lipton, 1994). Within actively infected human myeloid-monocytic cell lines or monocyte-derived
macrophages, HIV induces an increase in superoxide anions, with a concomitant increase in superoxide to
combat these factors (Kimura et al., 1993, Boven et al., 1999). Mollace and colleagues have demonstrated
that the supernatants from HIV-infected human primary macrophages induced oxidative stress in
astrocytes, as indicated by increases in malondialdeyde levels (Mollace et al., 2002). They further showed
that these supernatants, which contained excess superoxide, induced astrocytic apoptosis, confirming HIVmediated toxicity of this secreted product (Mollace et al., 2002). In a similar fashion, in HIV-infected
monocytes, an induction of nitric oxide synthase and subsequent increase nitric oxide was observed
(Bukrinsky et al., 1995). It is also interesting to note that elevated oxidative stress in the form of
intracellular singlet oxygen is capable of reactivating latent HIV through long terminal repeat (LTR)
transactivation in infected monocytes or lymphocytes, suggesting that the virus may rely on oxidative stress
signaling cascades for continuation of long-term infection or viral rebound (Piette and Legrand-Poels,
1994).

The amino acid and neurotransmitter glutamate is normally secreted from neurons into the synaptic cleft,
and is quickly removed and recycled through the actions of astrocytes. This molecule normally activates
the N-methyl D-aspartate (NMDA) receptor on neurons, and allows for Ca2+ entry into the cell. However,
it has been clearly demonstrated that excessive extracellular levels of glutamate resulting from
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overstimulation of neurons, impaired reuptake by astrocytes, or release from other cell populations within
the brain can lead to hyperactivation of NMDA channels and subsequent increases in Ca2+ levels in the
neuronal cytoplasm, resulting in excitotoxic neuronal death (Szydlowska and Tymianski, 2010). In 2001,
Jiang et al. demonstrated through a series of elegant experiments that the molecule responsible for the
neurotoxicity observed on neuronal cultures was a molecule of less than 3,000 kilodaltons, was not
sensitive to trypsin digestion, and that its neurotoxic effect was blocked by a selective NMDA receptor
antagonist, MK-801. It was through this study, as well as a subsequent study by O’Donnell et al. that the
increased levels of extracellular glutamate secreted by HIV-infected macrophages may be a major factor in
HIV-infected macrophage mediated indirect neuronal death (Jiang et al., 2001, O'Donnell et al., 2006). The
increases in extracellular glutamate appears to be an effect of dysregulation of the glutamate synthesis
pathway, as inhibition of the mitochondrial glutaminase enzyme blocks the production and the secretion of
glutamate from HIV-infected macrophages (Zhao et al., 2004, Erdmann et al., 2007, Huang et al., 2011).
As was distinctly noted in human patient samples, a marked deficiency of glutathione and an imbalance
between the oxidized and the reduced glutathione was observed. Within cells, glutaminase is the enzyme
which converts glutamine to glutamate. It is tempting to consider that the oxidative stress resulting from the
lack of the antioxidant properties of glutamine may be very tightly coupled to a depletion of glutamine
from cells by hyperactivation of glutaminase enzymes, precipitating an overproduction of glutamate and
triggering an excitotoxic neuronal death pathway.

Similar to effects of whole virus in vivo, when gp120 and Tat were injected into the brains of rats, both of
these viral proteins induced lipid peroxidation and glutathione depletion (Banerjee et al., 2010).
Additionally, both of these proteins significantly reduced intracellular glutathione, and increased
malondialdehyde in immortalized brain endothelial cells, showing that the oxidative status of these cells
would also be directly affected by the presence of virus. This is of particular importance as the altered
oxidative status of these endothelial cells comprising the BBB will have potential impact on not only the
integrity of the BBB, but also on the monocyte/macrophage transmigration to the CNS, an important factor
in the persistence of HAND (Price et al., 2005). Further, when applied to neurons in culture, gp120 and Tat
induce disruptions in the lipid metabolism, leading to increased levels of sphingomyelin, ceramide, and
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hydroxynoneal, paralleling disruptions in these pathways observed in the neurons of HAND patients
(Haughey et al., 2004).

Studies that investigated gp120 separately have revealed that it is capable of inducing ROS formation, and
activating the antioxidant response in astrocytes (Viviani et al., 2001, Reddy et al., 2011). Studies looking
into the production of oxidant species by gp120 have shown that superoxide ions as well as nitric oxide are
involved in neuronal toxicity (Dawson et al., 1993, Walsh et al., 2004). Mechanistically, gp120-induced
nitric oxide formation is dependent on a mannose-specific endocytic lectin in macrophages, while gp120induced expression and upregulation of iNOS selectively occurs in astrocytes in human fetal neuroglial
cultures astrocytes (Pietraforte et al., 1994, Walsh et al., 2004). Multiple studies have shown that in neurons
undergoing gp120-induced toxicity, a significant increase in intracellular Ca2+, likely released from
intracellular stores, preceded death, suggesting at a mechanism of activation of calpains or other pro-death
cellular machinery (Viviani et al., 2001, Agrawal et al., 2010).

Studies investigating Tat-induced neuronal death have revealed that this viral protein triggered the
accumulation of ROS when exogenously applied to a variety of cell types, including lymphocytes,
microglia, brain microvascular endothelial cells (BMECs) and neurons, as well as in HeLa cells expressing
Tat (Flores et al., 1993, Israel and Gougerot-Pocidalo, 1997, Kruman et al., 1998, Toborek et al., 2003).
When directly injected into striatum of rats, Tat produced dramatic increases in protein oxidative
modifications and protein carbonyls (Aksenov et al., 2001). Protein carbonyls were also markedly
increased in HeLa cells expressing Tat, supporting in vivo data (Flores et al., 1993). In addition, decreased
levels of glutathione were observed in cardiac myocytes and BMECs exposed to recombinant Tat protein,
Tat-expressing transgenic mice, and in Tat-expressing HeLa cells (Westendorp et al., 1995, Choi et al.,
2000, Raidel et al., 2002, Toborek et al., 2003). Two studies pinpointed the involvement of manganesedependent superoxide dismutase (Mn-SOD) as a key player in Tat- induced cellular changes. By expressing
Tat in HeLa cells, the laboratories of Lehman and McCord convincingly showed that Tat suppressed the
RNA, protein, and activity levels of Mn-SOD, while inducing no changes in the CuZn SOD enzyme levels
(Flores et al., 1993, Westendorp et al., 1995). In HIV-infected individuals, plasma levels of SOD were

54	
  

increased in plasma, and these changes were in parallel with disease progression to AIDS. If the results
from these HeLa cell studies can be expanded to other cell populations, it is tempting to speculate that
perhaps this overall increase in SOD activity is a compensatory mechanism resulting from the Tat-induced
alterations in Mn-SOD activity and the subsequent increases in superoxide ions that cannot be eliminated.
The overexpression of Tat in HeLa cells also led to decreases in overall glutathione levels, with a lower
ratio of reduced to oxidized glutathione in the remaining supply, mimicking the effect seen in HIV infected
individuals in vivo and in HIV-infected macrophages in vitro (Flores et al., 1993, Westendorp et al., 1995).

Finally, studies focusing on microglia have shown that the expression of HIV viral protein R (Vpr) can
induce oxidative stress pathways, and can activate HIV latent gene expression (Deshmane et al., 2009).
When exogenously applied to human fetal astrocytes, the oxidative stress caused by Vpr causes decreases
in intracellular ATP and glutathione, and skews remaining glutathione in favor of the oxidized versus
reduced form (Ferrucci et al., 2012).

In summary, exhaustive in vivo and in vitro studies indicate that HIV viral proteins themselves can induce,
precipitate, and augment oxidative stress in multiple cell types, of both peripheral and CNS tissue. These
findings further emphasize the importance of complete inhibition of viral replication in alleviating
oxidative stress via antiretroviral therapy. However, emerging evidence suggests that antiretroviral drugs
themselves might inadvertently lead to oxidative stress.

2.4: OXIDATIVE STRESS BY ART
Due to the requirement for lifelong adherence to antiretroviral regimens to prevent viremia and immune
system compromise, it is necessary to investigate the effects of these compounds in a cellular context.
Many of these drugs are associated with negative side-effects, and have been linked to the metabolic
syndrome, atherosclerosis, lipodystrophy, proteasome inhibition and the unfolded protein response (Zhou,
2005, 2006, Vidal et al., 2010). Additionally, it has become apparent that these compounds themselves
produce oxidative stress, even in the absence of virus, and may in fact be contributing to the persistence of
oxidative stress in patients with well-controlled viral load (Mondal et al., 2004, Blas-Garcia et al., 2011).
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HIV is highly susceptible to mutations, mostly due to the error-prone reverse transcription step during
replication, and underlies the emergence of drug resistant mutations over time in patients treated with
single antiretroviral drugs in the early 1990s. Additionally, the development of more sensitive methods for
HIV RNA detection revealed the presence of viral reservoirs in multiple tissues, including the CNS. These
findings led to the revision of antiretroviral therapy, which, until that time included mostly single
antiretroviral drug regimens. A multiple drug treatment approach, termed ART, was implemented to aim at
different steps in the HIV replication. Currently recommended ART regimens include a cocktail of
nucleoside/nucleotide reverse-transcriptase inhibitors (NRTIs), non-nucleoside reverse-transcriptase
inhibitors (nNRTIs), protease inhibitors (PIs), and to a lesser extent, entry inhibitors and integrase
inhibitors (Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents.
Available at http://aidsinfo.nih.gov/). This approach has led to improved immune function, long-term viral
suppression, and underlies the reductions in HIV-associated morbidity and mortality in the era of ART. The
recently updated guidelines recommend ART initiation to all HIV-infected, ART-naive individuals
irrespective of CD4+ counts. The impact of early initiation of ART on HIV-associated neurological
complications remain to be seen. While a consensus has been reached regarding the time to initiate ART
based on CD4 cell counts, AIDS-defining illnesses, and certain co-morbidity factors; the panel did not
clearly outline strategies to best eradicate the viral reservoirs in the CNS, and to decrease the risk of
developing HAND among infected patients.

In the meantime, one major approach to better control HAND has been to implement therapies that include
drugs which achieve therapeutic concentrations in the CNS. While HIV can circumvent the BBB barrier,
complex drug transport and efflux mechanisms at this junction hampers the achievement of effective
antiretroviral concentrations in the brain parenchyma. Recent efforts to address this hurdle have led to the
establishment of CNS penetrance effectiveness (CPE) score, an algorithm based on the chemical structure,
pharmacodynamic and pharmacokinetic data of antiretroviral drugs (Letendre et al., 2008, Tozzi et al.,
2009, Letendre et al., 2010). In summary, an antiretroviral drug with high CPE score is small in size
(molecular mass below 400-500 kDa), has high lipid solubility and low protein binding, and it is not a
substrate for drug transport or efflux proteins. Unfortunately, results of several clinical studies which

56	
  

incorporated CPE into the design and the analysis of outcomes are not conclusive (Letendre et al., 2008,
Cysique et al., 2009, Marra et al., 2009, Tozzi et al., 2009, Garvey et al., 2011, Lanoy et al., 2011,
Smurzynski et al., 2011). While a positive correlation between CPE scores and neurological outcomes are
observed in several studies, one study revealed that ART regimens with higher CPE scores might be
associated with worse neurocognitive performance (Marra, 2009).

These studies investigating the effect of CPE scores on neurological outcomes have inherent caveats. First,
due to limited methodologies, clinical studies cannot assess the drug concentrations in the brain
parenchyma, and instead depend on the CSF levels, which are usually based on measurements after a
single-dose administration of the drug. Several factors, such as poor drug adherence and the impact of coprescribed drugs on the pharmacokinetics of antiretroviral drugs can impact CNS concentrations and can
confound the measured outcomes. Additionally, the escape of drug-resistant viral species into the CNS and
their establishment in viral reservoirs early during infection can lead to the rise of drug-resistant HIV
species in the CNS, and can hinder the efforts to assess the impact of CPE scores on neurological
outcomes. Further, co-morbidity factors impacting the integrity of the BBB should also be considered in
assessing drug availability in the CNS. Among these factors are cancer, infections, and drug and alcohol
abuse, all of which are shown to alter BBB integrity independent of HIV infection, and should be
considered when CPE scores are established and evaluated (Shiu et al., 2007, Qin et al., 2008, Ramirez et
al., 2009). One final factor to consider in evaluating the long-term effectiveness of ART is the potential for
direct toxicities of antiretroviral drugs in the CNS, especially given the interest in implementation of ART
regimens with better CNS penetrance and possibly developing nanoART as part of treatment plans.
Antiretroviral drugs have known side-effects in the periphery, including dyslipidemia, and lipohypertrophy.
Furthermore, antiretroviral drug-associated toxicity is well documented in the peripheral nervous system,
and potential CNS toxicities secondary to ART exist. Oxidative damage elicited by antiretroviral drugs is
of particular interest, given ample evidence of ongoing oxidative stress in the HAND brain, as described
above.
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In several cavalier studies, researchers eloquently demonstrated in several cell populations (human
adipocytes, monocytes, myeloid cell lines, and human aortic endothelial cells) that a variety of drugs from
the PI and NRTI families, alone or in combinations, induced the production of ROS, hydrogen peroxide,
and factors promoting monocyte recruitment. The compounds reported to induce these changes included
PIs: Indinavir, Nelfinavir, Lopinavir, Ritonavir, Saquinavir, Atazanavir and NRTIs: Stavudine (d4T),
Zidovudine (AZT), and Didanosine (Mondal et al., 2004, Ferraresi et al., 2006, Lagathu et al., 2007,
Chandra et al., 2009, Touzet and Philips, 2010, Manda, 2011, Brandmann et al., 2012). The compounds
Amprenavir (PI) and Abacavir (NRTI) were consistently reported as lacking these effects, making these
drugs good candidates for inclusion in regimens to be prescribed to patients with HAND (Lagathu et al.,
2007).

As the first available antiretroviral drug, AZT has been extensively studied. While AZT may not be a
mainstay drug of choice for customized optimal regimens, as the primary ART compound available in
resource-limited developing countries, it is still of importance to understand its cellular effects. AZT was
approved for treatment in 1987, and as early as 1992 the Papoian laboratory reported deficits in
mitochondrial enzymes and uncoupling of the electron transport chain (ETC) (Lewis et al., 1992). The
disruption of the ETC is a primary cause of mitochondrial-based intracellular ROS accumulation and
mitochondrial DNA oxidation, an effect since expounded upon in multiple laboratories after acute AZT
exposure in isolated heart mitochondria and primary human cardiomyocytes, and after chronic gestational
AZT exposure in mouse liver and kidney and in the lung and brain of fetal patas monkeys (de la Asuncion
et al., 1999, Bialkowska et al., 2000, de la Asuncion et al., 2004, Gao et al., 2011). This compound has also
been shown to increase mitochondrial lipid peroxidation, deplete intracellular glutathione, and lead to
oxidation of remaining glutathione, ultimately inducing a caspase-3- and caspase-7- dependent apoptotic
death (Yamaguchi et al., 2002, de la Asuncion et al., 2004, Gao et al., 2011). When another NRTI, d4T was
investigated, it also was shown to produce ROS, mitochondrial oxidative stress, oxidized mitochondrial
DNA, and altered activity of mitochondrial oxidative phosphorylation enzymes (Gerschenson et al., 2001,
Velsor et al., 2004). Similarly, NRTI Zalcitabine (ddC) also induces oxidative stress, as evidenced by the
accumulation of protein carbonyls and nitrotyrosine modifications. Interestingly, this study also reported
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that the better-tolerated cytidine analog Lamivudine (3TC) did not produce these effects, suggesting that
3TC may be considered as an alternative to reduce oxidative stress, and that future compounds generated
from this structural base may behave similarly (Opii et al., 2007). Interestingly, in contrast to studies in
human lymphoid cells, Brandmann and colleagues have recently reported that in astrocytes AZT,
Lamivudine, Efavirenz, and Nevirapine do not appear to reduce intracellular levels of glutathione
(Brandmann et al., 2012). Whether or not these compounds behave similarly in neurons and other cell
populations in the CNS remains to be elucidated.

In the non-nucleoside reverse transcriptase inhibitor (nNRTI) drug class, Efavirenz applied to a human
hepatoblastoma cell line resulted in superoxide generation, depletion of intracellular glutathione, and
decrease in mitochondrial function and membrane potential that was independent of mitochondrial DNA
replication (Apostolova et al., 2010). In addition, Efavirenz has also been linked to neuropsychological side
effects in HIV-infected patients, and it is probable that the specific oxidative stress effects on mitochondria
and glutathione may play a role in the neurotoxicity of this compound, as neurons are particularly sensitive
to perturbations in the antioxidant system (Apostolova et al., 2010, Ciccarelli et al., 2011).

Within the protease inhibitor class, both Ritonavir and Amprenavir have been associated with increased
superoxide anion production, while Ritonavir has been shown to cause increases in nitrotyrosine levels in
porcine coronary arteries (Chai et al., 2005). On the other hand, both Indinavir and Nelfinavir have been
shown to induce a time and concentration dependent depletion of intracellular glutathione in astrocytes as
well as in pancreatic beta cells (Chandra et al., 2009, Brandmann et al., 2012). Nelfinavir is of particular
interest, as it suppresses cytosolic, rather than mitochondrial superoxide dismutase levels, and induces a
necrotic rather than apoptotic cell death cascade in an adipocyte cell line (Vincent et al., 2004, Chandra et
al., 2009). Future studies of this compound will undoubtedly prove interesting and may have important
implications in patients with regard to their neurocognitive outcomes associated with this compound.
Finally, it is interesting to note that multiple studies investigating the oxidative effects of the thymidine
analogs in the NRTI class have reported increased ROS, hydrogen peroxide, and nitric oxide intermediates
but no superoxide anions (Ferraresi et al., 2006, Amatore et al., 2010).
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Currently, there is no information on possible oxidative effects of the entry inhibitor, integrase inhibitor,
and mutation inhibitor drug classes. Similarly, the lack of published studies for the neuroglial cell
populations in the brains of HAND patients is surprising. In order to design custom drug regimens which
will not precipitate, or can ameliorate oxidative stress, cellular dysfunction and death, it is critical to have
an understanding of the cellular effects of each currently approved antiretroviral compound, and to design
future compounds with minimal oxidative effects. Further, it is possible that the continued dysfunction in
superoxide production and superoxide dismutase levels in patients may be due to the effects of more than
one drug in a multi-drug regimen. Thus, designing future combinations which do not precipitate oxidative
stress is of utmost importance in efforts to resolve the persistence of HAND observed in the ART era.

2.5 POTENTIAL THERAPEUTIC AVENUES FOR OXIDATIVE STRESS IN THE ART ERA
Since the manifestations of oxidative stress induced by HIV and ART have emerged, it has also become
evident to scientists that boosting the endogenous antioxidant response may be a valid and encouraging
adjunctive therapeutic option. Within the cell, the antioxidant response is mediated through the activation
of transcription factor NF-E2 (nuclear factor (erythroid-derived 2))-related factor-2 (Nrf2) and its myriad of
effector phase II and III detoxifying enzymes. Relevant to the previously discussed aberrations in oxidant
detoxification, this pathway upregulates superoxide dismutase, peroxiredoxins, thioredoxins, and multiple
glutathione biosynthesis enzymes (Shih, 2003, Li, 2009).

In vitro, multiple compounds which act upon the Nrf2 pathway have proven effective in ameliorating the
oxidative effects of viral infection, viral proteins, or antiretroviral drugs. Among these compounds are
resveratrol, dimethyl fumarate, N-acetylcysteine, and curcurmin (Chai et al., 2005, Touzet and Philips,
2010, Cross et al., 2011, Gao et al., 2011, Manda, 2011). Antioxidants which have not yet been shown to
act through the Nrf2 pathway, but which have similar effects in vitro include dihydroxybenzyl alcohol,
water soluble vitamin E (trolox), glutathione mimetic tricyclodecan-9-yl-xanthogenat, and acetyl-l-carnitine
(Ferraresi et al., 2006, Opii et al., 2007, Apostolova et al., 2010, Weakley et al., 2011). An alternative
approach to specifically inhibit the actions of NADPH oxidase through the compound diphenylene
iodonium, was able to specifically prevent the effects of PIs, but not NRTIs in human adipocytes (Lagathu
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et al., 2007). This interesting finding suggests that the different antiretroviral classes may lead to ROS
production through different mechanisms, and that specific therapeutics targeting individual oxidantproducing enzymes or pathways may need to be considered for specific ART regimens.

An alternative approach to activating Nrf2 pathway is supplementation with the antioxidant vitamin C
(ascorbate), which is capable of directly scavenging reactive oxygen and nitrogen species. This method has
been shown to be effective in counteracting the deleterious effects of gp120, as well as Nelfinavir in vitro,
and has been shown to have beneficial outcomes in patients, when supplemented to ART regimens (de la
Asuncion et al., 2004, Vincent et al., 2004, Walsh et al., 2004). Along these same lines, supplementation
with a variety of other antioxidants and micronutrients including minocycline, glutathione replenishing
peptide alpha-lipoic acid, selenium, vitamin A, Vitamin E, and a multivitamin regimen including vitamins
A, C, E selenium and coenzyme Q10 have demonstrated partial protection from the deleterious oxidative
effects of HIV/SIV and ART in vivo, with particular emphasis on restoration of the total blood glutathione
levels (Delmas-Beauvieux et al., 1996, Batterham et al., 2001, de la Asuncion et al., 2004, Jariwalla et al.,
2008, Meulendyke et al., 2012). Finally, the NMDA-receptor blocker memantine, and monoamide oxidase
type B inhibitor selegiline, approved for treatment in Alzheimer and Parkinson Diseases, respectively, have
also been proposed as potential therapeutics for HAND (Batterham et al., 2001, Lindl et al., 2010).
Memantine might exert therapeutic effects through reduction of residual virus-mediated glutamate
excitotoxicity, and selegiline has been reported to be capable of reducing oxygen-based free radicals
(Nagatsu and Sawada, 2006, Kutzing et al., 2012). The use of these compounds and their efficacy in
reducing oxidative damage in HAND are still in early stages. Initial studies were confounded by the fact
that much damage was already present in late stage HAD patients and a protective effect at this stage was
not evident (Schifitto et al., 2009). Further work with these compounds will require identifying patients
with ANI or MND to enroll in longitudinal studies to determine whether these compounds will have longterm benefit.

Going forward, it is imperative that the oxidative stresses imposed by HIV and ART are targeted by
adjunctive therapies. As research progresses with the quest for eliminating viral reservoirs and designing
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more effective, less toxic antiretroviral compounds, it is important to keep in mind that oxidative stress is
and will continue to be a persistent burden, especially in a patient population with a significantly enhanced
life expectancy.
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3.1 ABSTRACT
HIV-associated neurocognitive disorder (HAND), characterized by a wide spectrum of behavioral,
cognitive, and motor dysfunctions, continues to affect approximately 50% of HIV(+) patients despite the
success of combination antiretroviral drug therapy (cART) in the periphery. Of note, potential toxicity of
antiretroviral drugs in the central nervous system (CNS) remains remarkably underexplored, and may
contribute to the persistence of HAND in the cART era. Previous studies have shown antiretrovirals
(ARVs) to be neurotoxic in the peripheral nervous system in vivo and in peripheral neurons in vitro.
Alterations in lipid and protein metabolism, mitochondrial damage, and oxidative stress all play a role in
peripheral ARV neurotoxicity. We hypothesized that ARVs also induce cellular stresses in the CNS,
ultimately leading to neuronal damage and contributing to the changing clinical and pathological picture
seen in HIV-positive patients in the cART era. In this report, we show that ARVs are neurotoxic in the
CNS in both pigtail macaques and rats in vivo. Further, in vitro, ARVs lead to accumulation of reactive
oxygen species (ROS), and ultimately induction of neuronal damage and death. While ARVs alone caused
some activation of the endogenous antioxidant response in vitro, augmentation of this response by a
fumaric acid ester, monomethyl fumarate (MMF), blocked ARV-induced ROS generation and neuronal
damage/death. These findings implicate oxidative stress as a contributor to the underlying mechanisms of
ARV-induced neurotoxicity, and will provide an access point for adjunctive therapies to complement ARV
therapy and reduce neurotoxicity in this patient population.
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3.2 INTRODUCTION
Despite introduction of combination antiretroviral therapy (cART), HIV-associated neurocognitive disorder
(HAND) continues to affect approximately 50% of HIV(+) patients (Dore et al., 1999, Heaton et al., 2010).
Further, in the cART era, the underlying neuropathology has shifted from overt subcortical involvement to
a more insidious cortical damage (Gannon et al., 2011). Various factors, such as poor adherence to drug
regimen, emergence of resistant virus species, and residual viral DNA in the CNS, may contribute to these
changes (Gannon et al., 2011). However, another likely contributor to HAND in the cART era is the
virtually unstudied potential for antiretroviral (ARV)-related toxicity in the CNS. cART has decreased
HIV-related morbidity and mortality by limiting T-cell loss and controlling opportunistic infections.
However, cART regimens are associated with potentially serious side-effects, including dyslipidemia,
lipohypertrophy, and increased risk of atherosclerosis (Vidal et al., 2010). Additionally, cART-associated
toxicity in the peripheral nervous system is well-documented, and it is likely that cART would trigger
similar responses in the CNS. Pharmacokinetic studies suggest limited ARV penetrance into the CNS and
indicate low cerebrospinal fluid (CSF) and parenchymal drug concentrations (Yilmaz et al., 2004, Yilmaz
et al., 2009). However, direct blood-brain barrier (BBB) compromise by viral proteins and
neuroinflammation and indirect BBB impairment due to concomitant factors, such as coexisting infections,
can lead to increased CSF and parenchymal drug concentrations. Thus, the impact of ARVs in the CNS of
HIV(+) patients is clinically relevant and must be examined.

Initial cART usually includes two nucleoside/nucleotide reverse-transcriptase inhibitors (NRTIs) in
combination with a non-nucleoside reverse-transcriptase inhibitor (nNRTI) or with a protease inhibitor (PI)
boosted with a low dose of a second PI, Ritonavir. NRTIs and nNRTIs bind to the HIV reverse
transcriptase enzyme and inhibit pro-viral DNA synthesis; PIs inhibit viral proteases needed for virus
maturation and assembly. Despite some crossover, certain ARV classes are more highly associated with
particular side effects and toxicities than are other classes. PIs alter lipid metabolism and induce the
endoplasmic reticulum stress response in macrophages, linking PIs to increased risk of atherosclerosis
(Touzet and Philips, 2010). NRTIs inhibit DNA polymerase-γ and lead to decreased mitochondrial DNA,
loss of mitochondrial membrane potential and oxidative phosphorylation, consequently precipitating
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oxidative stress (Nolan and Mallal, 2004). Previous studies exploring possible side effects of ARVs in the
CNS are scarce and mostly involve cell lines (Cui et al., 1997). Due to mutations and aberrations in
immortalized cell lines, these studies may not reflect the ARV toxicity potentially occurring in biological
settings. Peripheral dorsal root ganglia neurons are the only primary cell type of neural lineage previously
studied for ARV toxicity (Werth et al., 1994). In this report, we examined effects of ARVs in primary CNS
neurons both in vivo and in vitro. Our findings suggest that cART induces oxidative stress and
neurotoxicity in the CNS, and that the patients on long-term cART regimens would benefit from adjunctive
therapies that include antioxidant strategies to overcome deleterious effects of cART in the CNS.

3.3 MATERIALS AND METHODS
Chemicals and reagents. AIDS Research and Reference Reagent Program, Division of AIDS, NIAID,
NIH: antiretroviral reagents. Abcam (Cambridge, MA): mouse monoclonal NAD(P)H:quinone
oxidoreductase-1 (NQO-1) antibody (A180), mouse monoclonal synaptophysin antibody (SY38). BioRad
(Hercules, CA): Biosafe coomassie stain, Immunblot polyvinylidene fluoride (PVDF) membrane, prestained broad range molecular weight ladder. Cell Signaling Technology (Danvers, MA): rabbit polyclonal
antibody raised against cleaved caspase-3. Citifluor, Ltd. (London, UK): citifluor AF1. Covance (Princeton,
NJ): mouse monoclonal microtubule-associated protein 2 (MAP2) antibody (SMI-52). Dako (Carpinteria,
CA): rabbit polyclonal glial fibrillary acidic protein (GFAP) antibody (Z0334). Enzo Life Sciences
(Farmingdale, N.Y): rabbit polyclonal antibody to heme-oxygenase-1 (HO-1). Frontier Scientific (Logan,
UT): Sn(IV) mesophorphyrin IX dichloride (SnMP). Jackson ImmunoResearch Labs (West Grove, PA):
fluorescein isothiocyanate-conjugated goat anti-mouse IgG and Cy3- conjugated goat anti-rabbit IgG
secondary antibodies. Invitrogen (Carlsbad, CA): Dulbecco’s Modified Eagle’s Medium (DMEM),
tetramethyl rhodamine methyl ester (TMRM), goat anti-mouse beta-lactamase TEM-1 conjugate,
fluorocillin green substrate, dihydroethidium (DHE), 4',6-diamidino-2-phenylindole (DAPI), neurobasal
media, B27 supplement. New England Biolabs (Ipswich, MA): tyramide amplification system. Peptide
International (Louisville, KY): poly-L-lysine. Sigma Aldrich (St. Louis, MO):

carbonyl cyanide m-

chlorophenyl hydrazone (CCCP), cytosine arabinoside (Ara-C), fetal bovine serum (FBS), monomethyl
fumarate (MMF), oligomycin, propidium iodide and protease inhibitor cocktail. ScyTek Labs (Logan, UT):

73	
  

normal antibody diluent. Thermo Scientific (Waltham, MA): goat anti-rabbit horseradish peroxidase (HRP)
antibody and goat anti-mouse HRP antibody, SuperSignal West Dura extended duration substrate. Tocris
Bioscience (Ellisville, MO): thapsigargin. The antibody against calpain-cleaved spectrin was a generous
gift from Dr. Robert Siman (Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA).

Primary Cortical Neuroglial Cultures. Primary rat cortical neuroglial, pure neuronal, and pure astrocytic
cultures were isolated from embryonic day 17 Sprague Dawley rat pups, with modifications of protocols
previously described (Wilcox et al., 1994). Briefly, the cortical cell suspensions isolated from rat pups
following standard protocols were plated on poly-L-lysine coated T25 tissue culture flasks (2 x 106
cells/flask), 96-well tissue culture plates (0.5 x 105 cells/well), or glass coverslips (0.25 x 106 cells/well).
These cultures were maintained in neurobasal media with B27 supplement at 37°C with 5% CO2 for the
generation of neuroglial cultures, as described previously (Wang et al., 2010, Akay et al., 2011b, White et
al., 2011). Half of the media was replaced with fresh media every 7 days and the experiments were
performed at 21 days in vitro (DIV), at which time the cultures contain approximately 85-90% neurons and
10-15% astrocytes/glia. For the preparation of pure neuronal cultures, cultures were treated with 10µM
Ara-C 48 hours after plating and maintained in neurobasal media with B27 supplement at 37°C with 5%
CO2; at 21 DIV, the age at which the experiments were conducted, no astrocytes are detectable by staining
for GFAP. Pure astrocytic cultures were prepared by initially plating the cortical cell suspensions in 10%
fetal bovine serum (FBS) in DMEM and maintaining at 37°C with 5% CO2 for 7-12 days, after which time
astrocytes constitute more than 90% of the cultures. These pure astrocytic cultures are then re-plated in T25
flask or poly-L-lysine-coated glass coverslips in DMEM/10% FBS and the experiments are conducted 3-5
days after re-plating.

SIV/pigtail macaque model of HIV CNS Disease. Juvenile pigtailed macaques (Macaca nemestrina)
were inoculated with SIV/DeltaB670 and SIV/17E-Fr, as described previously (Zink et al., 1999).
Beginning 12 days after inoculation, animals were treated daily with a four ARV drug combination (cART)
until necropsy (range, day 161–175). The treatment consisted of the NRTI Tenofovir (Gilead) at 30 mg/kg
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subcutaneously every day; the PIs Saquinavir (Roche) and Atazanavir (Bristol- Myers Squibb) at 205 and
270 mg/kg orally twice a day, respectively; and the integrase inhibitor L-870812 (Merck) (Hazuda et al.,
2004) at a dose of 10 mg/kg orally twice a day (Zink et al., 2010). The Tenofovir dose was determined on
the basis of previous studies (Tsai et al., 1997), while Atazanavir and Saquinavir doses were determined by
pharmacokinetic experiments conducted in pigtailed macaques, and reflected those that resulted in the same
area under the curve as detected in humans treated with Atazanavir and Saquinavir (Zink et al., 2010). The
dose of the integrase inhibitor was based on a previous study conducted in rhesus macaques (Hazuda et al.,
2004).

Rodent model of antiretroviral-induced neurotoxicity. All surgical procedures were performed with the
approval of the Institutional Animal Care and Use Committee. Adult male Sprague Dawley rats were
catheterized via jugular vein, as described previously (Thrivikraman et al., 2002). The drug cocktail
composed of AZT (100mg/kg/day), Ritonavir (20mg/kg/day), and Saquinavir (25mg/kg/day) was
administered twice daily for 7 days by continuous intravenous injection. Each drug dose was based on
previously published studies in rodents (Shibata et al., 2002, Huisman et al., 2003, Manda et al., 2010,
Pistell et al., 2010, Waring et al., 2010, Yang et al., 2010, du Plooy et al., 2011, Fontes et al., 2011, LledoGarcia et al., 2011, Wagner et al., 2011, Mak et al., 2013, Reyskens and Essop, 2013a, b, Reyskens et al.,
2013). The catheters were flushed with 0.3 ml heparin (50 IU/ml) in PBS until the end of treatments. At
time of euthanasia, preceding decapitation and tissue harvest, catheter patency was re-verified by response
to pre-euthanasia sedation (100mg/kg ketamine/ 10mg/kg xylazine). The brains were removed, the frontal
cortex and the hippocampus were dissected on ice, and the tissue samples were stored at -80 °C until
immunoblot analysis.

Immunofluorescence Staining of Tissue. Tissue slides of paraffin-embedded tissue sections from
hippocampus of male and female pig-tailed macaques (Macaca nemestrina) were prepared for
immunofluorescent staining, as described previously (Akay et al., 2011a). Briefly, glass slides containing
paraffin-embedded sections (10 mm) were heated to 55°C for at least 30 min, deparaffinized in Histoclear,
and rehydrated with consecutive 100%, 95%, 90% and 70% ethanol washes. Endogenous peroxidase
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activity was blocked with 3% H2O2 in methanol and antigen unmasking was achieved with target retrieval
solution at 95°C for 1 h. Tissue sections were blocked with 10% normal goat serum in phosphate-buffered
saline solution (PBS). Mouse monoclonal antibodies to synaptophysin, MAP2, and rabbit polyclonal
antibody to GFAP were used at empirically defined dilutions (synaptophysin at 1:500, MAP2 at 1:100;
GFAP at 1:80), and DAPI was used to stain nuclei. The tyramide amplification system was used to detect
synaptophysin. Slides were mounted in Citifluor AF1, and for each specimen, 5-10 randomly selected areas
within the CA1-CA3 layer of the hippocampus were scanned along the z-axis to create z-stack images at
high-magnification (600X) by laser confocal microscopy on a Biorad Radiance 2100 equipped with Argon,
Green He/Ne, Red Diode, and Blue Diode lasers (Biorad, Hercules, CA). Post-acquisition analysis was
conducted using MetaMorph 6.0 (Universal Imaging, Downingtown, PA). Total intensity for
synaptophysin, MAP2 and GFAP were determined by the measurement of integrated pixel intensity for
synaptophysin, MAP2 or GFAP per z-stack image, where the integrated pixel intensity is defined as total
pixel intensity per image times the area of pixels positive for synaptophysin, MAP2 or GFAP. Averages are
expressed as mean ± SEM. All data was analyzed by Prism 5.0 (GraphPad Software, San Diego, CA).

MAP2 Cell-Based ELISA. A MAP2 cell-based ELISA was performed to quantify neuronal damage/death
as previously described (White et al., 2011). Briefly, primary rat cortical neuroglial cultures plated in 96well plates were fixed for 30 min with 4% paraformaldehyde in 4% sucrose at the conclusion of treatments.
After blocking for 1 hour with 5% normal goat serum in PBS, the plates were incubated with monoclonal
MAP2 antibody overnight at 4°C, followed by washes with PBS with 0.1% Tween-20 (PBS-T). The plates
were then incubated for 30 min with goat anti-mouse secondary antibody conjugated to beta-lactamase
TEM-1 at room temperature, washed with PBS-T, and incubated in the dark at room temperature for 1 hour
in fluorocillin green substrate. Fluorescence intensity was measured using a Fluoroskan Ascent fluorometer
plate reader (Thermo Electron, Waltham, MA) with excitation at 485 nm and emission at 527 nm.

Hand-Counting of MAP2-Positive Cells. As a complementary method to MAP2 ELISA, neuronal
survival was verified by hand-counting of MAP2-positive neurons. 15mM propidium iodide was added to
primary cortical neuroglial cultures grown on coverslips 15 minutes before the end of the treatments. The
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coverslips were washed once with PBS and fixed for 30 min with 4% paraformaldehyde in 4% sucrose,
followed by blocking and permeabilization in 0.2% BSA + 0.1% Triton X-100 in PBS for 1 hour at room
temperature (RT). The coverslips were then washed twice with PBS and incubated with anti-MAP2
antibody (1:100) in normal antibody diluent for 2 hours at RT. After two washes with PBS-T, the
coverslips were incubated in a fluorescein isothiocyanate-conjugated goat anti-mouse IgG secondary
antibody (1:200) for 30 min at RT. The coverslips were mounted on slides and alive/dead neurons were
hand-counted based on MAP2 and PI-positive staining using a Nikon Eclipse E400 fluorescent microscope
(Nikon Corp, Tokyo, Japan) equipped with Olympus DP70 digital camera (Olympus Corp, Tokyo, Japan).
Live cells stain negative for PI, while dead cells retain it in their nuclei. The number of surviving MAP2positive neurons will be positive for MAP2 and negative for PI staining. The percentage of MAP2-positive
cells ± SEM were calculated from blinded counting of six fields at 200X in two adjacent vertical columns
through the center of each coverslip, proceeding from top to bottom and bottom to top. For each condition,
three coverslips were counted from two or more independent experiments.

Quantification of Synaptophysin. Cultures grown on coverslips, as described above, were
immunofluorescently stained for synaptophysin (1:1000), MAP2 (1:100), and DAPI. Tyramide
amplification was used for the detection of synaptophysin. For each treatment condition, images of 10
randomly selected areas from 3 coverslips from 3 independent experiments were captured by fluorescence
microscopy. Post-acquisition analysis was performed using the NIH ImageJ program (V1.36b, Bethesda,
MD). Briefly, synaptophysin-positive puncta were detected by background subtraction and manual
thresholding. The number of synaptophysin-positive puncta was determined by dividing the total number of
puncta within a dendrite segment by the length of the segment.

Measurement of Reactive Oxygen Species. The superoxide indicator dihydroethidium (DHE, Invitrogen)
was used to detect the presence of reactive oxygen species in vitro. 3mM DHE was added to culture media
15 min prior to conclusion of treatments. Cells were then washed with PBS, fixed with 4%
paraformaldehyde in 4% sucrose at RT for 8 min, and stained for DAPI. The coverslips were then mounted
on slides with CytoSeal and visualized using fluorescent microscopy, as described above. Post-acquisition
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analysis was performed using MetaMorph to determine the fluorescence intensity of DHE normalized to
the area of DAPI signal.

Immunoblotting. Whole cell extracts of rat tissue samples were prepared by homogenization in ice-cold
tissue extraction buffer (50mM Tris pH 7.5, 0.5M NaCl, 1% NP-40, 1% SDS, 2mM EDTA, 2mM EGTA,
5mM NaF, 0.4mM Na3VO4, 1mM dithiothreitol (DTT) and 1:100 protease inhibitor cocktail), followed by
centrifugation at 12,000 g at 4oC for 20 min. Whole cell extracts of primary rat cortical cultures were
prepared with ice-cold cell lysis buffer (50mM Tris pH 7.5, 120 mM NaCl, 0.5% NP-40, 10 mM EDTA,
0.4 mM Na3VO4, 100 mM DTT and 1:100 protease inhibitor cocktail), followed by centrifugation at 14,000
g at 4oC for 10 min. The protein concentrations of the collected supernatants were determined using the
Bradford method and 25-50 µg of protein was loaded into each lane of a 4-12% Bis-Tris gradient gel for
separation. A broad range molecular weight ladder was run on each gel. Subsequent to separation, proteins
were transferred onto PVDF membranes, and blocked in tris-buffered saline (TBS) with 0.1% Tween-20
(TBS-T) and 5% bovine serum albumin (BSA) for 1 hour at room temperature. The membranes were
incubated with the primary antibodies in TBS-T with 5% BSA at 4oC overnight, washed with TBS-T,
followed by incubation with corresponding HRP-conjugated secondary antibodies. The membranes were
developed using SuperSignal West Dura extended duration substrate. Loading controls were obtained by
staining the membranes and the gels with the Biosafe Coomassie Stain for 20 min, followed by destaining
with deionized water for 30 min. For densitometric analysis, autographs were scanned into Adobe
Photoshop (Adobe Systems, San Jose, CA) and regions of interests (ROI) of equal size were determined for
each band. The pixel intensities of ROIs were quantified using the NIH ImageJ program (V1.36b,
Bethesda, MD). Target band intensities were normalized to gel and membrane coomassie stain controls to
account for protein degradation and loading discrepancies, and the normalized target band intensities were
used to quantify fold changes over controls.

Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR). The expression of HO-1
and NQO-1 genes in rat neuroglial cells was quantified by qRT-PCR. Custom TaqMan® Gene Expression
Assays were purchased from Applied Biosystems for the genes: NQO-1 (Rn00566528_m1) and HO-1
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(Rn01536933_m1). Approximately 5ng cDNA was used per reaction. StepOne™ Software v2.0 was used
to construct the experimental protocol and the qRT-PCR took place in the StepOne Real-Time PCR System
(Applied Biosystems, Carlsbad, CA). Data was normalized using both b-actin (Rn00667869_m1) and 18S
(Hs99999901_s1) and was analyzed according to the ΔΔCT method. All samples were run in triplicate from
three biological replicates.

Statistical analysis. All data was analyzed by Prism 5.0 software (GraphPad Software, San Diego, CA).
Values are expressed as mean ± SEM, and values of p < 0.05 were considered significant for all statistical
analyses performed.

3.4 RESULTS
Antiretroviral drugs lead to neuronal damage in vivo
cART-induced peripheral neuropathy is well-documented (Power et al., 2009), and it is likely that cART
triggers similar damage to neurons in the CNS. To determine the neurotoxic potential of cART in the CNS,
we assessed the effects of an ARV regimen on the expression of synaptophysin and MAP2, indicators of
synaptic damage and neuronal loss, respectively, utilizing post-mortem tissue from a well-characterized
SIV/pigtail macaque model of HIV CNS disease, which was designed to address the efficacy of CNS
penetrant antiretroviral therapy in reducing viral load in the CNS (Zink et al., 2010). In this study, animals
infected with SIV either received no cART or received early cART treatment that included Tenofovir
(NRTI), Atazanavir (PI), Saquinavir (PI), and L-870812a (integrase inhibitor) 12 days after the virus
inoculation. Without cART, 90% of animals develop neurologic disease within 3 months post-inoculation
(p.i.). In contrast, animals receiving cART do not develop SIV encephalitis. Rather, they show a rapid
reduction in their plasma and CSF viral load followed by continued suppression of SIV replication with
maintenance of CD4+ T cell counts until elective euthanasia around day 160 p.i. Additionally, cARTtreated animals do not exhibit any outward signs of neurological deficits. Further, our quantitative
immunofluorescent analysis of hippocampal tissue sections revealed reduced astrogliosis in the
hippocampus of SIV-infected, cART-treated animals (SIV(+)/cART), compared with SIV-infected
macaques that did not receive cART ((SIV(+)/placebo)) (Figure 3.1B). However, we observed statistically
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significant decreases in synaptophysin expression in the hippocampi of the SIV(+)/cART group, compared
with that in either the uninfected or the SIV(+)/placebo group (Figure 3.1A and 3.1D). In addition,
examination of the expression of a second marker of synaptodendritic integrity, calmodulin kinase II
(CaMKII), by immunoblotting showed that CaMKII levels were significantly lower in the frontal cortex in
the SIV(+)/cART macaques than in their SIV(+)/placebo counterparts (Figure 3.1E and 3.1F). CaMKII is
highly expressed in neurons of macaque hippocampus and frontal cortex, whereas its expression in other
cell-types, including microglia, infiltrating macrophages, and multinucleated giant cells, is minimal; thus,
the differences in CaMKII expression in frontal cortex of the animals from our experimental groups are
neuron-specific (Gupta et al., 2010). Our results demonstrate synaptic injury in the presence of cART
despite effective control of SIV replication in the periphery and CNS. Interestingly, we did not observe
changes in MAP2 fluorescence in the hippocampus of infected and/or cART-treated animals compared
with untreated/uninfected animals (Figure 3.1A and 3.1C).

As studies of uninfected, cART-treated macaques have not been performed to determine the contribution of
cART to neuronal damage independent of SIV infection, we administered combinations of ARVs
intravenously to adult rats. In patients, initial cART usually includes two nucleoside/nucleotide reversetranscriptase inhibitors (NRTIs) in combination with a non-nucleoside reverse-transcriptase inhibitor
(nNRTI) or with a protease inhibitor (PI) boosted with a low dose of a second PI, Ritonavir (Rit). Thus, we
used Zidovudine (AZT), an NRTI, along with two PIs, Saquinavir (Saq) and Rit, at doses based on
previously published pharmacokinetic studies of these ARVs (Busidan and Dow-Edwards, 1999,
Kageyama et al., 2005, Pistell et al., 2010). In agreement with previous studies (Waring et al., 2010), the
animals showed no overt signs of distress during the course of the treatment. However, via
immunoblotting, we observed decreases in hippocampal synaptophysin expression in cART-treated rats
compared with vehicle-treated rats (Figure 3.1G), complementing our findings of synaptic damage in
SIV(+)/cART macaques and further supporting a role for ARV-associated neuronal injury in the CNS. Of
note, we also detected decreases in MAP2 levels in the cART-treated rat hippocampus (Figure 3.1G),
which likely reflects the acute drug toxicity in this treatment paradigm, compared to the subtler synaptic
injury observed in the cART-treated macaque brain.
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Antiretroviral compounds in therapeutically relevant combinations are neurotoxic in vitro
The only primary neural cell-type previously studied for ARV toxicity was dorsal root ganglia neurons in
models of peripheral neuropathy (Werth et al., 1994). Here, to expand our studies on ARV neurotoxicity in
the CNS, we used primary rat cortical neuroglial cultures aged 21 days in vitro (DIV) (O'Donnell et al.,
2006, Wang et al., 2007, White et al., 2011). We first evaluated the neuronal viability in response to
increasing concentrations of AZT, Rit, or Saq. We based the range of doses on reported plasma and CSF
levels of ARVs (Wynn et al., 2002, Anthonypillai et al., 2004). Importantly, animal studies predict brain
parenchymal levels to be equal to or greater than CSF levels (Anthonypillai et al., 2004, Anderson and
Rower, 2010). At 48 hours post-treatment with individual ARVs, Rit and Saq both led to dose-dependent
decreases in MAP2-positive cells, as determined via hand-counting (Figure 3.2A and 3.2B, respectively).
These results were confirmed with a cell-based MAP2 ELISA, which accurately reflects neuronal numbers,
as well as neuronal damage (Figure 3.2D and 3.2E) (White et al., 2011). Furthermore, neuronal damage and
death induced by Rit and Saq was time-dependent, as seen in Figure 2G, where the primary cortical
cultures were exposed to individual ARVs for up to eight days. Additionally, both Rit and Saq led to dosedependent decreases in synaptophysin expression after 16 hours of treatment, well before the loss of
MAP2-positive cells occurred (Figure 3.2H and 3.2I). However, AZT did not lead to decreases in MAP2positive cells, MAP2 fluorescence, or synaptophysin expression (Figure 3.2C, 3.2F, and data not shown,
respectively). Next, we treated primary cortical cultures with drug combinations that included AZT, Rit,
and Saq, alone or in combinations, for 48 hours, to assess acute neurotoxicity. As seen in Figure 3.2J and
3.2K, combination treatments that included Rit induced statistically significant neuronal damage/death,
which were preceded by loss of synaptophysin detected at 16 hours post-treatment (Figure 3.2L).
Additionally, we observed similar levels of neuronal damage in cortical cultures treated with a combination
of d4T, Rit, and Saq (not shown). However, as d4T is no longer prescribed in most developed countries and
the AZT/Rit/Saq combination reflects the first considered/prescribed combination in initial treatment plans,
we focused on AZT/Rit/Saq combination treatments for further experiments. Next, we determined that
treatment with either Rit or Saq, alone or in combination with AZT, lead to the activation of the Ca2+activated death protease, calpain, as evidenced by the increase of calpain-cleaved spectrin observed in these
cultures (Figure 3.3). Interestingly, none of the treatment combinations caused increases in the cleaved, and
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therefore active, form of caspase-3 (Figure 3.3), suggesting that neuronal death observed in our model may
be a necrotic cell death rather than an apoptotic cell death. Together the findings presented here suggest
that combination ARV treatments that include PIs are toxic to cortical neurons in vitro.

Combination antiretroviral drug treatments induce oxidative stress in neurons
An extensive number of studies have linked ARVs, especially PIs, to oxidative stress (Touzet and Philips,
2010). To determine whether neurons undergo oxidative stress when exposed to ARVs, we used
dihydroethidium (DHE) as a marker for the presence of reactive oxygen species (ROS) (Rodriguez-Pallares
et al., 2009). We included tert-Butyl hydroperoxide (tBHP), an organic pro-oxidant, at 100 mM, as a
positive control. As seen in Figure 3.4A and quantified in Figure 3.4D, Rit/Saq and AZT/Rit/Saq
combination drug treatments for 6 hours lead to ROS accumulation in cortical cultures, whereas ROS levels
in vehicle-treated cultures were comparable to those in untreated cultures.

The cortical cultures generated for our studies contain 85-90% neurons and 10-15% astrocytes (Figure
3.4B); thus, we also determined the presence of ROS in pure neuronal and pure astrocytic cultures exposed
to individual ARVs. As seen in Figure 3.4C and quantified in Figure 3.4E, Rit led to an early and sustained
ROS production in pure neuronal cultures, while Saq-induced ROS accumulation occurred 24 hours after
treatment. The transient ROS accumulation induced by AZT was resolved at 24 hours post-treatment. On
the other hand, in pure astrocytic cultures, none of the three ARVs examined induced an appreciable
sustained ROS generation, and only Rit caused a transitory ROS accumulation (Figure 3.5A and 3.5B).
These data further suggest that the ARV-induced ROS production observed in primary cortical neuroglial
cultures are occurring in neuronal cell populations.

Endogenous antioxidant response activation by combination antiretroviral drugs
Oxidative stress in cells triggers the transcriptional induction of oxidative stress responsive genes through
the activation of the endogenous antioxidant response element (ARE) in their promoter regions (Chen and
Kong, 2004). Thus, we determined the effect of ARVs on two such genes, NAD(P)H:quinone
oxidoreductase-1 (NQO-1) and heme oxygenase-1 (HO-1). By quantitative reverse transcription
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polymerase chain reaction (qRT-PCR), we observed increased mRNA levels of both NQO-1 and HO-1 in
cultures treated with any of the tested combinations of ARVs, when compared with the levels in untreated
cultures (Figure 3.6A and 3.6B, respectively), with the most striking increases observed in Rit/Saq-treated
cultures. To determine whether the changes in the mRNA levels were reflected in protein levels, we used
immunoblotting to examine protein levels of NQO-1 and HO-1. While we observed increases in NQO-1
and HO-1 protein levels at 16h (Figure 3.6C), the changes were more robust in cultures treated for 48 hours
(Figure 3.6D). Further, in vivo, we detected increased levels of HO-1 protein in hippocampal lysates from
cART-treated rats (Figure 3.6E and 3.6F). Interestingly, NQO-1 levels were not increased in cART-treated
rat hippocampus (Figure 3.6E). Of note, we did not observe an antioxidant response in ARV-treated pure
astrocytic cultures (Figure 3.5C, D and E). These data collectively suggest an activation of HO-1, as part of
the endogenous antioxidant response, following ARV treatments in neurons.

Monomethyl fumarate (MMF) protects against ROS generation and induces activation of the
endogenous antioxidant response
NQO-1 and HO-1 are targets of the fumaric acid ester, dimethyl fumarate (DMF), and of its hydrolyzed and
active metabolite, monomethyl fumarate (MMF) (Linker et al., 2011). Our recent study (Cross et al., 2011)
has shown that DMF and MMF reduce neurotoxin release from HIV-infected macrophages through
induction of HO-1. We reasoned that augmented or earlier induction of NQO-1 and HO-1 in neurons by
pre-treatment with the active metabolite, MMF, would provide protection in our in vitro model of ARVinduced neurotoxicity through an antioxidant effect. We first determined that MMF at 30-100 mM was not
toxic in neuronal cultures, as determined by MAP2 ELISA (data not shown). Next, we pre-incubated
primary cortical cultures with 100 mM MMF for 30 minutes before adding either Rit/Saq or AZT/Rit/Saq.
Pre-incubation with MMF blocked ROS generation induced by ARV treatments lasting 6 hours (Figure
3.7A), 16 hours, and 48 hours (data not shown). Quantification showed ROS levels in cultures preincubated with MMF to be comparable to those detected in untreated and vehicle-treated cultures (Figure
3.7B). Further, we observed an early increase in HO-1 protein levels at 4 hours in cultures pre-incubated
with MMF, whether or not pre-treatment was followed by ARV treatment (Figure 3.7C). This trend was
sustained at 16 hours after combination ARV treatment, as well. Next, we determined whether augmenting
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the endogenous antioxidant response by MMF blocks MAP2 loss induced by combination ARV treatments.
As detected by the cell-based MAP2 ELISA, MMF blocked neuronal damage/death in cultures treated with
Rit/Saq and AZT/Rit/Saq for 72 hours (Figure 3.7D). Finally, pre-treatment of the cultures with an HO-1
inhibitor, Sn(IV) mesophorphyrin IX dichloride (SnMP) (Zhao et al., 2004), reversed the MMF-induced
decreases in ROS accumulation (Figure 3.7E), suggesting that MMF protection occurs through its
augmentation of HO-1 expression.

3.5 DISCUSSION
Virus-related factors, such as resistant virus species and persistent viral DNA in the CNS, may contribute to
the persistence of HAND in the post-cART era. One recent focus in HIV neurovirology is the development
of ARVs with greater CNS penetrance (Letendre et al., 2008, Marra et al., 2009, Tozzi et al., 2009, Edén et
al., 2010, Heaton et al., 2010, Garvey et al., 2011, Smurzynski et al., 2011). However, potential ARV
toxicity in the CNS remains largely unexplored. Our study supports a possible contribution of the ARVs
themselves to neuronal and synaptic damage observed in patients with HAND.

In this study, we show cART-induced synaptophysin loss, indicative of synaptic injury in two animal
models. In our first model, in an in vivo model of SIV-infected pig-tailed macaques, we report decreased
synaptophysin and CaMKII levels in the SIV(+)/cART group compared with uninfected or SIV(+)/placebo
groups, indicating synaptodendritic damage. Interestingly, MAP2 levels did not change significantly across
groups, which may be due to the relatively short duration of infection in this retrospective study cohort.
While these data demonstrate potential effects of cART drugs in the presence of viral infection, there are
three variables to consider in interpretation of these findings: 1) the time to euthanasia from the start of the
experiments is different between SIV(+)/placebo and SIV(+)/cART groups, 2) persistent viral DNA in the
CNS of SIV(+)/cART group, and 3) the lack of SIV(-)/cART group. It is not yet known whether brain SIV
DNA is replication competent. As we utilized post-mortem samples obtained from a cohort of macaques
enrolled in a previous study addressing the efficacy of CNS penetrant cART in reducing viral loads in the
CNS, further experiments that include an additional control group receiving cART but not inoculation with
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SIV will be instrumental to more clearly determine the contribution of viral DNA and cART to synaptic
damage in this model.

In the second in vivo model presented here, adult rats received a therapeutically relevant combination of
ARVs (NRTI+PI+Rit boost). In the small number of studies where pharmacokinetics and effects of ARVs
in the CNS were examined, pathological read-outs of neuronal damage, such as MAP2 or synaptophysin
loss, were not determined (Huisman et al., 2003, Anthonypillai et al., 2004, Anthonypillai et al., 2006).
Synaptic injury is a known indicator of neuronal damage and dysfunction in various neurodegenerative
diseases, including HAND (Gupta et al., 2010) and synaptodendritic injury persists in HIV-infected
individuals in the post-cART era (Xu and Ikezu, 2009). We observed decreases in synaptophysin and
MAP2 protein levels in the hippocampus in response to ARV administration over 7 days. Thus, our model
demonstrates that ARV-associated neurotoxicity warrants consideration in developing therapeutic regimens
for HIV-infected patients.

We also show that the PIs, Rit and Saq, alone or in combinations with the NRTI, AZT, induce oxidative
stress and neuronal damage/death in primary cultures at clinically relevant doses. Previous studies
examined ARV-induced toxicity in cell lines, and Robertson et al. have provided the first evidence for
ARV-induced neurotoxicity in primary rat neurons (Robertson et al., 2012). Here, we provide further
evidence that PI-induced oxidative stress and neuronal death in primary neurons can be blocked by the
activation of the endogenous antioxidant response. Interestingly, in our experimental paradigm, the NRTI,
AZT, neither induced neuronal damage/death by itself, nor augmented PI-induced damage/death when used
in combination. We observed similar effects from a combination using another NRTI, stavudine (d4T) (not
shown). In agreement with our observations, a previous study presented similar findings, specifically that
neither AZT nor d4T inhibited cell growth or neurite regeneration in PC-12 cells after long-term drug
exposure (Cui et al., 1997). It should be noted that NRTIs are unequivocally tied to peripheral neuropathy,
where the underlying pathology is mitochondrial toxicity and oxidative stress. However, NRTIs affect only
certain cell populations, as they are formulated as pro-drugs and, to become active, need to be
phosphorylated by two kinases, thymidine kinase 1 and 2 (TK1, TK2), and the expression of the
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cytoplasmic TK1 is cell cycle-dependent (Bazzoli et al., 2010). Thus, in our model utilized to study postmitotic neurons, AZT is most likely not converted to its active form, and thus does not contribute to
neuronal damage/death. It is of note that our in vitro model of ARV-induced neurotoxicity utilized primary
neuroglial cultures rather than cell lines. Primary cells are untransformed, and therefore more accurately
reflect and predict ARV-associated effects occurring in the brains of patients on cART than would
immortalized cell lines. The molecular pathways we investigated in this study are highly conserved from
yeast to human cells; thus, the results obtained here in cells of rodent origin are likely conserved in human
cells as well.

The drug concentrations used in this study are based on the plasma and cerebrospinal fluid (CSF) levels
reported by various in vitro and in vivo studies (Huisman et al., 2003). As reported in such studies, AZT
can be detected in the CSF at concentrations that are similar to those measured in the plasma (Wynn et al.,
2002). Contrarily, as backed by various in vitro and in vivo studies (Wynn et al., 2002), both Rit and Saq
are predicted to have limited CNS penetrance due to the strong tendency of these drugs to bind plasma
protein because of their lipophilic nature and pharmacokinetic properties. However, a comprehensive study
conducted in an in situ guinea pig model suggests that Rit can achieve high concentrations in choroid
plexus and parenchyma through diffusion via the choroid plexus; in fact, the levels of Rit were comparable
to levels measured in plasma (Anthonypillai et al., 2004). Further, the study showed that, surprisingly, the
CSF levels of Rit were lower than the levels measured in the choroid plexus and the parenchymal
compartments. Thus, the authors concluded that CSF concentrations of Rit may not necessarily reflect the
parenchymal levels, which are indeed a better indicator of effective drug levels in the CNS. Rit and Saq
concentrations in our experiments fall well within plasma ranges reported in patients receiving cART.

Evidence of oxidative stress has long been associated with the most severe forms of HAND (Ngondi et al.,
2006, Mielke et al., 2010). Interestingly, despite systemic control of viral replication in cART-treated
patients, markers of oxidative stress, such as elevated levels of lipid and protein oxidation, are still
detectable in the brains of these individuals (Ances et al., 2008). Of note, oxidative stress is one of the
underlying mechanisms involved in NRTI and PI-induced toxicity in the periphery. Our data suggest that
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the sustained ROS accumulation in neurons due to prolonged exposure to ARVs might induce the oxidative
stress associated with cART-induced toxicity in the CNS, leading to the observed changes in synaptophysin
levels and the subsequent neuronal death.

Our data also suggests that astrocytes do not show either ROS accumulation or the endogenous antioxidant
response in vitro. We also observe that astrogliosis in SIV-infected animals is resolved in cART-treated
animals. While these findings suggest that astrocytes may not be highly impacted by ARVs in the short
term, it is possible that prolonged exposure to ARVs might overwhelm astrocytes, which help buffer ROS
accumulation in neurons under normal conditions, precipitating further neuronal damage.

We further show that the ARV drug-induced effects observed in this study can be blocked by MMF via
activation of an endogenous antioxidant response. Cells respond to oxidative stress by activating the
transcription of a subset of genes in an effort to clear excess ROS within the cell. Among these genes are
NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1) and heme oxygenase 1 (HO-1) (Chen and Kong,
2004). Here, we show increased levels of NQO-1 and HO-1 mRNA and protein in ARV-treated neuronal
cultures. Additionally, pre-treatment of cultures with MMF led to further increases in HO-1 protein levels
in ARV-treated cultures and provided protection against ARV-induced toxicity. Finally, our finding that the
protection provided by MMF is reversed with chemical inhibition of HO-1 further provides evidence that
ARV toxicity is mediated via induction of oxidative stress. The neuronal damage and death that occurs
despite the cellular initiation of the endogenous antioxidant response following exposure to ARVs suggests
that this response may be insufficient or too delayed to protect cultures from ARV toxicity. In support of
this explanation, we observed that MMF-mediated augmentation of antioxidant responses is strongly
protective against the neurotoxic effects of ARVs. Further studies using this in vitro model are warranted to
determine whether other clinically relevant ARV drug combinations induce neurotoxicity and, if so, to
establish whether similar pathways are involved.

DMF, a psoriasis treatment used in Europe since 1994, is currently being tested as a disease-modifying
agent for Multiple Sclerosis (MS) ((2011), Krieger, 2011, Linker et al., 2011). MMF is the active DMF
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metabolite in vivo. Our report is the first to show MMF as a neuroprotectant against ARV-induced damage.
Data from studies in MS patients show that DMF/MMF has good tolerability, can cross the blood-brain
barrier efficiently, and has relatively few and minor side-effects. Further, we have recently shown that
DMF suppresses HIV replication, induces the antioxidant response in macrophaghes, and blocks
neurotoxin release from macrophages (Cross et al., 2011). Overall, our findings make this
immunomodulatory and antioxidant agent a good potential adjunctive therapeutic for use in HAND.

One of the paradoxical outcomes of cART is the persistence of HAND, despite successful viral control.
Moreover, there is a shift from overt dementia to more subtle neurocognitive impairments. Based on data
presented here, we propose that different mechanisms by which HIV infection and cART induce neuronal
damage underlie the changing neuropathology of HAND. Extensive studies have shown that during
lentiviral infection, viral proteins and soluble factors secreted by infected cells lead to neuronal and
synaptic damage via several direct as well as indirect mechanisms involving several cell types, including
astrocytes. However, our data suggests that cART-mediated synaptic damage may involve direct
mechanisms occurring specifically in neurons, such as oxidative stress, and that neurons, and not
astrocytes, are the primary targets of cART-mediated damage in the CNS.

It is most likely that chronic exposure to cART regimens including neurotoxic ARVs over many years is
associated with a slower, nonetheless insidious changes including synaptic damage in the absence of
neuronal loss, and these neuronal perturbations may contribute to, and may even precipitate, some of the
clinical and pathological changes observed in the chronic course of HAND in the cART era. While
detrimental, such slow damage also suggests that alterations in cART regimens to include ARVs with low
neurotoxicity profiles, such as NRTIs or nNRTIs may halt synaptic damage, and provide a point where
previous damage may be reversed, either due to the withdrawal of the toxic drug, or with the help of an
adjuvant, such as fumaric acid esters. Future studies, first in primates, then in humans, will be crucial to
explore the specific impact of treatment interruption on recovery from cART-mediated neuronal damage
and to determine the efficacy of potential adjunctive therapies necessary to mitigate the side effects of
cART in the CNS.
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Figure 3.1 Antiretroviral drugs induce neuronal damage in vivo
(A, B, C and D) Formalin-fixed, paraffin-embedded tissue sections from hippocampus of pig-tailed
macaques that were either uninfected (n=6), SIV-infected but not cART-treated (n=7), or SIV-infected and
treated with cART (Tenofovir, Atazanavir, Saquinavir, and L-870812a) (n=4) were prepared for
immunofluorescent analysis and were triple-labeled for MAP2 (red), synaptophysin (green) and GFAP.
Sections were visualized by laser confocal microscopy and images were quantified for MAP2,
synaptophysin and GFAP expression. (A) Representative composite images of two cases per group which
were stained with MAP2 and synaptophysin are shown. Scale bar = 30µm. (B) Quantification shows the
resolution of GFAP immunoreactivity in SIV(+)/cART group, compared with SIV(+)/placebo group (OneWay ANOVA, *p<0.05). No changes were observed in MAP2 expression between groups (C), but there
were statistically significant decreases in synaptophysin immunoreactivity (D) in SIV(+)/cART group, as
compared with SIV(+)/untreated and uninfected groups (One-Way ANOVA, *p<0.05, ns: not significant).
(E and F) Fresh-frozen tissue sections from the frontal cortex of pig-tailed macaques that were either
uninfected (n=3), SIV-infected but not cART-treated (n=6), or SIV-infected and cART-treated (n=6) were
used for standard protein extraction and subsequent immunoblotting for the expression of CaMKII. Actin
was used as a loading control. A representative immunoblot is shown. Quantification shows statistically
significant decreases in CaMKII in the cART-treated group, as compared with the uninfected group or the
SIV(+)/untreated group (One-Way ANOVA, *p<0.05) (G) Whole-cell lysates prepared from hippocampus
of rats treated for 7 days with AZT/Rit/Saq (n=4) or vehicle (n=2) were immunoblotted for synaptophysin
and MAP2. A band from the coomassie blue staining is included to control for equal loading and protein
degradation.
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Figure 3.2 Therapeutically relevant combination antiretroviral drug treatments are neurotoxic in
vitro
(A, B, and C) Primary rat cortical neuroglial cultures aged 21 days in vitro (DIV) on coverslips were
exposed to Rit (A), Saq (B), or AZT (C) at increasing doses for 48 hours, followed by hand-counting for
MAP2-positive cells. (n=3, vehicle: 0.04% DMSO, *p<0.05, One-Way ANOVA with post-hoc NewmanKeuls). (D, E and F) 21DIV primary neuroglial cultures grown in 96-well plates were treated with
increasing doses of Rit (D), Saq (E), or AZT (F) for 48 hours, followed by MAP2 cell-based ELISA (n=2,
vehicle: 0.04% DMSO, *p<0.05, One-Way ANOVA with post-hoc Newman-Keuls). (G) Primary
neuroglial cultures were treated with AZT (25 mM), Rit (10 mM), or Saq (1 mM) at day zero. 90% of the
media was changed with conditioned media supplemented with a fresh drug stock every two days and
cultures were analyzed by MAP2 cell-based ELISA at days 4 and 8 (n=2, vehicle: 0.04% DMSO, *p<0.05,
One-Way ANOVA with post-hoc Newman-Keuls). (H and I) Cultures grown on coverslips were exposed
to the indicated treatments and synaptophysin-positive puncta were determined (n=3, vehicle: 0.04%
DMSO, *p<0.05, One-Way ANOVA with post-hoc Newman-Keuls). (J and K) Primary neuroglial
cultures were exposed to the indicated drug combinations (AZT: 25 mM, Rit: 10 mM, Saq: 1 mM) for 48
hours, followed by hand-counting for MAP2-positive cells (J) or MAP2 cell-based ELISA (K) (n=2,
vehicle: 0.04% DMSO, *p<0.05, # p<0.01, One-Way ANOVA with post-hoc Newman-Keuls). (L) Primary
neuroglial cultures that were exposed to the indicated drug combinations (AZT: 25 mM, Rit: 10 mM, Saq:
1 mM) for 16 hours were analyzed for synaptophysin-positive puncta (n=2, vehicle: 0.04% DMSO,
*p<0.05, One-Way ANOVA with post-hoc Newman-Keuls).
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Figure 3.3 Activation of Calpain in antiretroviral drug-treated neurons
Whole cell lysates were prepared from neuroglial cultures treated with the indicated single or combination
drugs (AZT: 25 mM, Rit: 10 mM, Saq: 1 mM), or with Thapsigargin (1mM) as a positive control, for 48
hours. Calpain activation was assessed using an antibody to detect the accumulation of calpain-cleaved
spectrin and an antibody raised against the cleaved and active form of caspase-3 was used for detection of
caspase activity. A band revealed by coomassie staining of the gel was used as a loading control (n=2,
vehicle: 0.04% DMSO).
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Figure 3.4 Combination antiretroviral drug treatments induce oxidative stress in neurons.
(A and D) Cortical neuroglial cultures grown on coverslips were treated for 6 hours with the indicated
drugs (AZT: 25 mM, Rit: 10 mM, Saq: 1 mM) and the presence of reactive oxygen species was detected by
DHE staining (red fluorescence)
(A) The images were captured with epifluorescent microscopy with uniform settings. (D) Quantification of
DHE fluorescence was generated by measurement of DHE pixel intensity per DAPI area (n=3; *p<0.05,
#p<0.01, One-Way ANOVA, post-hoc Newman-Keuls).
(B) Cortical neuroglial cultures grown on coverslips for 21 days and exposed to the indicated treatments
(AZT: 25 mM, Rit: 10 mM, Saq: 1 mM) were immunofluorescently labeled for MAP2 (green) and GFAP
(red). Note that the cultures are enriched for neurons.
(C) 21DIV pure cortical neuronal cultures grown on coverslips were treated with AZT (25 mM), Rit (10
mM), or Saq (1 mM) for 2, 12 or 24 hours. The presence of reactive oxygen species was detected by DHE
staining (red fluorescence) and MAP2 was used to stain neurons (green fluorescence). (E) The images
captured with confocal microscopy with uniform settings were analyzed for DHE pixel intensity per DAPI
area (n=3; *p<0.05, One-Way ANOVA, post-hoc Newman-Keuls).
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Figure 3.5 Antiretroviral drugs do not induce an endogenous antioxidant response in astrocytes.
(A) Pure astrocytic cultures grown on coverslips were treated with AZT (25 mM), Rit (10 mM), or Saq (1
mM) for 2, 12 or 24 hours. The accumulation of reactive oxygen species was detected by DHE staining
(red fluorescence) and GFAP was used to label astrocytes (green fluorescence). (B) The images captured
with confocal microscopy with uniform settings were analyzed for DHE pixel intensity per DAPI area
(n=3; *p <0.05, One-Way ANOVA, post-hoc Newman-Keuls). (C, D and E) Whole-cell lysates from pure
astrocytic cultures treated with the indicated drugs (AZT: 25 mM, Rit: 10 mM, Saq: 1 mM) for 16h were
immunoblotted for HO-1 and NQO-1. Representative blots from 3 independent experiments are shown in
(C). Coomassie staining of gels were used as loading controls and fold changes over untreated lysates were
determined. The quantification of HO-1 and NQO-1 band intensities from three independent experiments is
shown in (D) and (E) (n=3; *p <0.05, One-Way ANOVA, post-hoc Newman-Keuls).
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Figure 3.6 Combination antiretroviral drug treatments induce the endogenous antioxidant response
(A and B) Cortical neuroglial cultures were exposed to the indicated treatments (AZT: 25 mM, Rit: 10
mM, Saq: 1 mM) for 6 hours to determine changes in NQO-1 (A) and HO-1 (B) mRNA levels. A
representative of three experiments is shown. Actin was used as internal control and fold changes were
determined by the ΔΔCT method (*p<0.0001, One-Way ANOVA, post-hoc Newman-Keuls). (C and D)
Whole-cell lysates from cortical neuroglial cultures treated with the indicated drug combinations (AZT: 25
mM, Rit: 10 mM, Saq: 1 mM) for 16 and 48h were immunoblotted for NQO-1 (C) and HO-1 (D).
Representative blots from 3 independent experiments are shown. Coomassie staining of gels were used as
loading controls and fold changes over untreated lysates are indicated below each band of interest. (E and
F) Whole-cell lysates prepared from hippocampus of rats treated for 7 days with AZT/Rit/Saq (n=4) or
vehicle (n=2) were immunoblotted for HO-1 and NQO-1 (E) and fold change in HO-1 protein levels in the
cART group compared with the vehicle group is shown (F) (*p<0.05, Student’s t-test).
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Figure 3.7 MMF induces activation of a cellular antioxidant response and blocks neuronal
damage/death
(A) In the absence (upper panel) or presence (lower panel) of MMF (100 mM), 21 DIV rat neuroglial
cultures on coverslips were treated for 6 hours with the Rit/Saq, AZT/Rit/Saq (AZT: 25 mM, Rit: 10 mM,
Saq: 1 mM), or were left untreated. ROS generation was detected by DHE staining (red fluorescence). (B)
Quantification of nuclear DHE was done as described above (n=3, *p<0.01, One-Way ANOVA with posthoc Newman-Keuls). (C) Whole cell lysates of cultures exposed to Rit/Saq or AZT/Rit/Saq treatments
(AZT: 25 mM, Rit: 10 mM, Saq: 1 mM) in the absence or presence of MMF (100 mM) for 4 or 16 hours
were immunoblotted for HO-1. A representative blot from 3 independent experiments is shown. A
coomassie band from the gel was used as loading control. Quantification of band intensities is shown under
each corresponding lane. (D) Primary cortical neuroglial cultures were either pretreated with MMF (100
mM) for 30 min or received no pre-treatment; cultures were then treated with Rit/Saq or AZT/Rit/Saq
(AZT: 25 mM, Rit: 10 mM, Saq: 1 mM) for 72 hours to assess neuronal damage/death by MAP2 ELISA
(n=3; vehicle=0.04% DMSO; *p<0.05 vs. untreated, @p<0.05 vs. Rit/Saq, #p<0.05 vs. AZT/Rit/Saq, OneWay ANOVA with post-hoc Newman-Keuls). (E) Primary cortical neuroglial cultures were pre-incubated
with SnMP (20 mM) and/or MMF (100 mM) for 30 min before the addition of the indicated antiretroviral
drugs (AZT: 25 mM, Rit: 10 mM, Saq: 1 mM) and were assessed for nuclear DHE accumulation at 16
(n=3; *p<0.01 vs. untreated, **p<0.05 vs. untreated, @p<0.01 vs. Rit/Saq, #p<0.05 vs. AZT/Rit/Saq, OneWay ANOVA with post-hoc Newman-Keuls).
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4.1 ABSTRACT
Despite effective viral suppression through combined antiretroviral therapy (cART), approximately half of
HIV(+) individuals suffer from HIV-Associated Neurocognitive Disorders (HAND). Studies of
antiretroviral treated patients have revealed persistent white matter pathologies including diffuse myelin
pallor, diminished white matter tracts, and decreased myelin protein mRNAs. Loss of myelin can contribute
to neurocognitive dysfunction, as the myelin membrane generated by oligodendrocytes is essential for rapid
signal transduction and axonal maintenance. We hypothesized that myelin changes in HAND are partly due
to effects of antiretrovirals on oligodendrocyte survival and/or maturation. We showed that primary mouse
oligodendrocyte precursor cell cultures treated with therapeutic concentrations of HIV protease inhibitors
Ritonavir or Lopinavir displayed dose-dependent decreases in oligodendrocyte maturation. However, this
effect was rapidly reversed following drug removal. Conversely, nucleoside reverse transcriptase inhibitor
Zidovudine had no effect. Furthermore, in vivo Ritonavir administration to adult mice reduced frontal
cortex myelin protein levels. Finally, prefrontal cortex tissue from HIV(+) individuals with HAND on
cART showed a significant decrease in myelin basic protein compared with untreated HIV(+) individuals
with HAND or HIV-negative controls. These findings demonstrate that antiretrovirals can impact myelin
integrity, and have implications for myelination in juvenile HIV patients, and myelin maintenance in adults
on lifelong therapy.
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4.2 INTRODUCTION
Approximately 50% of patients infected with human immunodeficiency virus-1 (HIV) present with a broad
spectrum of cognitive, motor, and behavioral disturbances collectively termed HIV-Associated
Neurocognitive Disorders (HAND) (Kaul, 2005, Ozdener, 2005) despite effective viral control through
combined antiretroviral therapy (cART) (Heaton, 2010, McArthur et al., 2010, Heaton, 2011, Sacktor and
Robertson, 2014). cART is designed to simultaneously target multiple stages of HIV replication, thereby
delaying viral mutational selection to acquire drug resistance. Most commonly prescribed regimens include
viral reverse transcriptase inhibitors (nucleoside/nucleotide reverse-transcriptase inhibitors (NRTIs)), and
HIV protease inhibitors (PIs) which prevent maturation of viral precursor proteins (WHO, 2013). While
cART successfully reduces peripheral viral loads to undetectable levels in adherent individuals,
inflammation and latent viral reservoirs remain in the central nervous system (CNS) (Chun, 1997, Finzi,
1997, Wong, 1997, Anthony, 2005, Persidsky, 2006).

Although pathology has shifted from subcortical to cortical manifestations since cART introduction,
dendritic pruning and astrogliosis persist (Gray, 2003, Brew, 2004, Heaton, 2011, Sacktor and Robertson,
2014). Notably, white matter pathologies are prevalent, with the degree of neurocognitive impairment
correlating with the amount of damage (Muller-Oehring et al., 2010, Tate et al., 2010). Imaging studies
have revealed cortical myelin disruption, volume loss, and diminished structural integrity of the corpus
callosum in HAND patients, which were even more pronounced in cART-treated individuals (Ragin et al.,
2004, Tate et al., 2011, Kelly et al., 2014). Furthermore, transcriptome analysis in HAND patients on cART
revealed dysregulation of genes critical to oligodendrocyte maturation and myelination, including myelinassociated oligodendrocyte basic protein, myelin transcription factor 1, and myelin basic protein (Borjabad
et al., 2011).

In pediatric HIV patients, neurological complications such as encephalopathy and progressive multifocal
leukoencephalopathy are frequent, with data suggesting emerging neurocognitive deficits and
developmental delays (Wilmshurst et al., 2006, Crowell et al., 2014, Wilmshurst et al., 2014). WHO
guidelines urge that all infected children be treated, with those under 3 years of age receiving a
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Lopinavir/Ritonavir first-line regimen (WHO, 2013). Importantly, this PI-based therapy is advised during
the critical period for myelination (Miller et al., 2012), yet an understanding of the effects of HIV and
antiretroviral drugs on myelin formation and maintenance is lacking.

The myelin membrane is critical for axons to transmit rapid neuronal impulses as well as axonal
maintenance (Lappe-Siefke et al., 2003, Edgar and Garbern, 2004). Conversely, impaired myelination can
disrupt proper signaling, and hasten axonal degeneration, resulting in neurological dysfunctions (Criste et
al., 2014, Mighdoll et al., 2015). Although sustained effects of continuing viral replication and treatment
noncompliance are suggested to underlie continuing neurocognitive impairment, antiretrovirals themselves
may contribute to HAND pathogenesis (Marra, 2009, Joska et al., 2010, Kahouadji et al., 2013). Crucially,
while antiretroviral-mediated toxicity has been reported in primary rat cortical neurons (Robertson et al.,
2012, Akay et al., 2014), to date there are no published studies addressing the effects of antiretrovirals on
oligodendrocytes, the myelin forming cells of the CNS. Here we examine whether antiretrovirals affect the
survival and maturation of developing oligodendrocytes using a well-established primary mouse cortical
cell culture model (See et al., 2004) and the effects of cART compounds on myelin maintenance in a mouse
model and in patients with HAND. Our results support a role for a subset of cART agents in the white
matter changes seen in HIV(+) individuals with HAND.

4.3 MATERIALS AND METHODS
Chemicals and Reagents
Abcam (Cambridge, United Kingdom): rabbit polyclonal anti-inositol-requiring enzyme 1 antibody
(IRE1α, ab37073), rabbit polyclonal anti-inositol-requiring enzyme 1 antibody (IRE1α, phospho S724,
ab48187), rabbit polyclonal anti-NAD(P)H:quinone oxidoreductase antibody (NQO1, ab34173).
Affymetrix (Santa Clara, CA): terminal deoxynucleotidyl transferase, recombinant (rTdT). AIDS Research
and Reference Reagent Program, Division of AIDS, NIAID, NIH: antiretroviral reagents. BD Transduction
Laboratories: mouse monoclonal anti-BiP/Grp78 antibody (610978). Cell Signaling Technology (Beverly,
MA): rabbit polyclonal anti-eukaryotic initiation factor 2 alpha antibody (eIF2α, 9722S), rabbit polyclonal
anti-phospho-eukaryotic initiation factor 2 alpha (Ser51) antibody (p-eIF2α, 9721S). Chemicon
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International (Temecula, CA): mouse monoclonal anti-cyclic-nucleotide-3’phosphodiesterase antibody
(CNPase, MAB326R), mouse monoclonal anti-glyceraldehyde 3-phosphate dehydrogenase antibody
(GAPDH, MAB374). Covance Laboratories (Conshohocken, PA): mouse monoclonal anti-myelin basic
protein antibody (MBP, SMI-99). Enzo Life Sciences (Plymouth Meeting, PA): rabbit polyclonal antiHeme Oxygenase-1 antibody (HO-1, SPA-896). Life Technologies (Carlsbad, CA): B27 Supplement, 412% Bis-Tris gradient gels, CAS-block,

dihydroethidium,

Dulbecco’s Modified Eagle’s Medium

(DMEM), DMEM/F12, Deoxyribonuclease 1 (Dnase), Ham’s F12, L-glutamine, Hank’s Balanced Salt
Solution (HBSS), rabbit polyclonal anti-small/large myelin-associated glycoprotein antibody (S/L MAG),
Neurobasal Medium, Penicillin/Streptomycin. Jackson Immunoresearch Laboratories (West Grove, PA):
Rhodamine-conjugated goat anti-mouse IgM, FITC-conjugated goat anti-mouse IgG3, Rhodamineconjugated goat anti-rat IgG, FITC-conjugated goat anti-rat IgG, Rhodamine-conjugated streptavidin.
LiCOR (Lincoln, NE): Odyssey goat anti-mouse IRdye 800CW, goat anti-mouse IRdye 680RD, goat antirat IRdye 800CW, goat anti-rat IRdye 680RD, goat anti-rabbit IRdye 800CW, goat anti-rabbit IRdye
680RD. Peprotech (Rocky Hill, NJ): neurotrophin-3 (NT-3). Peptide International: poly-D-lysine.
Proteintech (Chicago, IL): rabbit polyclonal anti-activating transcription factor 6 beta antibody (ATF6β,
15794-1-AP). R&D Systems (Minneapolis, MN): basic fibroblast growth factor (bFGF), platelet-derived
growth factor -AA (PDGF-AA). Roche Diagnostics (Basil, Switzerland): biotin-16-dUTP. Sigma Aldrich
(St. Louis, MO): mouse monoclonal anti-α-tubulin antibody (T5168), biotin, dimethyl sulfoxide (DMSO),
fast green FCF, insulin, monomethyl fumarate (MMF), TRITC-conjugated phalloidin, progesterone,
protease inhibitor cocktail, putrescine, sodium cacodylate, selenium, tert-Butyl hydroperoxide (tBHP),
thyroxine (T4), transferrin. Thermo Fisher Scientific (Waltham, MA): Restore Western Blot Stripping
Buffer. Vector Laboratories (Burlingame, CA): Vectashield with DAPI.

Additional antibodies: anti-A2B5 mouse hybridoma supernatant (ATCC (Eisenbarth et al., 1979)), antigalactocerebroside mouse hybridoma supernatant (GalC H8H9, (Ranscht et al., 1982)), anti-myelin
oligodendrocyte glycoprotein (MOG, (Piddlesden et al., 1991), anti-myelin basic protein rat hybridoma
supernatant (MBP, gift of Virginia Lee, University of Pennsylvania), anti-proteolipid protein rat hybridoma
(AA3, gift of Dr. Alex Gow, Wayne State University).
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Primary Cortical Oligodendrocyte Cultures
All experiments were performed in accordance with the guidelines set forth by The Children's Hospital of
Philadelphia and The University of Pennsylvania Institutional Animal Care and Use Committees (IACUC).
Primary mouse oligodendrocyte precursor cell (OPC) cultures were isolated from postnatal day 1 CD1 pups
obtained from Charles River Laboratories, with modifications from previously described protocols (See et
al., 2004). Briefly, cortical cell suspensions isolated from mouse pups using standard protocols were plated
on poly-D-lysine coated T-75 flasks in Neurobasal medium with B27 supplement at 37°C with 5% CO2.
After 24 hours, cultures were switched to growth medium consisting of Neurobasal medium with B27
which contained 10 ng/ml bFGF, 2 ng/ml PDGF-AA, and 1 ng/ml NT-3. Within 7 days, confluent cells
were purified to 90-95% OPCs and 5-15% astrocytes using a gentle wash-down procedure (Feigenson et
al., 2009), and sub-cultured onto poly-lysine-coated flasks, coverslips, or Petri dishes. For differentiation
experiments, growth medium was replaced with differentiation medium, consisting of 50% DMEM, 50%
Ham’s F12, Pen/Strep and 2 mM glutamine with 50 µg/ml transferrin, 5 µg/ml putrescine, 3 ng/ml
progesterone, 2.6 ng/ml selenium, 12.5 µg/ml insulin, 0.4 µg/ml T4, 0.3% glucose, and 10 ng/ml biotin
(Feigenson et al., 2009).

Immunofluorescence
Cells on coverslips were processed for detection of specific antigens as described previously (Grinspan and
Franceschini, 1995, See et al., 2004). Prior to fixation, live cells were labeled for cell surface marker
detection using anti-A2B5 (mouse hybridoma supernatant, undiluted), and anti-GalC (mouse hybridoma
supernatant, undiluted). For detection of internal antigens following acid alcohol fixation and
permeabilization, antibodies used were anti-MBP (rat hybridoma supernatant, 1:2 dilution) or anti-PLP (rat
hybridoma supernatant, 1:2 dilution). Secondary antibodies used at a 1:100 dilution were Rhodamine or
Fluorescein conjugated. Vectashield with DAPI was used to mount coverslips, and to stain all nuclei.
Antigen-positive and DAPI-positive cells were counted in 10 fields in each of 3 to 4 coverslips from at
least 3 biologically separate preparations of cells using a Leica DM6000B fluorescence microscope at 40x
magnification. A total of approximately 2000 cells were counted per condition. The chosen and accepted
standard method for quantification of differentiation determines the number of cells progressing through
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various stages using well-defined stage-specific markers (Scherer et al., 1994, Miller, 2002, Feigenson et
al., 2009). For phalloidin staining, cell surface markers were stained as above. Next, cells were fixed with
4% paraformaldehyde for 8 minutes, washed with PBS, solubilized with 0.5% Triton X-100 in PBS, and
blocked for 30 minutes with a 1:1 dilution of 100 mg/ml BSA and CAS-block. Cells were then incubated
with TRITC-conjugated phalloidin at a final concentration of 500 nM for 2 hours. Cells were mounted and
visualized as described above. To assess cells committed to apoptotic cell death, a TUNEL staining
protocol adapted from that of Gavrieli et al. was utilized (Gavrieli et al., 1992). Cells were fixed with icecold acetone for 10 minutes, washed with PBS, and solubilized with 0.5% Triton X-100 in PBS for 15
minutes. Positive control coverslips were generated during this period by incubating in DN buffer (30 mM
Trizma base pH 7.2, 140 mM Na cacodylate, 4 mM MgCl, and 0.1 mM DTT) for 2 minutes, followed by
DNase (1:200) in DN buffer for 10 minutes. All coverslips were washed with PBS then placed in TDT
buffer for 2 minutes (30 mM Trizma base pH 7.2, 140 mM Na cacodylate, 1 mM CoCl). Cells were
incubated for 1 hour with TdT and biotin-UTP in TDT buffer (8 µL of each in 1mL TDT Buffer).
Following a subsequent PBS wash, cells were placed in TB buffer for 15 minutes (300 mM NaCl, 30 mM
sodium citrate), and then a 2% BSA solution for 30 minutes. Finally cells were incubated with Rhodamineconjugated streptavidin for 20 minutes prior to a final PBS wash and mounting on slides with Vectashield
containing DAPI. Visualization and counting were performed as described above.

Jugular Vein Antiretroviral Administration Mouse Model
Surgical procedures were performed with the approval of the Institutional Animal Care and Use Committee
of the University of Pennsylvania. Adult male C57BL/6 mice were catheterized via jugular vein, as
described previously (Thrivikraman et al., 2002, Briand et al., 2012). Briefly, mice were anesthetized prior
to surgery with 80 mg/kg ketamine and 12 mg/kg xylazine. An indwelling silastic catheter (Strategic
Applications, Inc.) was placed into the right jugular vein and sutured in place. The catheter was connected
to a mesh platform which was subcutaneously placed on the animals back and sutured in place. Catheters
were flushed daily with 0.1 ml of the antibiotic Timentin dissolved in heparinized saline (0.93  mg/ml).
Treatment regimens were composed of Vehicle (DMSO) or Ritonavir (20 mg/kg), administered twice daily
for 14 days by continuous intravenous injection (Vehicle n= 6, Ritonavir n= 7). This drug dose was based
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on previously published pharmacokinetic studies (Kageyama et al., 2005, Pistell et al., 2010, du Plooy et
al., 2011). At time of euthanasia, catheter patency was verified by response to pre-euthanasia sedation (80
mg/kg ketamine and 12 mg/kg xylazine). Brains were removed, the frontal cortex, cerebellum, and
hippocampus were dissected on ice, and tissue samples were stored at -80 °C until immunoblot analyses
were performed.

Human Subjects
For immunoblotting analyses, samples from a cohort of individuals were obtained from the National
NeuroAIDS Tissue Consortium (NNTC) and the Texas NeuroAIDS Research Center. The cohort
encompasses 20 HIV(-), 20 HIV(+) cART-naïve, and 20 HIV(+) cART-medicated for greater than 12
months (HIV(+)/ART) cases. Six HIV(+) cART-naïve and 14 HIV(+) cART-medicated subjects had
clinically diagnosed HAND. The pathological diagnosis of HIV encephalitis was established in six HIV(+)
cART-naïve and one HIV(+) cART-medicated patients. Diagnosis of HAND by neuropsychological
assessment was based on the results from the NNTC neurocognitive test panel guided by Frascati Criteria,
which entails evaluation of seven domains of cognitive functioning at six-month intervals prior to death
(Antinori, 2007). NNTC site pathologists rendered nosological diagnoses of HIVE according to established
criteria (Budka et al., 1991). Evaluation of regimen history determined that 85% of cART-medicated
patients were HIV protease inhibitor (PI) experienced, and 100% were nucleoside reverse transcriptase
inhibitor (NRTI) experienced. Table 4.1 contains complete cohort demographics and clinical data.

The human studies were conducted in accordance with human subject protection protocols, with written
consent obtained at four collections sites within the USA. The following institutions maintained the IRBs
set forth to provide oversight for the protection of human subjects: 1) The University of Texas Medical
Branch Office of Research Subject Protections (Galveston, TX), 2) Mount Sinai Medical Center Program
for the Protection of Human Subjects (New York, NY), 3) University of California (San Diego, CA), 4)
University of California Los Angeles, Office of the Human Research Protection Program (Los Angeles,
CA).
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Immunoblotting
Whole cell extracts of primary mouse oligodendrocyte cultures were prepared with ice-cold cell lysis buffer
(50 mM Tris pH 7.5, 120 mM NaCl, 0.5% NP-40, 10 mM EDTA, 0.5 mM Na3VO4, and 1:100 protease
inhibitor cocktail), followed by centrifugation at 14,000 rpm at 4°C for 30 minutes. Whole cell extracts of
mouse and human tissue samples were prepared by homogenization of 100 mg dissected frontal cortex
tissue in ice-cold tissue extraction buffer (50 mM Tris pH 7.5, 0.5 M NaCl, 1% NP-40, 1% SDS, 2 mM
EDTA, 2 mM EGTA, 5 mM NaF, 0.4 mM Na3VO4, 1 mM DTT and 1:100 protease inhibitor cocktail),
followed by centrifugation at 14,000 rpm at 4°C for 30 minutes. Protein concentrations of collected
supernatants were determined by the Bradford Method. 10-25 µg of protein was loaded into each lane of 412% Bis-Tris gradient gels for separation. For detection of PLP, gels were run under non-reducing
conditions due to antibody specificity. A broad-spectrum molecular weight ladder was run on each gel.
Following separation, proteins were transferred onto Millipore Immobilon-FL membranes, and blocked in
PBS with 0.1% Tween-20 (PBST) and 5% milk for 20 minutes at 4°C. Membranes were incubated
overnight at 4°C with primary antibodies in PBST + 5% milk. The following primary antibodies were used:
MBP (SMI-99, 1:1000 dilution), PLP (1:1000 dilution), MAG (1:500 dilution), CNPase (1:1000 dilution),
HO-1 (1:1000 dilution), NQO1 (1:1000 dilution), BiP (1:1000 dilution), phospho-eIF2α (1:1000), total
eIF2α (1:1000), phospho-IRE1α (1:1000), total IRE1α (1:1000), and ATF6β (1:1000). Membranes were
washed with PBST, re-blocked for 20 minutes in PBST+ 5% milk, and incubated with corresponding
antigen-specific fluorescent probe-conjugated secondary antibodies (1:10,000 dilution) in PBST + 5% milk.
Membranes were visualized using an Odyssey Infrared Imaging System (LiCOR). Loading controls were
obtained by reblotting for GAPDH (1:1000 dilution), α-tubulin (1:1000 dilution), or FastGreen FCF. To
obtain ratios of phosphorylated to total protein levels for eIF2α and IRE1α, first phosphorylated proteins
were detected. Following visualization, membranes were stripped using Restore Western Blot Stripping
Buffer and re-examined using the Odyssey to ensure all detectable first-round antibodies were removed.
Membranes were then re-blocked and incubated with the corresponding primary antibodies for total eIF2α
or IRE1α. Bands of interest were specified to determine pixel intensities for each treatment using the NIH
ImageJ program (V 1.36b, Bethesda, MD), and the band intensities were normalized to loading controls to
ensure equal loading. Proteins of interest were quantified by analyzing bands corresponding to the
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appropriate molecular weight reported by the manufacturers and observed in our previous studies. In mouse
and human brain tissue in which myelin proteins are found in high abundance, MBP and MAG present as
doublets, which were evaluated simultaneously and quantified. FastGreen staining was used for samples
from in vivo tissue, to ensure protein integrity as well as equal loading. To quantify FastGreen
densitometry, a horizontal section of the membrane spanning a broad molecular weight range was scanned
together, and overall intensity was determined for each lane. This method allows for normalization across
lanes within gels without bias towards a single representative protein loading control. Due to large sample
size in the human studies, a standard combined sample was run on each gel, and values were then
normalized across gels.

Measurement of Reactive Oxygen Species
The superoxide indicator dihydroethidium (DHE) was used to detect the presence of reactive oxygen
species (ROS) in vitro. Fifteen minutes prior to conclusion of treatments, 3 µM DHE was added to the
culture medium. Oxidation of DHE to ethidium allows for ethidium intercalation with nuclear DNA,
emitting a quantifiable red fluorescence (Zhao, 2003). Cells were washed with F12 medium, and fixed with
4% paraformaldehyde at room temperature for 8 minutes. The coverslips were then washed with F12
medium, mounted on slides with DAPI-containing Vectashield, and visualized using fluorescent
microscopy, as described above. The oxidant tert-Butyl hydroperoxide (tBHP, 2.5 µM) was used as a
positive indicator of ROS in culture. Post-acquisition analysis was performed using MetaMorph 6.0
software (Molecular Devices, Sunnyvale, CA) to determine the fluorescence intensity of nuclear
intercalated DHE normalized to the area of DAPI signal.

Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR)
The expression of HO-1, NQO1, spliced X-box Binding Protein-1 (XBP-1), total XBP-1, Binding
Immunoglobulin Protein (BiP), C/EBP homologous protein (CHOP), IRE1α, ATF6β and activating
transcription factor 4 (ATF4) mRNA in oligodendrocyte cultures were quantified by qRT-PCR. OPC
cultures were grown on 100-mm dishes and harvested after treatment with specified antiretrovirals for 6
hours. RNA was extracted with Trizol, and 5 µg of RNA was converted to cDNA by the Invitrogen
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Superscript First-strand kit. q-PCR was performed using Power SYBR Green, as previously described
(French et al., 2009, Feigenson et al., 2011). Samples were measured in triplicate for each experiment from
three biological replicates (n=3). Data were normalized using Protein Kinase Gene 1 (PKG1), and analyzed
according to the ΔΔCT method. Primer pairs obtained from Integrated DNA Technologies for each gene
can be found in Table 4.2.

Statistical Analysis
All data were analyzed by Prism 5.0 software (GraphPad Software, San Diego, CA). Values are expressed
as mean ± SEM. All statistical tests compared Zidovudine (AZT) to untreated as it was dissolved in water,
and Lopinavir and Ritonavir to the vehicle (DMSO) in which they were resuspended. Following
differentiation, untreated and vehicle do not statistically differ in the number of cells staining with GalC,
which marks immature oligodendrocytes, or MBP and PLP, which mark mature oligodendrocytes (data not
shown). One-way ANOVA with post-hoc Newman-Keuls multiple comparison test, One-way ANOVA
with post-hoc Dunnett’s multiple comparison test or Student’s t-test were performed where indicated. For
comparison of specific treatment groups at two time-points, One-way ANOVA with post-hoc Bonferroni
correction was performed. Values of p < 0.05 were considered significant for all analyses.

4.4 RESULTS
HIV Protease Inhibitors Prevent Oligodendrocyte Differentiation
The potential impacts of antiretroviral compounds on oligodendrocyte survival, maturation, or myelination
have not been determined to date. We chose to test three widely prescribed antiretroviral drugs: Zidovudine
(AZT), a nucleoside/nucleotide reverse-transcriptase inhibitor (NRTI), and Ritonavir and Lopinavir, two
protease inhibitors (PI). We based our range of antiretroviral doses on previously reported plasma and
cerebrospinal fluid (CSF) levels in humans, as measurements from human brain parenchyma have not been
performed (Wynn et al., 2002, Noor et al., 2006, Cusini et al., 2013, Tiraboschi et al., 2014, Decloedt et al.,
2015). Many antiretrovirals are thought to have limited CNS penetrance due to pharmacological properties
which impair transport across the blood brain barrier (BBB) and promote active exclusion through efflux
transporters (McGee et al., 2006, Cysique and Brew, 2009, Varatharajan, 2009). However, there is
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extensive evidence of HIV-mediated disruption of the BBB resulting in increased entry of normally
excluded small molecules and serum proteins (Toborek et al., 2005, Wang et al., 2008, Nakagawa et al.,
2012). In addition to HIV-mediated effects, even in the absence of virus, CNS accessibility is not
necessarily as restricted as anticipated, as brain entry can be facilitated if drugs are given in combination
(Marzolini et al., 2013). Importantly, animal studies predict that parenchymal concentrations reach levels
equal to, or greater than those found in the CSF, suggesting that concentrations attained in human brain
may be higher than current clinical estimates (Anthonypillai et al., 2004, Anderson and Rower, 2010).

We first determined the dose-dependent effects of these compounds on differentiation utilizing our
previously described paradigm (See et al., 2004). Primary mouse oligodendrocyte precursor cells (OPCs)
were purified and grown in the presence of bFGF, PDGF-AA, and NT-3 to 75% confluence, at which time
growth factors were removed and thyroid hormone was added to initiate differentiation, allowing OPCs to
progress first to immature then mature oligodendrocytes. OPCs were allowed to differentiate for 72 hours
in the presence of Vehicle (DMSO) or the antiretrovirals tested: AZT (1 µM, 10 µM, or 25 µM), Ritonavir
(100 nM, 1 µM, or 3 µM), or Lopinavir (150 nM, 1.5 µM, or 15 µM). Oligodendrocyte maturation is well
defined and regulated; therefore, cellular markers correlating to specific stages of differentiation are
commonly used to illustrate lineage progression (Miller, 2002). A2B5 was used as a marker of OPCs,
galactocerebroside (GalC) as a marker of immature oligodendrocytes, and myelin basic protein (MBP) or
proteolipid protein (PLP) as markers of mature oligodendrocytes.

Immunofluorescent staining following treatments revealed that the PIs Ritonavir and Lopinavir but not
NRTI AZT resulted in fewer cells expressing differentiation markers, compared with controls.
Representative images of oligodendrocytes after 72 hours in differentiation medium demonstrate dosedependent maturation decreases with PIs (Figure 4.1A), with the extent of maturation determined by
comparing the percentage of GalC+ cells and MBP+ cells across treatments (Figure 4.1B-C). Following PI
treatment, the number of cells expressing the immature marker GalC after three days of differentiation was
reduced by 69.43% ± 6.07% for the highest dose of Ritonavir and by 95.63% ± 0.96% with the highest
dose of Lopinavir, compared with vehicle controls (p < 0.001) (Figure 4.1B). Similarly, the number of
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MBP+ cells was significantly reduced by 75.14% ± 4.94% with Ritonavir and by 97.62% ± 1.03% with
Lopinavir treatments compared with vehicle (p < 0.001) (Figure 4.1C). In contrast, AZT treatment did not
alter the number of GalC+ or MBP+ cells, compared with controls (Figures 4.1B-C). Quantification of
PLP+ cells mirrored that of MBP+ cells for all conditions (data not shown).

Changes in the number of cells expressing markers of oligodendrocyte differentiation could be attributed to
cell death, altered precursor proliferation, or inhibition of differentiation. To address changes in cell death
or OPC proliferation, we determined the number of total cells (DAPI+ cells) (Figure 4.2A) and A2B5+
OPCs (Figure 4.2B) following treatments. AZT, which did not cause a loss of GalC+ or MBP+
oligodendrocytes compared to controls, did not lead to a loss of OPCs or total cells at any dose as expected.
Interestingly, Ritonavir, at any dose, also did not lead to loss of OPCs or total cell number in culture,
suggesting that Ritonavir treatment decreased GalC+ and MBP+ oligodendrocytes by inhibition of the
differentiation process. In contrast, Lopinavir treatment trended towards a reduction in total cell number at
the 1.5 µM dose (81.5% ± 5.52%) and significantly decreased total cell numbers at the 15 µM dose
(73.9%± 6.29% of vehicle total) (p < 0.05) (Figure 4.2A). A significant reduction between the 1.5 µM and
15 µM concentrations was not observed. Lopinavir did not alter A2B5 precursor cell number at any
concentration (Figure 4.2B). These observed decreases, although statistically significant, are modest
compared to the near total loss of GalC+ and MBP+ cells with 15 uM Lopinavir treatment. To verify that
the dramatic reductions observed in expression of GalC and MBP following Lopinavir treatment were due
to inhibition of differentiation and not apoptotic cell death, we assessed whether remaining cells were
committed to the apoptotic cell death cascade using the TUNEL assay, which labels double-stranded DNA
breaks in extensively damaged cells. Treatment with 15 µM and 1.5 µM concentrations of Lopinavir
resulted in negligible TUNEL+ cells, similar to vehicle treatment (Figure 4.2C). Together, these results
suggest that Lopinavir inhibits proper oligodendrocyte maturation in a dose-dependent manner. The modest
reductions in GalC+ and MBP+ cells observed at 1.5 µM (57.0% ± 12.43% and 56.7% ± 12.72% of control
differentiation levels) plummets to 4.37% ± 0.96% and 2.38% ± 1.03%, respectively, at 15 µM without
activation of the apoptotic cascade or a significant reduction in cell number between these two
concentrations.
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Lopinavir Reduces the Expression of Myelin Proteins
Given that PI-treated cultures contained fewer GalC+, MBP+ and PLP+ cells, as compared with vehicle by
immunofluorescence, next we determined whether this effect resulted from decreased protein levels. The
cultures were treated as described above for 72 hours, and protein lysates were prepared for immunoblot
analysis. The highest dose of Lopinavir (15 µM) led to a significant decrease in MBP levels when
compared with vehicle (p < 0.01) (Figure 4.3C). In contrast, neither AZT nor Ritonavir significantly altered
MBP expression levels (Figure 4.3A-B). Additionally, PLP and cyclic-nucleotide-3’phosphodiesterase
(CNP), two other major myelin proteins, were also decreased in 15 µM Lopinavir-treated cells compared
with controls, whereas no change in either protein was observed following high dose (25 µM) Azt or (3
µM) Ritonavir treatments (Figure 4.3D-E). This immunoblotting analysis of Lopinavir treated cells
parallels that of the immunofluorescence results in Figure 1, with dramatic reductions in protein markers of
maturation observed between the 1.5 µM and 15 µM concentrations of Lopinavir (Figure 4.2A).
Intriguingly, all doses of Ritonavir and the intermediate dose of Lopinavir (1.5 µM) decreased the number
of GalC+ and MBP+ cells by immunofluorescence, but not myelin protein levels by immunoblot.

Protease Inhibitor-Mediated Reduction of Differentiation is Reversible
Our observation that at low doses of PIs there were significantly fewer mature oligodendrocytes, despite
unchanged levels of myelin proteins prompted us to determine whether oligodendrocyte processes were
elaborated but myelin proteins were not being properly localized. Therefore, we utilized phalloidin staining
to visualize actin microfilaments. Cells were treated with vehicle, 3 µM Ritonavir, or 15 µM Lopinavir and
allowed to mature for 72 hours, followed by phalloidin staining. As shown in the representative images of
Figure 4.4A, cells maintained normal differentiated geometry and process extension after treatment,
however the immature oligodendrocyte stage marker GalC did not appear to correctly localize to the cell
surface.

To determine if the effects of the PIs were permanent, or if cells were still capable of proper myelin protein
production and localization, we differentiated OPCs in the presence of 3 µM Ritonavir or 15 µM Lopinavir
and allowed 72 hours for maturation. At this time, a subset of cultures was switched into fresh
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differentiation medium lacking further treatment for an additional 24 hours. Cultures that underwent a drug
washout period were analyzed for markers of oligodendrocyte differentiation and compared with the
cultures that did not undergo drug washout but were exposed to PI treatments for 72 hours. As we have
shown in Figure 4.1, while 72 hour treatment with 3 µM Ritonavir or 15 µM Lopinavir resulted in fewer
GalC+ cells compared with vehicle, this effect was completely reversed after the removal of both PIs
(Figure 4.4B). Similarly, drug washout for 24 hours resulted in the reversal of the deficit in MBP levels
following treatment with 15 µM Lopinavir (0.28 ± 0.12 fold of control levels, p < 0.05), as detected by
immunoblotting (Figure 4.4C). In 15 µM Lopinavir treated cultures, the rapid restoration of maturation to
vehicle-treated levels following drug washout further corroborates the findings from Figures 4.1-4.3, which
together substantiate that cell death did not cause the original reduction in myelin proteins and cell surface
markers of differentiation following Lopinavir treatment.

Antiretroviral Drugs Induce Oxidative Stress
Previous work from our laboratory has shown that oxidative stress is capable of halting oligodendrocyte
differentiation (French et al., 2009, Reid et al., 2012). We have also demonstrated in primary neuroglial
cultures that antiretroviral compounds (PIs and NRTIs) evoke the generation of reactive oxygen species
(ROS) (Akay et al., 2014). In light of this, we postulated that oxidative stress could be the instigating factor
for altered differentiation in the presence of Ritonavir and Lopinavir. OPCs were exposed to AZT,
Ritonavir, and Lopinavir for 30 minutes, 1 hour, 2 hours, 6 hours, 12 hours, or 24 hours at the doses used in
previous experiments, followed by staining with dihydroethidium (DHE) as an indicator of ROS. This
method is a readout for cellular ROS levels, as oxidation of DHE to ethidium allows for ethidium
intercalation with DNA, emitting a quantifiable red fluorescence which overlaps with DAPI area (Zhao,
2003). Tert-butyl hydroperoxide (tBHP, 2.5 µM) treatment was used as positive indicator of ROS
generation for each timepoint. Following the timecourse outlined above, we found that Ritonavir produced
a dose-dependent, rapid and robust accumulation of ROS by 1 hour (1756% ± 360.8% compared with
vehicle, p < 0.001), while AZT produced a more modest effect, which was not observed until 2 hours posttreatment (505% ± 80.4% compared with control, p < 0.001) (Figure 4.5). Interestingly, Lopinavir did not
produce detectable ROS levels at any time-point up to 24 hours (not shown).
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The Endogenous Antioxidant Response is not Activated with Antiretroviral Drugs in Developing
OPCs
Robust ROS were rapidly detectable following Ritonavir and AZT treatments. The typical cellular response
to such an imbalance in redox homeostasis is activation of the endogenous antioxidant response (EAR) (Li,
2009). Therefore, we investigated whether exposure of antiretroviral compounds to developing
oligodendrocytes activated this cellular stress signaling pathway. OPCs were treated with the highest dose
of each antiretroviral at the time of differentiation. Then, mRNA or protein was extracted 6 or 16 hours
later, respectively. The analysis of principle cellular targets of the EAR: Heme Oxygenase-1 (HO-1) and
NAD(P)H:quinone oxidoreductase (NQO1), revealed no changes in mRNA levels after 6 hours of
treatment with AZT. Surprisingly, Lopinavir led to a decrease in HO-1 mRNA levels to 0.654 fold
compared with vehicle, with a range between 0.331 and 1.294 fold (p < 0.001). In contrast, NQO1 levels
were significantly increased with both Ritonavir to 1.716 fold (1.474-2.00 fold range, p = 0.015) and
Lopinavir to 1.272 fold (0.554-2.921 fold range, p < 0.001) (Table 4.3). The incremental changes in NQO1
in our treatments, as compared with the robust increases normally seen with EAR activation with classical
pathway inducers suggest that the response may not be functionally significant (Table 4.3). Consistent with
this interpretation, immunoblotting for HO-1 and NQO1 showed no alterations in protein levels following
16 hours of treatment with any of the compounds tested (Figure 4.6A-B).

Effective Reduction of Reactive Oxygen Species Does not Rescue Maturation Defects
Robust oxidative stress was evident following treatment with Ritonavir, yet the EAR was not activated
following treatment with any of the antiretroviral drugs tested. Therefore, we sought to determine if
decreasing the accumulation of ROS would rescue the observed differentiation defects. To do this, we
utilized the fumaric acid ester, monomethyl fumarate (MMF). MMF is the active metabolite of dimethyl
fumarate (DMF), which is now approved for treatment of the demyelinating disorder Multiple Sclerosis
(FDA, 2013, Limmroth, 2013). Importantly, we have previously shown that MMF successfully ameliorates
ROS accumulation and antiretroviral-induced toxicity in neuroglial cell cultures (Akay et al., 2014). To
determine whether MMF was effective at reducing ROS accumulation triggered by antiretrovirals in
oligodendrocyte cultures, OPCs were pre-treated with 10 µM MMF for 6 hours, followed by
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supplementation with MMF and/or treated with 25 µM AZT or 3 µM Ritonavir for 2 hours or 15 µM
Lopinavir for 6 hours. DHE staining revealed that MMF pre-treatment significantly attenuated ROS
accumulation after AZT and Ritonavir treatments (Figure 4.7A). As we previously established, Lopinavir
did not induce ROS at 6 hours, and MMF had no effect on endogenously detectable ROS levels (Figure
4.7A). We next assessed if reducing oxidative stress by attenuating ROS accumulation by MMF would
increase the number of mature oligodendrocytes in the presence of PIs. OPCs were pre-treated with MMF
for 24 hours prior to switching to differentiation medium, and were treated with 3 µM Ritonavir or 15 µM
Lopinavir. MMF was replenished at the time of PI treatment and again every 24 hours. After 72 hours in
differentiation medium, cells were stained for GalC and compared with vehicle or cells incubated with
MMF without PIs. There was no difference between the number of GalC+ cells in cultures treated with
Ritonavir +MMF or Lopinavir +MMF (Ritonavir 35.2% ± 0.77%, Lopinavir 36.4% ± 18.2% of vehicle)
and those exposed to Ritonavir or Lopinavir alone (Ritonavir 29.9% ± 5.90%, Lopinavir 19.9% ± 14.5%)
(Figure 4.7B). Thus MMF decreased oxidative stress but did not improve oligodendrocyte differentiation.

The Unfolded Protein Response is Not Triggered by Antiretroviral Drugs in Maturing
Oligodendrocytes
We and others have demonstrated that antiretroviral drugs induce the unfolded protein response (UPR) in
neuroglial and somatic cell types (Gannon and Jordan-Sciutto, personal communication, Zhou, 2005,
2006). It has also been well documented that the UPR plays an important role in a variety of demyelinating
disorders (Gow and Wrabetz, 2009). This complex signaling pathway is modulated by the actions of three
branches, PKR-like ER kinase (PERK), inositol-requiring enzyme 1 (IRE1), and activating transcription
factor 6 (ATF6), all of which complex with ER-resident chaperone protein Binding Immunoglobulin
Protein ((BiP)/GRP78) in the absence of ER stress (Reviewed in (Hetz et al., 2015)). Activation of these
pathways leads to attenuation of global protein translational in conjunction with selective upregulation of
pro-survival proteins (Bertolotti et al., 2000, Lee and Ozcan, 2014, Hetz et al., 2015).

Therefore, we analyzed whether the UPR was activated in OPCs treated with antiretroviral drugs for 6 or
16 hours by assessing mRNA and protein levels of markers of UPR activation. Upon disruption of
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endoplasmic reticulum homeostasis and activation of the UPR, X-box binding protein 1 (XBP-1) mRNA is
spliced to promote the production of the active XBP-1 protein (Yoshida et al., 2001, Calfon et al., 2002).
The relative ratio between spliced and total XBP-1 mRNA is an accepted standard for UPR activation
(Yoshida et al., 2001, Calfon et al., 2002). The analysis of this ratio revealed no increases in XBP-1 mRNA
splicing in antiretroviral treated cells at 6 hours, suggesting that UPR activation did not occur upon
treatment of OPCs with these drugs (Table 4.4). While Lopinavir treatment led to a significant decrease in
XBP-1 mRNA splicing (0.398 fold as compared with vehicle, with a range of 0.297-0.534 fold (p < 0.001))
(Table 4.4), this effect is negligible compared with biologically relevant changes, and does not correspond
to the robust increases in the ratio of spliced-to-total XBP-1 mRNA which would indicate UPR activation.
Additional genes targeted by the UPR pathway were also examined by this method. No significant
alterations in transcript levels were noted for CHOP, BiP, ATF6, or ATF4 with any antiretroviral tested
(Table 4.4). IRE1α was not altered with AZT or Ritonavir, but was highly upregulated following Lopinavir
treatment (8.664 fold compared with vehicle, with a range of 8.532-8.797 fold). Binding immunoglobulin
protein (BiP) served as an indicator of UPR activation at the protein level. As the primary sensor of
endoplasmic reticulum stress, its cellular levels are tightly regulated by transcription, translation, and
selective stabilization during stress conditions (Brown and Naidoo, 2012). Additionally, BiP is known to be
upregulated in oligodendrocytes under conditions promoting UPR activation (Cortopassi et al., 2006).
Immunoblotting for BiP protein showed no difference between PI-treated and vehicle cultures (Figure
4.8A). To further examine the individual arms of the UPR, western blotting was performed for posttranslational modifications of representative proteins. As eIF2a phosphorylation was not increased
following 16 hours of treatment with any antiretroviral, the PERK pathway is likely not involved at this
timepoint (Figure 4.8B). ATF6β cleavage was also not observed; suggesting these antiretrovirals do not
modulate ATF6-mediated transcriptional activity (Figure 4.8C). Finally, despite a significant increase in
IRE1α mRNA observed by RT-PCR following Lopinavir treatment, total protein IRE1α protein level was
not increased in this condition compared to vehicle (Figure 4.8D). More importantly, activation of the
IRE1α branch of the UPR is dependent on protein dimerization facilitated by phosphorylation status. IRE1α
phosphorylation status was not increased with Lopinavir or any antiretroviral condition (Figure 4.8E).
Functional activation of the IRE1α pathway arm leads to the splicing event of XBP1 (Bertolotti et al., 2000,
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Lee and Ozcan, 2014, Hetz et al., 2015). Rather than increasing, we observed that XBP1 splicing was
significantly decreased following Lopinavir treatment, suggesting potential IRE1 pathway suppression,
complete with compensatory increase of regulator IRE1α transcription as was also observed by RT-PCR
(Table 4.4). In summary, these findings suggest that neither the EAR nor the UPR are activated in OPCs by
any of the antiretrovirals tested during the timeframe that was previously determined to induce responses
within these pathways neuroglial culture. Thus we do not currently ascribe the observed negative
maturation effects to actions of either of these pathways.

Myelin Protein Expression In Vivo is Reduced after Treatment with a Ritonavir Regimen
After investigating how antiretrovirals altered oligodendrocyte maturation in vitro, we asked whether these
compounds also had detrimental effects to established myelin in vivo. To this end, we examined the effects
of a repeated/chronic antiretroviral exposure. We administered Ritonavir or vehicle intravenously to adult
male mice through implanted jugular vein catheters over a two-week period, according to the same protocol
followed in our previous studies (Briand et al., 2012, Akay et al., 2014). Recommendations for treatment
regimens are constantly changing to improve patient outcomes while reducing adverse effects, as well as
incorporating new drug classes and next-generation therapeutics. For our purposes, Ritonavir was chosen as
a representative antiretroviral compound for our in vivo study. Ritonavir is globally used clinically as a
boost for other antiretrovirals to increase bioavailability, as it is a potent inhibitor of cytochrome P450
which metabolizes these compounds (Moyle, 2001). Increased bioavailability of co-administered
compounds with high CNS penetrance likely leads to higher brain levels of these compounds (Marzolini et
al., 2013). Additionally, Ritonavir-boosted regimens are still commonly prescribed in resource-limited
settings as first-line treatment, making it globally among the most-prescribed treatment options
(AIDSTAR-One, 2012). The dose of Ritonavir was based on previously published pharmacokinetic studies
(Kageyama et al., 2005, Pistell et al., 2010, du Plooy et al., 2011). The animals showed no signs of distress
or gross phenotypic alterations over the course of treatment. To determine the effects of Ritonavir on
established myelin, myelin protein levels were assessed by immunoblotting cellular lysates prepared from
frontal cortex. In addition to myelin basic protein (MBP), other components of mature myelin were also
evaluated in vivo: myelin oligodendrocyte glycoprotein (MOG), cyclic-nucleotide-3’phosphodiesterase
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(CNPase), myelin-associated glycoprotein (MAG), and proteolipid protein (PLP). We observed that protein
levels of MOG and CNPase were significantly decreased with Ritonavir compared with vehicle treatment
(p < 0.05), whereas MBP, MAG, and PLP levels were not significantly altered (Figure 4.9).

Myelin Protein Expression in Humans is Altered by HIV- and Antiretroviral Treatment-Status
To address potential translational relevancy of our observations, we examined prefrontal cortex autopsy
specimens from cohort of HIV-infected patients who were exposed to antiretroviral agents. To date,
diffusion tensor and magnetic resonance imaging studies and a single transcriptome study have been
performed to examine white matter dysfunction in HIV and HAND patients (Borjabad et al., 2011, Tate et
al., 2011, Kelly et al., 2014), but changes in post-mortem myelin protein levels have not been reported. The
cohort contained age-matched HIV(-), HIV(+) patients who were cART-naïve (HIV(+)), and HIV(+)
cART-medicated >12 month individuals (HIV(+)/ART) (n = 20 for each group). The HIV(+) cART-naïve
group was comprised of six individuals with diagnosed HAND, one who was neurocognitively normal, five
with neuropsychological impairment that was potentially due to factors other than HIV infection. Eight of
the cases did not undergo a structured ante-mortem neurocognitive assessment. The HIV(+) cARTmedicated >12 month group (HIV(+)/ART) contained 14 individuals with HAND, two who were
neurocognitively normal, and four with neuropsychological impairment potentially due to factors other than
HIV infection. The full details of their demographics and clinical data are in Table 4.1. The prefrontal
cortex was selected for analysis for the following reasons: 1) This brain region is utilized in performing the
functional modalities in which HAND patients display impairments (Antinori, 2007), 2) Synaptodendritic
damage has been previously reported in this region in affected patients (Ellis et al., 2007), and 3) A region
of mixed white and grey matter was desired for analysis as is seen in the cortex, so that the overall myelin
contribution and relative protein amounts could be assessed. Previous studies have shown that the volume
of the corpus callosum is reduced in HIV and with antiretroviral treatment, however as this is an extremely
myelin-rich environment, to observe a quantitative change in immunoblot analysis would require a sizable
loss of myelination. For all cases, the myelin proteins MBP, MOG, CNPase, and MAG were examined by
immunoblot analysis. When subdivided according to HIV status alone, no statistically significant
alterations were noted in the myelin protein levels between uninfected controls and the HIV(+) patients
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(Figure 4.10). However, when the cohort was stratified into categories based on antiretroviral therapy
status, CNPase protein was significantly increased in the HIV(+) cART > 12 month group (HIV(+)/ART)
compared with the HIV(-) group (p < 0.01) (Figure 4.11A). Finally, individuals for whom neurocognitive
data was not known, who were neurocognitively normal, or who had neuropsychological impairment due to
factors other than HIV-infection were excluded from analysis to remove potential confounding factors, and
to allow us to examine only those cases with known HAND diagnosis in relation to cART-medication
status. This analysis revealed a statistically significant decrease in MBP protein levels in the HIV(+)/ART
group, as compared with the HIV(-) (p < 0.05), and HIV(+) groups (p < 0.05) (Figure 4.11B). On the other
hand, a significant increase in CNPase protein was observed in the HIV(+)/ART group, compared with the
HIV(-) group (p < 0.001) (Figure 4.11B). These results indicate that HIV infection compounded with the
effects of antiretroviral therapy can lead to alterations in myelin protein levels in patients.

4.5 DISCUSSION
Despite effective viral suppression through antiretroviral therapy, HIV-Associated Neurocognitive
Disorders (HAND) persists in infected individuals and is frequently accompanied by white matter
pathologies (Tate et al., 2010, Kelly et al., 2014, Sacktor and Robertson, 2014). Here, we investigate the
effects of antiretrovirals in vitro on oligodendrocyte survival and maturation, and in vivo on myelin
maintenance in both adult mice and HIV(+) individuals and provide novel, compelling evidence that the
protease inhibitors Ritonavir and Lopinavir impair both the maturation of oligodendrocyte precursors into
myelin-producing cells, and the maintenance of myelin proteins in vivo. Furthermore, human brain
specimens demonstrated a reduction in MBP and an increase in CNPase in HAND patients who had been
cART-medicated for greater than one year, suggesting a loss of myelin integrity yet failure of successful
remyelination. These novel observations of the effects of a subset of antiretrovirals on oligodendrocyte
development and maintenance may have critical clinical repercussions for both pediatric and adult HIVpatients.

Utilizing stage-specific markers, we have shown that PIs Ritonavir and Lopinavir prevent oligodendrocyte
maturation in vitro while NRTI AZT does not. Interestingly, myelin protein levels as evaluated by
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immunoblotting remained unchanged under most conditions, except at the highest dose of Lopinavir.
During normal maturation, OPCs enter into differentiation and proceed with upregulation of myelin
component mRNAs (Miller, 2002). During this progression, cells extend actin filaments to elaborate
processes. Most myelin proteins are then translated in the perinuclear endoplasmic reticulum and trafficked
through the secretory pathway to be inserted into the forming myelin membrane (Colman et al., 1982). An
exception is MBP, in which mRNA is trafficked to sites proximal to membrane insertion where the protein
is then translated on free-ribosomes (Colman et al., 1982, Ainger et al., 1997). In that context, our data
suggest that treatment with PIs prevents proper membrane insertion of both myelin proteins traversing the
secretory network and locally synthesized MBP as we have detected by immunofluorescence; however, in
these conditions, protein levels remain unchanged, as determined by immunoblotting. Specifically, even at
the highest Ritonavir dose where we observed substantial decreases in maturation by immunofluorescence,
we did not detect parallel changes at the protein level. This finding, while unusual, is not unprecedented in
oligodendrocytes. Maier et al. (2009) demonstrated that reduction in cellular cholesterol levels can result in
decreased PLP surface expression with minimal reduction at the protein level. Along these lines, a recent
study also suggested that myelin membrane lipid composition may be altered under two models of
demyelination. In this work, MBP surface localization to myelinated processes by immunohistochemistry
was diminished, while total MBP levels remained unchanged (Frid et al., 2015). Additionally, a study
investigating the role of mammalian target of rapamycin in oligodendrocyte differentiation observed
maintenance of normal myelin protein levels despite a significant reduction in the number of maturing
oligodendrocytes (Wahl et al., 2014). Further, we observed that cells treated with either PI adopted properly
elaborated mature oligodendrocyte morphology, as evidenced by normal actin cytoskeleton morphology
despite reduction in myelin protein expression at the cell surface. The effect of PIs was reversible, as cells
proceeded to differentiate rapidly following drug removal, with both cell surface marker expression and
myelin protein levels indistinguishable from controls after 24 hours. The accelerated rescue of maturation
deficits further suggests that required components are already present within the treated cells, and that these
PIs are most probably suppressing maturation on a post-translational level. Drug removal alleviates this
blockade, resulting in appropriate protein localization to the myelin membrane.
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We have observed differences in the effects of Ritonavir and Lopinavir. While both are PIs, their differing
chemical structures likely result in disparate cellular uptake, metabolism, and intracellular interactions. In
agreement with this notion, other commonly prescribed PIs behave differently within cells of the same
lineage. For example, inhibition of differentiation was observed with Nelfinavir and Indinavir, but not
Amprenavir in adipocytes (Caron et al., 2003). Similarly, in CNS-derived astrocytes, Nelfinavir and
Indinavir displayed striking differences in ROS production, glutathione export, and toxicity (Brandmann et
al., 2012). Regardless of the differing subcellular effects that Lopinavir and Ritonavir invoke, it is clear
based on our observations that properly functioning myelin would not arise following exposure to either PI
even at low concentrations.

Several antiretroviral drugs induce ROS, mitochondrial depolarization and neurotoxicity in mixed
neuroglial cultures (Robertson et al., 2012, Akay et al., 2014), and we have shown that oxidative stress can
hinder the process of oligodendrocyte differentiation (French et al., 2009). While both AZT and Ritonavir
induced robust ROS accumulation, Lopinavir did not, even at extended timepoints. When we assessed
whether the EAR, which is triggered by cellular redox imbalance, was activated following antiretroviral
exposure, no biologically relevant increases in target gene mRNAs or proteins, such as HO-1 or NQO1
were detected (Li, 2009). Furthermore, scavenging of ROS with the antioxidant compound MMF did not
rescue PI-induced decreases in oligodendrocyte differentiation despite previously demonstrated
neuroprotection (Akay et al., 2014). PIs have also been shown to activate the UPR in non-CNS cells, which
potently suppresses protein translation while upregulating stress-response proteins (Zhou, 2005, 2006,
Brown and Naidoo, 2012). However, we found no evidence of UPR activation in oligodendrocytes
following antiretroviral treatments at two timepoints where such activation was evident in neuroglial
cultures (Akay et al., 2014), although we acknowledge that there may be activation at earlier or later time
points. Thus, our data suggest that PIs inhibit oligodendrocyte maturation through an alternate mechanism.
An intriguing possibility is whether PIs disrupt the crucially important myelin-lipid balance, which may
result in inappropriate organization of myelin components, as previously reported (Maier et al., 2009,
Chrast et al., 2011, Lee et al., 2014, Frid et al., 2015). Since PIs have been shown to cause dyslipidemia in
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patients and in non-CNS cell types (Carr, 1998, Haughey et al., 2004, Zhou, 2005), this could contribute to
the white matter loss seen in HAND patients (Tate et al., 2010, Kelly et al., 2014).

The effects of antiretrovirals on myelin in vivo using both a mouse model and human autopsy cases also
indicate alterations in myelin proteins. In mice, we detected reduced levels of less abundant myelin proteins
in as little as 14 days of chronic exposure. Levels of the abundant structural myelin components MBP and
PLP were not affected in this short-term administration model. Changes in these critical proteins may be
unexpected in such a short time frame, as gross changes in myelin may be necessary to result in detectable
alterations. In our human cohort, we did observe a reduction in MBP in cART-experienced individuals with
HAND compared with cART-naïve individuals with HAND, and HIV(-) controls. This finding correlates
with a transcriptome analysis of virally controlled patients with HAND, which showed reduction of MBP
mRNA (Borjabad et al., 2011). The HIV(+)/ART group also displayed a significant increase in the amount
of CNPase over both HIV(-) and HIV(+) cART-naïve individuals, regardless of their neurocognitive status.
CNPase is the earliest myelin protein to be expressed during maturation (Scherer et al., 1994), and our
observation may reflect a remyelination attempt that is prematurely halted, failing to form mature myelin.

Current WHO guidelines urge immediate treatment of all infected children under the age of 5 years, and
adults with a CD4 count ≤ 350 cells/mm3. Guidelines suggest that first-line cART consist of two NRTIs
and a non-nucleoside reverse-transcriptase inhibitor (nNRTI). When second-line cART is necessary due to
acquired drug resistance, recommended regimens are composed of two NRTIs plus a Ritonavir-boosted PI,
either Lopinavir or Atazanavir. All infected children under 3 years of age are recommended a
Lopinavir/Ritonavir first-line regimen (WHO, 2013). As is clear from these guidelines, PI-based regimens
are extensively used in HIV treatment, particularly in children, during a time of critical cortical myelination
which primarily occurs from the postnatal period until late adolescence (Miller et al., 2012). Neurological
complications are common in infected children, with documentation of encephalopathy, progressive
multifocal leukoencephalopathy, cerebrovascular events, and emerging neurocognitive deficits leading to
developmental delays, motor, cognitive, and behavioral deficits (Wilmshurst et al., 2006, Crowell et al.,
2014, Wilmshurst et al., 2014). Our results showing an effective disruption in myelination following PI
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exposure may underlie these clinical presentations, and therefore have important ramifications for the
future treatment of pediatric HIV infection.

PI-supplemented regimens are generally prescribed to adults as second-line options. However, as lifelong
cART adherence is necessary, over the course of regimen alterations, most patients will be exposed to a
boosted PI. The maintenance and replacement of myelin in the brain is an active and ongoing process,
which is critical for proper neuronal functioning and survival (McLaurin and Yong, 1995). Remyelination
of neurons in the adult has been well documented, particularly through investigation into pathology and
potential treatments for Multiple Sclerosis (Hartley et al., 2014, Kutzelnigg and Lassmann, 2014).
Additionally, while traditionally viewed as an early life event, active myelin formation in adulthood is
required for motor learning (Long and Corfas, 2014, McKenzie et al., 2014). We have shown through our
mouse model that prolonged PI exposure may lead to reductions in adult cortical myelin proteins. More
importantly, human patients with HAND who had been treated with antiretrovirals for at least a year
demonstrated a significant reduction in MBP compared with uninfected individuals and HAND patients
who were cART-naïve. Therefore, therapeutics which will preserve the capacity for myelin formation and
the integrity of existing structures are of vital importance.

In summary, this study implicates antiretrovirals as a contributor to HAND pathology and its persistence in
virologically suppressed individuals. In human patients, the underlying viral infection complicates analysis
of consequences solely due to antiretrovirals. Our observed effects of antiretrovirals in conjunction with the
potential contribution of HIV-induced pathogenesis on oligodendrocytes highlight the necessity for
strategic drug development for new therapeutics with fewer deleterious side effects. While this study has
highlighted the effects of antiretroviral compounds, future work investigating the consequences of HIV
infection in the CNS on the oligodendrocyte population are also essential for a more complete
understanding of the changes to white matter in HIV-positive patients.

Furthermore, we must consider adjunctive therapies designed not only to alleviate neuronal dysfunction,
but also to preserve myelin formation and maintenance by oligodendrocytes. Persistent ROS elevation and
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oxidative damage are seen in treated HIV(+) individuals (Roc et al., 2007, Blas-Garcia et al., 2011). HO-1
deficiency has recently been reported in HIV(+) and HAND patients, suggesting inactivity of the EAR
pathway (Gill et al., 2014). Supporting this notion, we have reported that EAR and HO-1 upregulation by
the antioxidant MMF was successful in preventing ARV-induced oxidative stress and neuronal toxicity in
neuroglial cultures (Akay et al., 2014). Unfortunately, based on our current findings, while neurons may be
initially protected by adjunctive antioxidant therapy, oligodendrocytes would remain vulnerable and
neuronal pathology caused by myelin disruption would still persist. Thus, the effects of antiretrovirals on
oligodendrocyte maturation and myelin unveiled in this study illuminate the need for greater understanding
of viral- and therapy-mediated repercussions to the critically important oligodendroglial cell population in
order to attenuate neurocognitive deficits in HIV(+) individuals in the cART era.
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Table 1: Demographics of Human Subjects

Characteristic:

HIV (-)

HIV (+)
ARTnaïve

HIV (+)
ARTmedicated
>12mo

20

20

20

-

42.8 ± 5.6

39.7 ± 7.3

45.3 ± 6.7

0.032a

9.9 ± 5.7

10.0 ± 6.4

12.4 ± 7.9

0.455a

80%
20%

90%
10%

80%
20%

0.619b

Race
White (%)
Black (%)
Other/Unknown (%)

11 (55%)
7 (35%)
2 (10%)

12 (60%)
8 (40%)
0 (0%)

15 (75%)
5 (25%)
1 (5%)

0.498b

Ethnicity
Hispanic (%)
Non-Hispanic (%)

5 (25%)
15 (75%)

3 (15%)
17 (85%)

3 (15%)
17 (85%)

0.641b

0.009b

Number of Subjects
Age at death, mean ± SD
Hours post-mortem, mean ± SD
Sex
Male (%)
Female (%)

Neurocognitive Impairment Status
HAND (%)
Neuropsych. Impair. Other Origin (%)
Neurocognitively Normal (%)
No Neurocognitive Data (%)

-

6 (30%)
5 (25%)
1 (5%)
8 (40%)

14 (70%)
4 (20%)
2 (10%)
0 (0%)

ARV Treatment Status
PI-Experienced (%)
PI-Naïve (%)
NRTI-Experienced (%)
NRTI-Naïve (%)

-

-

17 (85%)
3 (15%)
20 (100%)
0 (0%)

Disease Parameters
HIVE (%)
Log Plasma HIV c/mL, mean ± SD
Log Brain HIV g/mL, mean ± SD
Log CSF HIV c/mL, mean ± SD
CD4+lymphocytes/mm3, mean ± SD

-

6 (30%)
4.1 ± 1.4
3.4 ± 1.9
3.4 ± 1.8
108 ± 118

1 (5%)
4.7 ± 1.1
4.1 ± 0.9
2.8 ± 1.1
85 ± 118

p-value

0.196c
0.358c
0.261c
0.624c

Table 4.1: Demographics of Human Subjects
Summary of human cohort demographics, antiretroviral therapy history, and clinical data utilized for postmortem analysis. Abbreviations: Antiretroviral Therapy (ART), standard deviation (SD), HIV-Associated
Neurocognitive Disorders (HAND), Antiretroviral (ARV), HIV protease inhibitor-experienced (PIexperienced), nucleoside reverse transcriptase inhibitor-experienced (NRTI-experienced), HIV encephalitis
(HIVE). aAnalysis of Variance (ANOVA) p-value, bChi-square test p-value, c Student’s t-test p-value.
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Table 4.2 Primers Used for q-RT PCR
Primer pairs used for qRT-PCR are shown, which were obtained from IDT. Abbreviations are: PKG1,
Protein Kinase Gene 1; HO-1, Heme Oxygenase-1; NQO1, NAD(P)H:quinone oxidoreductase; XBP-1, Xbox Binding Protein 1; BiP, Binding Immunoglobulin Protein; CHOP, C/EBP homologous protein; Ire1α,
inositol-requiring enzyme 1 alpha; ATF6, activating transcription factor 6; ATF4, activating transcription
factor 4.
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Table 4.3 mRNA alterations in Endogenous Antioxidant Response Genes Following Antiretroviral
Application in Primary OPCs
Extracted RNA (5 µg) was converted to cDNA using the Superscript First-strand kit and q-PCR was
performed using Power SYBR Green. All measurements were normalized first to the oligodendrocyte
housekeeping gene PKG1, and then to controls. Analysis was performed by the ΔΔCT method.
Endogenous Antioxidant Response genes: HO-1 and NQO1 were probed. ΔΔCT ±SEM, fold change, and
fold change range are presented from 3 independent biological replicates (n = 3). P-values are indicated,
(*= p< 0.05).
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Table 4.4 mRNA alterations in Unfolded Protein Response Genes Following Antiretroviral
Application in Primary OPCs
Extracted RNA (5 µg) was converted to cDNA using the Superscript First-strand kit and q-PCR was
performed using Power SYBR Green. All measurements were normalized first to the oligodendrocyte
housekeeping gene PKG1, and then to controls. Analysis was performed by the ΔΔCT method. Unfolded
Protein Response genes: XBP-1 spliced, XBP-1 total, BiP, CHOP, Ire1α, ATF6, and ATF4 were probed.
ΔΔCT ±SEM, fold change, and fold change range are presented from 3 independent biological replicates (n
= 3). P-values are indicated, (*= p< 0.05).
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Figure 4.1: Antiretrovirals Inhibit Oligodendrocyte Differentiation
Primary mouse OPCs plated on coverslips were put into differentiation medium and treated with vehicle
(DMSO), doses of AZT (1 µM, 10 µM, or 25 µM), Ritonavir (100 nM, 1 µM, or 3 µM), or Lopinavir (150
nM, 1.5 µM, or 15 µM). After 72 hrs, cells were fixed and stained with antibody to MBP (green) with
DAPI (blue) for total cell nuclei. Epifluorescent images were captured, with 10 fields on three coverslips
per condition. Results from n= 4 independently prepared cultures.
A) Representative images from immunofluorescent staining, scale bar indicates 25 µm.
B-C) Immature oligodendrocytes (GalC+ cells) (B) and mature oligodendrocytes (MBP+ cells) (C) were
counted using ImageJ software, represented as percentage normalized to untreated. Results from AZT are
in the top row, Ritonavir in the center, and Lopinavir in the bottom row respectively. Data are presented as
mean ±SEM. One-way ANOVA followed by post-hoc Newman-Keuls determined statistical significance.
Significance compared with control (###= p< 0.001, ##= p< 0.01).
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Figure 4.2: Antiretrovirals Do Not Alter Oligodendrocyte Precursor Number or Induce Apoptotic
Cell Death
A-B) Primary mouse OPCs plated on coverslips were put into differentiation medium and treated with
vehicle (DMSO), doses of AZT (1 µM, 10 µM, or 25 µM), Ritonavir (100 nM, 1 µM, or 3 µM), or
Lopinavir (150 nM, 1.5 µM, or 15 µM). After 72 hrs, cells were fixed and stained with antibody to A2B5
with DAPI (blue) for total cell nuclei. Results from AZT are in the top row, Ritonavir in the center, and
Lopinavir in the bottom row respectively. Epifluorescent images were captured, with 10 fields on three
coverslips per condition.
A) Total cell number (DAPI+ nuclei) were counted using ImageJ software from the biological replicates
utilized for the dose curves in Figures 1 and 2 (n=8). Results are represented as percentage normalized to
untreated. Significance compared with control (#= p< 0.05). Data are presented as mean ±SEM. One-way
ANOVA followed by post-hoc Newman-Keuls determined statistical significance.
B) Oligodendrocyte precursor cells (A2B5+ cells) were counted using ImageJ software and are represented
as percentage normalized to untreated. Data are presented as mean ±SEM. Results from n= 3 independently
prepared cultures. One-way ANOVA followed by post-hoc Newman-Keuls determined statistical
significance.
C) Primary mouse OPCs plated on coverslips were put into differentiation medium and treated with vehicle
(DMSO), or doses of Lopinavir (1.5 µM, or 15 µM). After 72 hrs, cells were fixed and stained using a
TUNEL assay to label cells with double-stranded DNA breaks indicative of activation of the apoptotic
cascade. DNase was used as a positive control. Epifluorescent images were captured at 40x magnification,
with 10 fields on three coverslips per condition. Results from n= 2 independently prepared cultures. Data
are presented as mean ± SEM. One-way ANOVA followed by post-hoc Dunnett’s comparison determined
statistical significance. Significance compared with control (###= p< 0.001).
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Figure 4.3: Lopinavir Reduces Myelin Proteins but AZT and Ritonavir Do Not
OPCs were treated with vehicle, AZT (1 µM, 10 µM, or 25 µM), Ritonavir (100 nM, 1 µM, or 3 µM) or
Lopinavir (1.5 µM or 15 µM) at the time of differentiation. After 72 hrs cells were harvested for protein,
undifferentiated OPCs were harvested at time 0. Cell lysates were immunoblotted for MBP protein (A-C),
CNP protein (D), or PLP protein (E).
A) Representative Western blot image and quantification of band intensities normalized to loading control
GAPDH from 5 separate culture groups (n= 5) reveals the typical increase in MBP expression over 72
hours between OPC and untreated, however no significant change with any dose of AZT.
B) Analysis as in A) from n= 5 reveals the typical increase in MBP expression over 72 hours between OPC
and vehicle treatment, however no change with any dose of Ritonavir.
C) Representative Western blot image and quantification of band intensities normalized to loading control
GAPDH from n= 4 reveals treatment with 15 µM Lopinavir resulted in significantly less MBP expression
over 72 hours than with vehicle alone or with the lower 1.5 µM dose of Lopinavir.
D) Representative Western blot images with loading control GAPDH reveals less CNP expressed at 72
hours following treatment with 15 µM Lopinavir than with the vehicle alone, 25 µM AZT, or 3 µM
Ritonavir.
E) Representative Western blot images with loading control GAPDH reveals less PLP expressed at 72
hours following treatment with 15 µM Lopinavir than with the vehicle alone, 25 µM AZT, or 3 µM
Ritonavir.
Data are presented as mean ± SEM. One-way ANOVA followed by post-hoc Newman-Keuls determined
statistical significance across concentrations. Undifferentiated and controls (untreated or vehicle) were
compared by Student’s t-test (##= p< 0.01, #= p< 0.05).
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Figure 4.4: Antiretroviral Inhibition of Differentiation is Reversible
A) OPCs were treated with vehicle, 3 µM Ritonavir, or 15 µM Lopinavir at the time of differentiation.
After 72 hrs, cells were fixed and stained for GalC (green) with DAPI (blue) and Phalloidin (red) for actin.
Sample images reveal that cells in Ritonavir and Lopinavir treatments have elaborated morphology but lack
the appropriate maturation marker GalC co-staining. Scale bar indicates 25 µm.
B) OPCs were treated as in A. After 72 hrs, the washout group received new differentiation medium
without antiretrovirals and was allowed to further mature for 24 hrs. Cells were fixed and stained for GalC
with DAPI. Cells were counted as in Figure 1 for 15 fields in 3 coverslips per condition at 40x
magnification. Data are presented as mean ± SEM, n= 4. One-way ANOVA followed by post-hoc
Bonferroni correction compared vehicle and treatment conditions at the two time-points (#= p< 0.05, ##=
p< 0.01, ###= p< 0.001, ns= not significant).
C) OPCs were treated with Vehicle or 15 µM Lopinavir at the time of differentiation. After 72 hrs, the
washout group received new differentiation medium without treatment and was allowed to further mature
for 24 hrs. Cell lysates were immunoblotted for MBP protein. Representative Western blot image shown.
Quantification of band intensities normalized to a loading control reveals that Lopinavir-treated cells
expressed less MBP protein compared with vehicle; however this level rose to be comparable to vehicle 24
hours after washout. Data are presented as mean ± SEM, n= 3. One-way ANOVA followed by post-hoc
Bonferroni correction compared vehicle and treatment conditions at the two time-points (#= p< 0.05).
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Figure 4.5: Antiretrovirals Induce Oxidative Stress
OPCs were treated with vehicle, AZT (1 µM, 10 µM, or 25 µM), Ritonavir (100 nM, 1 µM or 3 µM),
Lopinavir (150 nM, 1.5 µM, or 15 µM), or positive control tBHP (2.5 µM) for 30 min, 1 hr, 2 hrs, 6 hrs, 12
hrs, and 24 hrs to determine if reactive oxygen species (ROS) were generated. DHE staining was used as an
indicator of ROS, with DAPI staining for cell nuclei. Epifluorescent images were captured at 40x
magnification, with 10 fields on three coverslips per condition at the time-point where ROS began to
accumulate for each antiretroviral compound. Scale bar indicates 25 µm. In treatments up to 24 hrs,
Lopinavir produced no accumulation. Analysis using Metamorph determined fluorescence intensity of
DHE normalized to nuclear DAPI area. Representative experiments shown, values are presented as mean
±SEM, n= 2 for each time-point tested. One-way ANOVA followed by post-hoc Newman-Keuls
determined statistical significance (##= p< 0.01, ###= p< 0.001).
A) Representative images of 1 hr tBHP- and Ritonavir-treated and 2 hr AZT-treated OPCs, with DHE
fluorescence (red) and cell nuclei stained with DAPI (blue).
B) Quantification of these experiments.
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Figure 4.6: The Endogenous Antioxidant Response is Not Triggered by Antiretrovirals in Developing
OPCs
OPCs were treated with vehicle, 25 µM AZT, 3 µM Ritonavir, or 15 µM Lopinavir at the time of
differentiation. After 16 hrs cells were harvested for protein. Cell lysates were immunoblotted for Heme
Oxygenase-1 (HO-1) (A) and NAD(P)H:quinone oxidoreductase (NQO1) (B), target proteins upregulated
following activation of the endogenous antioxidant response. Representative Western blot images shown,
with quantification of band intensities normalized to GAPDH loading controls revealing no change with
any treatment condition. Data are presented as mean ± SEM from 3 separate cultures (n= 3). One-way
ANOVA followed by post-hoc Dunnett’s multiple comparison determined statistical significance.
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Figure 4.7: Effective Reduction of Reactive Oxygen Species Does not Rescue Maturation Defects
A) OPCs were pre-treated with 10 µM monomethyl fumarate (MMF) for 6 hrs. Cultures were then
supplemented with MMF and/or treated with vehicle, 25 µM AZT or 3 µM Ritonavir for 2 hrs or 15 µM
Lopinavir for 6 hrs. DHE staining, imaging and analysis was performed as in Figure 4. Representative
experiment shown, values are presented as mean ± SEM, n= 2. Student’s t-test determined significance for
direct comparisons (#= p< 0.05, ##= p< 0.001).
B) OPCs plated on coverslips were pre-treated with 10 µM MMF for 24 hrs. Cells were then switched into
DM, supplemented with MMF and/or treated with vehicle, 3 µM Ritonavir or 15 µM Lopinavir. MMF was
replenished at 24 and 48 hrs. After 72 hrs, cells were fixed and stained for GalC and DAPI, and were
imaged and analyzed as in Figure 1. Data are presented as mean ± SEM, from 3 separate cultures (n= 3).
Student’s t-test determined significance for direct comparisons (##= p< 0.01, ###= p< 0.001).
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Figure 4.8: The Unfolded Protein Response is Not Triggered by Antiretrovirals in Developing OPCs
OPCs were treated with vehicle, 25 µM AZT, 3 µM Ritonavir, or 15 µM Lopinavir at the time of
differentiation. After 16 hrs cells were harvested for protein. Cell lysates were immunoblotted for protein
alterations indicating activation of the unfolded protein response.
A) Representative Western blot images shown of BiP, with quantification of band intensities normalized to
GAPDH loading controls from 3 independent biological replicates graphed.
B-E) Levels of phosphorylated compared to total eIF2a protein B), cleaved compared to total ATF6β
protein C), total IRE1α protein D), and phosphorylated compared to total IRE1α protein E), were each
analyzed from three separate biological replicates (n=3). Quantification of band intensities normalized to
GAPDH loading controls revealed no changes in any of these proteins following treatment with the
antiretrovirals tested. Data are presented as mean ± SEM. One-way ANOVA followed by post-hoc
Dunnett’s multiple comparison test determined statistical significance.
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Figure 4.9: In Vivo Ritonavir Administration Leads to Reduction in Myelin Proteins
Brain lysates derived from our jugular vein administration model were immunoblotted for various myelin
proteins: MBP, Myelin Oligodendrocyte Glycoprotein (MOG), CNP, Myelin-Associated Glycoprotein
(MAG), and PLP. The drug regimen was composed of vehicle (DMSO) or 20 mg/kg/day of Ritonavir for
14 days.
A) Western Blot images from frontal cortex lysates are shown (vehicle n= 6, Ritonavir n= 7).
B) Quantification of band intensities normalized to FastGreen FCF reveals statistically significant
decreases in MOG and CNP protein levels. Data are presented as mean ± SEM. Student’s t-test determined
statistical significance for direct comparisons (#= p< 0.05).
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Figure 4.10: Myelin Protein Expression in Humans is Not Affected by HIV Status
Lysates from prefrontal cortex specimens of HIV(-) controls, HIV(+) cART-naïve, and HIV(+) cARTmedicated >12mo (HIV(+)/ART), were immunoblotted for myelin component proteins MBP, MOG, CNP,
and MAG (n=20 for each group). Protein expression levels were determined by quantification of band
intensities normalized to a FastGreen total protein loading control. Patient samples were stratified by HIV
status with HIV(-) individuals compared with the HIV(+) cases, both cART-naïve and cART-medicated
combined, with red data points indicating patients diagnosed with HAND. Black lines indicate mean ±
SEM. Student’s t-test determined statistical significance for direct comparisons, result was not statistically
significant.
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Figure 4.11: Myelin Protein Expression in Humans is Affected by cART-Medication Status
Lysates from prefrontal cortex specimens of HIV(-) controls (n= 20), HIV(+) cART-naïve (n= 20), and
HIV(+) cART-medicated >12mo (HIV(+)/ART) (n= 20), were immunoblotted for myelin component
proteins MBP, MOG, CNP, and MAG. Protein expression levels were determined by quantification of band
intensities normalized to a FastGreen total protein loading control.
A) Patient samples were stratified by HIV-treatment status, with red data points indicating patients
diagnosed with HAND. Black lines indicate mean ± SEM. One-way ANOVA followed by post-hoc
Newman-Keuls determined statistical significance (##= p< 0.01).
B) Individuals satisfying criteria for HAND diagnosis were stratified by HIV-treatment status, Black lines
indicate mean ± SEM. One-way ANOVA followed by post-hoc Newman-Keuls determined statistical
significance (#= p< 0.05, ###= p< 0.001).
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5.1 ABSTRACT
Events leading to autoimmune targeting of myelin in Multiple Sclerosis (MS) patients remain unknown, yet
chronic oxidative stress is a pervasive disease feature. Tecfidera, (dimethyl fumarate), a recently released
drug that reduces MS relapse rates is thought to target oxidative stress. Tecfidera is rapidly metabolized to
monomethyl fumarate (MMF), which effectively promotes transcription factor Nrf2-mediated activation of
the endogenous antioxidant response (EAR) in neurons and macrophages. Effects of MMF have not been
examined in oligodendrocytes. Effective therapy will require both prevention of myelin loss and promotion
of re-myelination through maturation of oligodendrocyte precursors. We have previously demonstrated that
oxidative stress can halt oligodendrocyte differentiation. Also, we have shown that MMF can attenuate
oxidative stress-induced neurotoxicity through EAR upregulation. We hypothesized that MMF may reverse
stress-induced differentiation deficits in oligodendrocytes by EAR upregulation and subsequent attenuation
of oxidative stress. Treatment of mouse oligodendrocyte precursors and mature oligodendrocytes with an
oxidant resulted in accumulation of reactive oxygen species (ROS) and significant reduction in
differentiation; however, EAR target genes were not upregulated. MMF significantly reduced ROS
accumulation induced by multiple oxidants, but did not coincide with EAR activation. MMF also did not
rescue maturation defects, as comparable significant decreases were evident in oxidant alone and oxidant+
MMF conditions. Our results suggest that oligodendrocytes do not properly activate the EAR to restore
redox homeostasis, even after treatment with antioxidants such as MMF. As such, the therapeutic effect of
MMF in patients is likely due a mechanism other than direct antioxidant effects on oligodendrocytes.

5.2 SUMMARY STATEMENT
The biological metabolite of Multiple Sclerosis drug Tecfidera neither activates the endogenous antioxidant
response in oligodendrocytes, nor rescues oxidative stress-mediated differentiation deficits. These findings
suggest that Tecfidera reduces relapse rates in patients via a mechanism other than direct antioxidant
activity in oligodendrocytes, or that antioxidant effects are mediated through indirect actions of other cell
populations.
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5.3 INTRODUCTION
Multiple Sclerosis (MS) affects 2.3 million people worldwide, yet precipitating events leading to the
autoimmune targeting of myelin in patients are not well understood. Symptoms arise from disruption of
myelin integrity within white matter tracts in the brain, as the myelin membrane synthesized by CNS
oligodendrocytes is vital for proper transmission of rapid neuronal impulses through their axons (For recent
reviews see (Markowitz, 2013) and (Mallucci et al., 2015)). Cellular pathology includes both destruction of
myelin sheaths and death of the associated oligodendrocytes, as well as axonal damage and neuronal cell
death (Criste et al., 2014, Mallucci et al., 2015). In addition to disruption of proper action potential signal
facilitation, impaired myelination can alter the trophic support provided to neurons from oligodendrocytes,
hastening axonal degeneration (Lappe-Siefke et al., 2003, Edgar and Garbern, 2004, Criste et al., 2014,
Mighdoll et al., 2015).

Despite the unknown etiology of MS, two well-documented pathological observations are chronic oxidative
stress and inflammation (reviewed in (Friese et al., 2014, Mahad et al., 2015)). Studies have also identified
oxidative damage as one of the key driving elements in the aberrant loss of myelination observed in
children who suffer from periventricular white matter injury (PWMI) (Back and Rosenberg, 2014). This
brain damage occurring in pre-term infants targets white matter in particular, and is a major contributor to
subsequent neurological dysfunctions, which commonly includes cerebral palsy (Volpe, 1981, 2001).
While PWMI can be triggered by several independent events, one of the principal causes is lack of cerebral
oxygenation, which leads to the generation of oxidative stress and cell death of the particularly vulnerable
oligodendrocyte precursor cells (OPCs) (Back and Rosenberg, 2014). In several perinatal rat
hypoxia/ischemia models, reactive oxygen species generated by the insult resulted in injury and death of
OPCs, which led to subsequent decreased numbers of mature oligodendrocytes and hypomyelination of
white matter (Levison et al., 2001, Reid et al., 2012). Additionally, in vitro studies have demonstrated
maturation-stage specific vulnerability to oxidative stress, with OPCs and developing immature
oligodendrocytes displaying significantly more sensitivity than mature oligodendrocytes due to lower levels
of glutathione and antioxidant enzymes, as well as higher rates of oxygen consumption (Halliwell, 1992,
Back et al., 1998, Fern and Moller, 2000, Baud et al., 2004).
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In the developing brain, loss of this critical OPC population profoundly impacts the total capacity of initial
myelination. Potential depletion of the pool of OPCs in the adult from chronic oxidative stress has similar
repercussions for the capability for effective re-myelination of affected areas in MS. In addition to OPC
dropout due to oxidative stress-induced toxicity, we have previously demonstrated that at sub-toxic levels,
oxidative stress generated by multiple compounds halts oligodendrocyte differentiation (French et al.,
2009). Together, these reports highlight the necessity for reduction of oxidative stress to facilitate recovery
of function in demyelinating conditions, as the pool of cells responsible for re-myelination are negatively
affected both by functional and toxicity-based mechanisms.

The recently FDA-approved drug Tecfidera (BG-12, (dimethyl fumarate)) has been demonstrated to reduce
relapse rates in MS patients (FDA, 2013, Limmroth, 2013, Fox et al., 2014, Dubey et al., 2015, English and
Aloi, 2015). Intriguingly, while suspected to act as an antioxidant, the mechanism of action by which this
compound is effective has not been elucidated. The chemical formulation of this drug is dimethyl fumarate
(DMF), a fumaric acid ester, which is rapidly metabolized to monomethyl fumarate (MMF) (Litjens et al.,
2004, Schmidt et al., 2007, Limmroth, 2013, Fox et al., 2014). Within minutes of administration, MMF is
the primary metabolite found in blood plasma, with DMF no longer detectable (Schmidt et al., 2007).
Critically, marked reduction of macrophage recruitment into actively demyelinating brain regions was
observed following oral DMF administration in a rodent experimental autoimmune encephalomyelitis
model of MS, demonstrating that therapeutic levels of MMF cross the blood brain barrier (Schilling et al.,
2006). In neurons and macrophages, antioxidant effects of MMF have been reported, through NF-E2
(nuclear factor (erythroid-derived 2))-related factor-2 (Nrf2) mediated activation of the endogenous
antioxidant response (EAR) and upregulation of target antioxidant and detoxifying genes (Cross et al.,
2011, Linker et al., 2011, Albrecht et al., 2012, Scannevin et al., 2012, Akay et al., 2014). We have
demonstrated successful MMF amelioration of oxidative stress-mediated neuronal toxicity through such
activation (Akay et al., 2014). Surprisingly, the direct effects of MMF on signaling pathways of primary
oligodendrocytes, the initially affected cell population in MS pathology, have not been explored.
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Here, we investigated whether MMF was capable of reducing oxidative stress and upregulating the EAR in
oligodendrocytes, and if this led to a reversal of stress-induced deficits in differentiation. Our results
indicate that oligodendrocytes do not activate the EAR under conditions of oxidative stress to restore redox
homeostasis. Furthermore, in contrast to other CNS-resident cell populations, MMF does not upregulate
this pathway in oligodendrocytes through Nrf2-mediated transcription of canonical EAR target genes.
These findings suggest that the beneficial effect of Tecfidera in MS patients is likely due to a mechanism
other than direct antioxidant effects on oligodendrocytes, either through alternative anti-inflammatory
pathway actions, or through upregulation of EAR proteins in other cell types which act cell nonautonomously to provide protection to mature oligodendrocytes and OPCs differentiating to restore
insufficient myelination.

5.4 MATERIALS AND METHODS
Chemicals and Reagents
Abcam: rabbit polyclonal anti-NAD(P)H:quinone oxidoreductase antibody (NQO1, ab34173). Chemicon
International (Temecula, CA): mouse monoclonal anti-glyceraldehyde 3-phosphate dehydrogenase
antibody (GAPDH, MAB374). Covance Laboratories (Conshohocken, PA): mouse monoclonal anti-myelin
basic protein antibody (MBP, SMI-99). Enzo Life Sciences (Plymouth Meeting, PA): rabbit polyclonal
anti-Heme Oxygenase-1 antibody (HO-1, SPA-896). Life Technologies (Carlsbad, CA): B27 Supplement,
4-12% Bis-Tris gradient gels, dihydroethidium, Dulbecco’s Modified Eagle’s Medium (DMEM),
DMEM/F12, Ham’s F12, L-glutamine, Hank’s Balanced Salt Solution (HBSS), Neurobasal Medium,
Penicillin/Streptomycin. Jackson Immunoresearch Laboratories (West Grove, PA): FITC-conjugated goat
anti-mouse IgG3, Rhodamine-conjugated goat anti-rat IgG, LiCOR (Lincoln, NE): Odyssey goat antimouse IRdye 800CW, goat anti-mouse IRdye 680RD, goat anti-rabbit IRdye 680RD. Peprotech (Rocky
Hill, NJ): neurotrophin-3 (NT-3). Peptide International: poly-D-lysine. R&D Systems (Minneapolis, MN):
basic fibroblast growth factor (bFGF), platelet-derived growth factor AA (PDGF-AA). Sigma Aldrich (St.
Louis, MO): L-Buthionine-sulfoximine (BSO), biotin, dimethyl sulfoxide (DMSO), hydrogen peroxide
solution, insulin, monomethyl fumarate (MMF), progesterone, protease inhibitor cocktail, putrescine,
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selenium, tert-Butyl hydroperoxide (tBHP), thyroxine (T4), transferrin. Vector Laboratories (Burlingame,
CA): Vectashield with DAPI.

Additional antibodies: anti-galactocerebroside mouse hybridoma supernatant (GalC H8H9, (Ranscht et al.,
1982)), anti-myelin basic protein rat hybridoma supernatant (MBP, gift of Virginia Lee, University of
Pennsylvania).

Primary Mouse Oligodendrocyte Cultures
All experiments were performed following the guidelines set forth by The Children’s Hospital of
Philadelphia Institutional Animal Care and Use Committee (IACUC). Primary oligodendrocyte precursor
cell cultures were generated from postnatal day 1 CD1 mouse pups with modifications from previously
described methods (See et al., 2004). Briefly, cortical cell suspensions isolated from pups obtained from
Charles River Laboratories were plated on poly-D-lysine (PDL) coated flasks in Neurobasal Medium with
B27 supplement at 37°C with 5% CO2. Cells were switched into growth medium consisting of Neurobasal
Medium +B27 supplemented with 10 ng/ml bFGF, 2 ng/ml PDGF-AA, and 1 ng/ml NT-3 24 hours after
isolation. After growing to confluence, cultures were purified to 90-95% oligodendrocyte precursor cells
(OPCs) and 5-15% astrocytes using a wash-down procedure (Feigenson et al., 2009), after which cells were
sub-cultured onto PDL-coated coverslips or Petri dishes. To facilitate transition of OPCs into maturing
oligodendrocytes, growth medium was replaced with differentiation medium, consisting of 50% DMEM,
50% Ham’s F12, Pen/Strep, 2 mM glutamine, 50 µg/ml transferrin, 5 µg/ml putrescine, 3 ng/ml
progesterone, 2.6 ng/ml selenium, 12.5 µg/ml insulin, 0.4 µg/ml T4, 0.3% glucose, and 10 ng/ml biotin
(Feigenson et al., 2009).

Detection of Reactive Oxygen Species
Dihydroethidium (DHE) was used to detect the presence of reactive oxygen species in vitro for cells grown
on coverslips, as oxidation of DHE by superoxide allows for intercalation with nuclear DNA, and emission
of a quantifiable red fluorescence (Zhao, 2003). 3 µM DHE was added to the culture medium 15 minutes
prior to the end of treatments. Cells were then washed with F12 medium, fixed with ice-cold acid alcohol
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for 8 minutes, re-washed, and then mounted on slides with Vectashield containing DAPI to stain nuclei.
Ten non-overlapping fields per coverslip were imaged from 3 independent wells for each treatment from at
least 3 biologically independent primary cell preparations. The Advanced Fluorescence Leica Application
Suite was used for image acquisition, coupled with a Leica DM6000B fluorescence microscope equipped
with a DFC240 camera at 40x magnification (HCX PL APO 40x/0.85 CORR objective). MetaMorph 6.0
software (Molecular Devices, Sunnyvale, CA) was used for post-acquisition analysis, which determined the
fluorescence intensity of nuclear intercalated DHE normalized to the total DAPI area.

Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR)
The expression of Heme Oxygenase-1 (HO-1), NAD(P)H:quinone oxidoreductase (NQO1), NF-E2
(nuclear factor (erythroid-derived 2))-related factor-2 (Nrf2), and Myelin Basic Protein (MBP) mRNA were
quantified by qRT-PCR. For endogenous antioxidant response targets HO-1, NQO1, and Nrf2, OPC
cultures or 72 hour matured oligodendrocytes grown on 100-mm dishes were harvested 6 hours following
treatment. To isolate RNA for myelin component protein MBP, cells were treated at the time of
differentiation and harvested 72 hours later. Following Trizol extraction, 5 µg of RNA was converted to
cDNA (Invitrogen Superscript First-strand kit). q-PCR was performed as previously described using Power
SYBR Green, with samples measured in triplicate from three independent biological replicates (n=3)
(French et al., 2009, Feigenson et al., 2011). Data was analyzed according to the ΔΔCT method, with
normalization to Protein Kinase Gene 1 (PKG1). Table 5.1 details the primer pairs for each gene, obtained
from Integrated DNA Technologies (IDT).

Immunoblotting
Whole-cell extracts were prepared from primary mouse oligodendrocyte cultures using ice-cold lysis buffer
(50 mM Tris pH 7.5, 120 mM NaCl, 0.5% NP-40, 10 mM EDTA, 0.5 mM Na3VO4, and 1:100 protease
inhibitor cocktail), followed by centrifugation at 14,000 rpm at 4°C for 30 minutes. Protein concentrations
were determined using a NanoDrop 1000 Spectrophotometer A280 absorbance assay. A broad spectrum
molecular weight ladder was run alongside treatment samples containing 25-50 µg of protein per lane of 412% Bis-Tris gradient gels for separation. Following electrophoresis, proteins were transferred onto
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Immobilon-FL membranes (Millipore), and blocked in PBS with 0.1% Tween-20 (PBST) and 5% milk for
20 minutes at room temperature (RT). Membranes were then incubated overnight with primary antibodies
in PBST+ milk at 4°C. The following primary antibodies were utilized: HO-1 (1:1000 dilution), NQO1
(1:1000 dilution), and MBP (SMI-99, 1:500 dilution). Membranes were rinsed with PSBT, re-blocked for
20 minutes at RT in PBST+ milk, then incubated with secondary antibodies with corresponding antigenspecific fluorescent probes (1:10,000 in PBST+ milk). An Odyssey Infrared Imaging System (LiCOR) was
used to visualize membranes. Re-blotting for GAPDH (1:1000 dilution) obtained loading controls for each
membrane. Pixel intensities for each treatment were determined by quantifying specified bands of interest
using the NIH ImageJ program (V1.36b, Bethesda, MD). These values were normalized to those obtained
from analysis of loading control GAPDH.

Immunofluorescence
Detection of specific antigens for primary oligodendrocyte lineage cells grown on coverslips was
performed as previously described (Grinspan and Franceschini, 1995, See et al., 2004). Live cells were
labeled for cell surface marker detection prior to fixation using anti-GalC (mouse hybridoma supernatant,
undiluted) followed by FITC-conjugated goat anti-mouse IgG3 (1:100 dilution). Following acid alcohol
fixation and permeabilization, internal antigens were detected using anti-MBP (rat hybridoma supernatant,
1:2 dilution) followed by Rhodamine-conjugated goat anti-rat IgG (1:100 dilution). Vectashield with DAPI
was used to mount slides while also staining all cell nuclei. Images were acquired as previously described
for DHE staining, with 10 non-overlapping fields in each of 3 coverslips per condition from at least 3
independent primary cell isolations. Antigen-positive and DAPI-positive cells were counted from each
sampled field, with approximately 2000 cells counted per treatment condition.

Statistical Analysis
Prism 5.0 software (GraphPad Software, San Diego, CA) was used to analyze all data. Values are
expressed as mean ± SEM, with p < 0.05 considered significant. Student’s t-test or One-way ANOVA with
post-hoc Dunnett’s multiple comparison test were performed where indicated.
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5.5 RESULTS
Reactive oxygen species accumulate in oligodendrocytes following oxidant treatment
There is a large body of evidence gathered from in vitro, animal, and human patient studies to suggest that
oligodendrocyte precursor cells (OPCs) and immature oligodendrocytes are particularly vulnerable to
oxidative stress (Halliwell, 1992, Back et al., 1998, Fern and Moller, 2000, Levison et al., 2001, Baud et
al., 2004, Back and Rosenberg, 2014). It critical to understand how oxidative stress affects the processes of
differentiation and myelination of these susceptible precursor cells. The process of oligodendrocyte
maturation is well defined, with tightly regulated transcription factor activity and characteristic cellular
markers corresponding to specific stages of differentiation utilized to track lineage progression (Miller,
2002). Previous work within our laboratory determined that oligodendrocyte differentiation is halted
following oxidant treatment using these established methods (French et al., 2009, Reid et al., 2012).

Surprisingly, the mechanism by which oligodendrocytes respond to oxidative stress is not understood. To
model oxidative stress in an in vitro model of oligodendrocyte differentiation, we used the oxidant tertbutyl hydroperoxide (tBHP), a cell-permeable compound that generates tert-butoxyl radicals, resulting in
depletion of intracellular glutathione and lipid peroxidation (Back et al., 1998, Zhao et al., 2005, French et
al., 2009). Oligodendrocyte lineage cells were isolated as OPCs and induced to differentiate over a 72 hour
period into maturing oligodendrocytes (OLs) following our previously described maturation paradigm (See
et al., 2004). OPCs and 72hr differentiated OLs were exposed to 2.5 µM tBHP for 30 minutes, 1 hour, 2
hours, 6 hours, 12 hours, or 24 hours. Cells were then stained with the ROS indicator dihydroethidium, a
cell-permeable fluor that intercalates into DNA when oxidized to ethidium (Zhao, 2003). Following the
timecourse outlined above, we found that tBHP treatment produced robust ROS accumulation by 1 hour in
both OPCs (677% ± 76.2%, p < 0.01) (Figure 5.1A), and in OLs (3451% ± 1454%, p < 0.01) when
compared with untreated (Figure 5.1B).

Oxidative insult does not upregulate the EAR in oligodendrocytes
High levels of ROS were evident following application of the oxidant tBHP in both OPCs and mature OLs.
In many cell types including neurons and astrocytes, when such a cellular imbalance in redox homeostasis
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occurs, there is activation of the endogenous antioxidant response (EAR) (Chen et al., 2009, Li, 2009). We
next examined whether oligodendrocyte lineage cells activated this cellular signaling pathway following
exposure to oxidants and subsequent ROS accumulation. OPCs or OLs were treated with tBHP for 6 or 16
hours and assayed for EAR targets by qPCR and immunoblot analysis. Quantification of mRNA following
tBHP application to OPCs revealed no significant changes after 6 hours in the principle targets of the EAR:
Nrf2, Heme Oxygenase-1 (HO-1), and NAD(P)H:quinone oxidoreductase (NQO1) (Table 5.2). Consistent
with these results, immunoblotting for HO-1 and NQO1 following 16 hours of treatment also revealed no
significant changes in protein levels (Figure 5.2A-B). In mature OLs, analysis of the EAR targets also
revealed no changes in mRNA levels after 6 hours of tBHP treatment (Table 5.2). Similarly, following 16
hours of treatment, no significant alterations in HO-1 or NQO1 protein levels were observed (Figure 5.2CD). Therefore, in contrast to many other cell types, both oligodendrocyte precursors and mature OLs do not
appear to activate the EAR despite robust accumulation of ROS.

Oxidative Insult Inhibits Oligodendrocyte Maturation
In our previous work we described alterations in levels of transcription factors responsible for induction of
oligodendrocyte differentiation, and a consequent reduction in the number of cells expressing immature
oligodendrocyte cell surface marker Galactocerebroside (GalC) following treatment with 5 µM tBHP
(French et al., 2009). Here we have expanded on those findings to encompass markers for mature
oligodendrocytes by immunofluorescent staining, mRNA, and protein evidence using our differentiation
paradigm. Following tBHP treatment for 72 hours in differentiation medium, immunofluorescent staining
reveals that the lower dose of 2.5 µM tBHP used in the present study significantly reduced the number of
cells expressing differentiation markers, while not reducing total cell number. Representative images of
untreated and tBHP treated oligodendrocytes 72 hours after differentiation illustrate differentiation deficits,
with extent of maturation determined by quantifying the percentage of GalC+ and MBP+ cells across
treatments (Figure 5.3A). Following tBHP treatment, the number of cells expressing the immature marker
GalC was significantly reduced by 23.11% ± 5.4% (p < .01). Similarly, the number of MBP+ mature
oligodendrocytes was significantly reduced by 22.42% ± 6.71% (p < .05). The number of total cells in the
tBHP treated condition was not significantly affected (Figure 5.3A).
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We next examined whether this reduction in maturation at the cell surface was reflected in a reduction in
myelin basic protein (MBP) mRNA and protein. OPCs were treated with tBHP at the time of
differentiation, with mRNA and protein harvested 72 hours later. Analysis determined that while a
significant upregulation of MBP mRNA was observed between undifferentiated OPCs and 72 hour mature
OLs (p < .05), the levels of MBP mRNA were comparable between the untreated OLs and the tBHP treated
condition (Figure 5.3B). At this same point in differentiation, the amount of MBP protein in the untreated
oligodendrocytes had significantly increased by approximately 2 fold over OPCs (p < 0.05). Notably, tBHP
treatment resulted in a dramatic reduction in MBP protein expression levels when compared with untreated
(p < 0.05) and no significant increase observed when compared with OPCs (Figure 5.3C). Taking these
results together, we conclude that oxidative stress induced by tBHP halts oligodendrocyte maturation by
altering expression of myelin component proteins levels.

MMF reduces ROS accumulation induced by various oxidant compounds
Oxidative stress generated by tBHP caused the accumulation of ROS and differentiation deficits in
maturing OPCs without activation of the EAR. Therefore, we next determined if attenuating ROS would
prevent the oxidant-induced maturation blockade. We utilized the fumaric acid ester monomethyl fumarate
(MMF), which is the active metabolite of the FDA approved MS therapeutic compound dimethyl fumarate
(FDA, 2013, Limmroth, 2013). In neurons and macrophages, MMF behaves as an antioxidant through
Nrf2-mediated EAR activation (Cross et al., 2011, Linker et al., 2011, Albrecht et al., 2012, Scannevin et
al., 2012, Akay et al., 2014). We have previously demonstrated MMF-mediated protection from oxidative
stress-induced toxicity in neurons through EAR pathway activity (Akay et al., 2014). In order to determine
whether MMF is effective at reducing oxidant-induced ROS accumulation, OPCs were pre-treated with 10
µM MMF for 6 hours to allow for potential upregulation of EAR target proteins. Cells were then treated
with oxidants for an additional 2 hours. In addition to 2.5 µM tBHP, 100 µM hydrogen peroxide, and 100
µM L-buthionine sulfoximine (BSO) were utilized. Hydrogen peroxide is a strong, oxidizing agent which
will generate abundant highly reactive hydroxyl radicals within the cell (Sies, 1993). BSO was selected as
it is a selective inhibitor of γ-glutamylcysteine synthetase, the enzyme which catalyzes the rate-limiting
step of glutathione synthesis (Meister, 1992, French et al., 2009). This set of compounds allows for analysis
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of oxidants with various properties, and can potentially differentiate between effects caused by tBHP and
BSO-mediated glutathione depletion versus whole-cell effects caused by hydroxyl radical-based
modifications. Following treatment, DHE staining revealed that MMF pre-treatment significantly reduced
the amount of ROS accumulation induced by tBHP (Figure 5.4A), hydrogen peroxide (B), and BSO (C).

MMF fails to rescue differentiation defect caused by oxidative insult
MMF was successful at reducing the accumulation of ROS in OPCs induced by multiple oxidant
compounds. We next assessed whether this reduction of oxidative stress would increase the number of
mature oligodendrocytes following oxidant treatment. OPCs were pre-treated with MMF for 24 hours, after
which they were switched into differentiation medium and treated with the oxidants as previously
described. MMF was replenished at the time of differentiation, and at 24 and 48 hours. After 72 hours of
differentiation, cells were stained for GalC and MBP to assess maturation. Significantly fewer cells
expressed the immature marker GalC following treatment with each oxidant, with significantly fewer cells
expressing the mature marker MBP with tBHP and hydrogen peroxide treatment (Figure 5.5A-B). Notably,
concomitant treatment with MMF did not rescue the observed maturation deficits caused by any of the
oxidants. The effects of BSO were milder than that of the other two oxidants, with modest though not
significant reduction in percentage of cells maturing to the MBP+ stage (Figure 5.5B). At this dose,
hydrogen peroxide appears to cause both a significant loss of cells due to toxicity (Figure 5.5C) as well as
an oxidant-mediated inhibition of differentiation, as a negligible number of the remaining cells progressed
to either the GalC+ or MBP+ maturation stages (Figure 5.5A-B). Together these results suggest that despite
effectively reducing ROS accumulation and oxidative stress, MMF failed to rescue the oligodendrocyte
differentiation deficits caused by several oxidant compounds.

MMF does not upregulate components of the EAR in developing oligodendrocytes
While MMF has been shown to upregulate components of the EAR in other CNS cell populations (Cross et
al., 2011, Linker et al., 2011, Albrecht et al., 2012, Scannevin et al., 2012, Akay et al., 2014), the direct
effects of this compound on the EAR pathway of primary oligodendrocytes have not been examined. In
order to investigate if MMF acts to stimulate the EAR pathway in oligodendrocytes, we examined
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expression of downstream EAR targets in maturing oligodendrocytes following MMF application over
time. OPCs were treated with 10 µM MMF at the time of differentiation. Lysates were harvested for protein
analysis at 0, 2, 6, 12, and 24 hours. Surprisingly, neither HO-1 (Figure 5.6A) nor NQO1 (Figure 5.6B)
protein levels were increased in MMF treated cells at any time point tested. We do not discount that EAR
upregulation may occur at a later time interval. We feel that this is unlikely however, as in our neuroglial
culture studies we saw effects within 6 hours, and MMF replenishment was required every 24 hours to
maintain efficacy (Akay et al., 2014). Therefore, in contrast to other CNS cell types, MMF does not
upregulate the EAR in oligodendrocytes.

5.6 DISCUSSION
Multiple Sclerosis is a devastating demyelinating condition for which the etiology is still not understood.
At present, therapies which reduce chronic levels of oxidative stress and inflammation have been aimed at
restoring quality of life and reducing relapse rates in patients (Friese et al., 2014, Mahad et al., 2015). Here,
we investigate the consequences of oxidative stress on oligodendrocyte maturation, and the potential
actions of an FDA approved MS therapeutic compound, which has been proposed to act through
antioxidant means. This compound, Tecfidera, potentially works by boosting activation of Nrf2
transcription factor-mediated induction of the endogenous antioxidant response (EAR) element in the
promoters of a specific cohort of genes which clear excess reactive oxygen species (ROS) from cells. The
regulation of this pathway in oligodendrocytes and its role in directly decreasing oxidative damage in
oligodendrocytes has not previously been tested. We provide compelling evidence that exposure to
oxidants produces ROS accumulation in both oligodendrocyte precursors and mature oligodendrocytes, yet
unlike other neural cell types fails to elicit a consequential activation of the endogenous antioxidant
response element. As a possible result of this failure, when OPCs are exposed to an oxidant at the time of
differentiation, they are unable to differentiate into immature and then mature oligodendrocytes and do not
express myelin proteins nor traffic them appropriately for insertion into their cell membranes. We have
shown that MMF, the active metabolite of Tecfidera (BG-12, dimethyl fumarate), successfully attenuated
ROS accumulation in OPCs and mature oligodendrocytes caused by various oxidant compounds as
anticipated. However, MMF failed to rescue oxidative-stress mediated differentiation deficits induced by
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these compounds. Contrary to expectations, based on previously reported evidence in cells of a wide
variety of neuroglial cell lineages (Cross et al., 2011, Linker et al., 2011, Albrecht et al., 2012, Scannevin et
al., 2012, Akay et al., 2014), MMF did not upregulate EAR target genes at any time during an extended
timecourse. These observations may suggest that the antioxidant effects of Tecfidera in reducing MS
relapse rates by lowering oxidative stress levels to allow for oligodendrocyte survival and maturation are
indirect and mediated through other neural cell types.

The mechanism by which myelin is initially targeted in MS is not understood, however it is clear that once
initiated, chronic inflammation and oxidative stress drive much of the pathology. Activated immune cells
secrete a variety of pro-inflammatory cytokines and reactive oxygen species (Haider, 2015). Immature
oligodendrocytes and oligodendrocyte precursors in particular are exceptionally vulnerable to oxidative
insults due to high energy demands and low glutathione and antioxidant enzyme levels (Halliwell, 1992,
Back et al., 1998, Fern and Moller, 2000, Baud et al., 2004). Disruption of myelin caused by the effects of
oxidative stress on oligodendrocytes can then lead to degeneration, both of affected oligodendrocytes and
the neurons they no longer effectively insulate. Concomitantly, oxidative stress stops OPCs from
differentiating and replacing the damaged mature oligodendrocytes. The breakup of myelin and cellular
loss can then lead to further macrophage recruitment to clear cellular debris, thus perpetuating the cycle
(Friese et al., 2014, Mahad et al., 2015). The primary cellular response leading to attenuation of oxidative
stress is the EAR pathway, through targeted Nrf2-mediated transcriptional upregulation of genes with an
antioxidant response element in their promoter regions (Li, 2009). Activation of this pathway increases the
expression of Phase II detoxifying enzymes and antioxidants, including NADP(H) quinone oxidoreductase
(NQO1) and Heme oxygenase-1 (HO-1) (Li, 2009).

The consistent observation of oxidative stress in active demyelinating MS lesions prompted investigation
into whether cells within these regions upregulate their EAR in an effort to combat the persistently high
levels of ROS. The Nrf2 target protein, NQO1, was found to be highly abundant in chronic and active
lesions, though this was restricted to the astrocyte and macrophage cell populations (van Horssen et al.,
2006). In animal models of MS, HO-1 was found in high abundance in macrophages, microglia, and
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astrocytes during the acute phase of injury, and in oligodendrocytes in early lesions (Stahnke et al., 2007).
Recently, the presence of Nrf2 and its targets was identified in oligodendrocytes in MS lesions. LichtMayer et al examined active demyelinating regions from MS patients and found strong nuclear expression
of the transcription factor Nrf2 and its downstream target HO-1 in oligodendrocytes, though the highest
enrichment of these proteins is found in degenerating cells (Licht-Mayer et al., 2015). The authors
comment that because Nrf2 is already highly expressed in oligodendrocytes in active lesions, it is doubtful
that further stimulating the ARE by fumarates would protect oligodendrocytes in any way. Additionally, it
can be difficult to draw conclusions regarding stress response proteins in diseased tissue, as cells viewed
from a single point in time can either be effectively combatting the unfavorable stressful situation, or fated
for cell death after an unsuccessful attempt at overcoming such conditions.

In contrast to other cell types examined, little is known about the protective effects of the EAR in
oligodendrocytes. Studies using OLN-98 cells and primary rat oligodendrocytes exposed to hydrogen
peroxide have demonstrated HO-1 upregulation by immunoblotting (Goldbaum and Richter-Landsberg,
2001, Stahnke et al., 2007). However, the oxidative insult applied also culminated in loss of mitochondrial
function and apoptosis, suggesting this upregulation was not sufficient to protect the cells (Goldbaum and
Richter-Landsberg, 2001). In our current work, we have examined the role of the EAR in protecting
oligodendrocytes from oxidative stress in more detail. We demonstrated that ROS accumulate in OPCs and
mature OLs following oxidant exposure, yet this failed to promote upregulation of the EAR at the mRNA
or protein level in either stage of the oligodendrocyte lineage. Furthermore, exposure of OPCs to an oxidant
at the time of differentiation resulted in reduced maturation evaluated both by myelin protein expression, as
well as characteristic maturation-stage specific surface marker levels. Within this background, we
attempted to exogenously activate the EAR by directly treating oligodendrocyte lineage cells with a newly
approved drug aimed at ameliorating the chronic inflammation and oxidative stress seen in MS.

Tecfidera effectively reduces MS relapse rates (FDA, 2013, Limmroth, 2013, Fox et al., 2014, Dubey et al.,
2015, English and Aloi, 2015). This drug is composed of dimethyl fumarate (DMF), yet despite much
investigation, the cellular mechanism by which this compound is effective remains elusive. Antioxidant
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effects of DMF have been reported from in vitro studies in neurons, with Nrf2-mediated upregulation of
EAR target genes such as HO-1 conferring effective protection from oxidant challenge (Lehmann et al.,
2007, Albrecht et al., 2012, Wang et al., 2015). It is also suggested through these studies that DMF
culminates in antioxidant effects by directly interacting with glutathione via Michael-addition and affecting
glutathione recycling. Reduced to oxidized glutathione ratio serves as a critical redox homeostasis sensor
within the cell, and modulates amounts of xenobiotic and antioxidant enzymes accordingly (Ishii and
Mann, 2014, Espinosa-Diez et al., 2015). Normally, following electron donation oxidized glutathione is
reduced back to its original form by glutathione reductase (Ishii and Mann, 2014, Espinosa-Diez et al.,
2015). In the process of Michael-addition however, such as that which occurs between the Michael-donor
glutathione and Michael-acceptor dimethyl fumarate, a new carbon bond is formed between the nucleophile
glutathione the α,β-unsaturated carbon bond present within the DMF molecule, preventing subsequent
glutathione recycling (Lehmann et al., 2007, Albrecht et al., 2012, Wang et al., 2015). By depleting the
cellular store of this critical redox regulator, DMF causes a transient oxidative stress within the cell and
consequently an upregulation of EAR pathway activity (Lehmann et al., 2007, Albrecht et al., 2012).

Within our present study, we chose to evaluate the effects of the primary metabolite of DMF, monomethyl
fumarate (MMF). A critical and previously overlooked element of many studies aiming to determine the
mechanism of action of Tecfidera, is that DMF is extremely rapidly metabolized when administered orally,
so that a vast majority of the effects seen in animal models and in human patients are likely caused by
metabolic byproducts and not DMF directly. In vivo animal studies have shown that DMF is rapidly
hydrolyzed to MMF or adducted to glutathione via Michael-addition (Schmidt et al., 2007). In rodents,
when given orally no detectable levels of free DMF are found in blood plasma (Schmidt et al., 2007), and
similarly when administered directly to the small intestine none can be detected in the portal vein (Dibbert
et al., 2013). MMF is the dominant metabolite generated by DMF breakdown (Litjens et al., 2004, Dibbert
et al., 2013). Similar to the findings from DMF in vitro studies, MMF has also been demonstrated to
upregulate Nrf2-mediated EAR activity in neurons and macrophages (Cross et al., 2011, Linker et al., 2011,
Albrecht et al., 2012, Scannevin et al., 2012, Akay et al., 2014). Contrary to expectations, MMF did not
upregulate Nrf2-pathway antioxidant genes HO-1 or NQO1 at any point during a 24-hour timecourse in
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oligodendrocytes, and was unsuccessful at rescuing cells from an oxidant-induced maturation deficit. In an
experimental model of MS, in which animals ingesting the copper chelator cuprizone develop a specific
and reversible demyelinating lesion in the corpus callosum, boosting the Nrf2 pathway with either DMF or
MMF had only minor effects on remyelination and were not protective against cell death (MoharreghKhiabani et al, 2010). While in vitro differentiation was not examined by this group, they also
demonstrated that pre-application of DMF or MMF to an oligodendrocyte–like cell line that was then
treated with hydrogen peroxide showed no rescue from oxidative stress-induced toxicity (MoharreghKhiabani et al, 2010). The lack of activation for this supposedly ubiquitous cellular stress response pathway
to a variety of oxidant and antioxidant compounds which cause target gene upregulation in other cell types
may help to explain the selective vulnerability of oligodendrocytes to oxidative stress.

One possible explanation for the lack of EAR pathway activation observed in the current work regards the
regulation of glutathione synthesis and recycling in oligodendrocytes. The oxidant utilized in the initial
component of this study to investigate the effects of oxidative stress was tBHP, which has been
demonstrated to deplete cellular glutathione (Back et al., 1998, Zhao et al., 2005, French et al., 2009). In
later experiments, the oxidant BSO was used, which selectively inhibits glutathione synthesis (Meister,
1992, French et al., 2009). Hydrogen peroxide was also used, which does not have as targeted effects with
the cell, but rather generates highly reactive hydroxyl radicals which interact with proteins, lipids, as well
as reducing agents such as glutathione (Sies, 1993). MMF was unable to rescue differentiation deficits
caused by the cellular effects induced by any of these oxidants. While higher concentrations than DMF
were required to attain comparable cellular effects, MMF itself has also been shown to reduce cellular
glutathione levels in astrocytes (Schmidt and Dringen, 2010). The isoform of the enzyme responsible for
glutathione conjugation to electrophilic compounds, glutathione s-transferase (GST), expressed in
oligodendrocytes is GST-pi. Within the brain, this form of GST is uniquely found in oligodendrocytes
(Cammer et al., 1989, Cammer and Zhang, 1992), and has been widely used as a marker for mature
oligodendrocytes in vivo (Girolamo et al., 2011, Li et al., 2013, Yatomi et al., 2015). Furthermore,
immunofluorescent studies have demonstrated that GST-pi is found in the nucleus of OPCs, and during
differentiation attains a cytoplasmic distribution, which may account for some of the sensitivity of
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oligodendrocytes to oxidative stressors during early lineage stages (Tamura et al., 2007). It may be that the
glutathione system for monitoring redox homeostasis operates differently in oligodendrocytes, such that if
levels are depleted the EAR is not effectively activated, particularly in OPCs and maturing cells.
Interestingly, a recent study has demonstrated that DMF treatment can increase the glutathione level in a
human oligodendrocyte cell line, suggesting that fumarate compounds can potentially impact cells of the
oligodendrocyte cell lineage, although how metabolism in this cell line compares to primary cells is
unknown (Huang et al., 2015). In our study, neither tBHP nor MMF caused EAR pathway upregulation. It
will be intriguing to discover if alternative oxidants, which impact redox sensors other than glutathione, are
capable of EAR upregulation in primary oligodendrocytes, or if the canonical pathway is not present in this
cell lineage.

With this in mind, the mechanism of action by which Tecfidera reduces MS relapse rates is likely not due
to direct effects on oligodendrocytes. Alternatively, secondary effects from upregulation of the EAR in
neurons and macrophages may play a role in oligodendrocyte protection (Cross et al., 2011, Linker et al.,
2011, Albrecht et al., 2012, Scannevin et al., 2012, Akay et al., 2014). Furthermore, while not examined in
the present work, the effects of Tecfidera may also be modulated by a DMF-mediated reduction of secreted
inflammatory cytokines (Lehmann et al., 2007, Albrecht et al., 2012) or inhibition of the NF-κB pathway
(Gillard et al., 2015).

Reducing levels of chronic oxidative stress is key to enabling functional recovery for affected patients, as
remyelination will not proceed unless conditions are favorable. Our study suggests that reduction in
oxidative stress will most likely require the concerted efforts of multiple CNS cell populations, with
neurons, macrophages, and/or astrocytes together providing an environment free of oxidative stress with
restored redox homeostasis for the susceptible oligodendrocyte cell population to survive, mature, and remyelinate affected areas.
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Gene:

Primer Sequences:

PKG1

Forward: 5’ ATG CAA AGA CTG GCC AAG CTA C 3’
Reverse: 5’ AGC CAC AGC CTC AGC ATA TTT C 3’

HO-1

Forward: 5’ TGT AAG GGA GAA TCT TGC CTG GCT 3’
Reverse: 5' TGC TGG TTT CAA AGT TCA GGC CAC 3’

NQO1

Forward: 5’ AAG AGC TTT AGG GTC GTC TTG GCA 3’
Reverse: 5’ AGC CTC CTT CAT GGC GTA GTT GAA 3’

Nrf2

Forward: 5’ TCA CAC GAG ATG AGC TTA GGG CAA 3’
Reverse: 5’ TAC AGT TCT GGG CGG CGA CTT TAT 3’

MBP

Forward: 5’ TGG TAC ACA CTA ACC TCG GTG GAA 3’
Reverse: 5’ AGC GAC TCG ATT CAG TGA CAG GAA 3’

Table 5.1: q-RT PCR Primers
Primer pairs used for qRT-PCR are shown. Abbreviations are: PKG1, Protein Kinase Gene 1; HO-1, Heme
Oxygenase-1; NQO1, NAD(P)H:quinone oxidoreductase; Nrf2, NF-E2 (nuclear factor (erythroid-derived
2))-related factor-2; MBP, Myelin Basic Protein. Primers were obtained from IDT.
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Oligodendrocyte Precursor Cells
Gene:

ΔΔCT ±SEM:

P value:

Nrf2

3.482 ± 1.189

0.1721

HO1

2.423 ± 0.709

0.1824

NQO1

3.655 ± 1.935

0.3037

Mature Oligodendrocytes
Gene:

ΔΔCT ±SEM:

P value:

Nrf2

1.422 ± 0.322

0.3199

HO1

2.357 ± 1.140

0.3560

NQO1

0.499 ± 0.206

0.1354

Table 5.2: mRNA alterations in Endogenous Antioxidant Response Genes Following 6hr tBHP Insult
Extracted RNA (5 µg) was converted to cDNA using the Superscript First-strand kit and q-PCR was
performed using Power SYBR Green. All measurements were normalized first to the oligodendrocyte
housekeeping gene PKG1, and then to controls. Analysis was performed by the ΔΔCT method.
Endogenous Antioxidant Response genes: Nrf2, HO-1, and NQO1 were probed. ΔΔCT ±SEM are
presented from 3 independent biological replicates (n=3), with p-values indicated.
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Figure 5.1: Oxidant tBHP Induces Reactive Oxygen Species in OPCs and Mature Oligodendrocytes
Cells were treated with 2.5 µM tBHP for 1 hour to determine if reactive oxygen species (ROS) were
produced. ROS accumulation was assayed by DHE staining, with cell nuclei stained by DAPI. Images were
captured at 40x magnification, with 10 fields on 3 coverslips per condition. Scale bar indicates 25 µm.
Metamorph image analysis determined DHE fluorescence intensity normalized to nuclear DAPI area.
A)

Representative images of 1 hr treated OPCs, with DHE fluorescence (red) and cell nuclei stained

with DAPI (blue), and quantification of this experiment.
B)

Representative images of 1 hr treated mature oligodendrocytes, with DHE fluorescence (red) and

cell nuclei stained with DAPI (blue), and quantification of this experiment.
Representative experiments shown from n=2 biological replicates, values are presented as mean ±SEM.
Student’s t-test determined statistical significance (##= p< 0.01).
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Figure 5.2: Oxidative Insult does not Upregulate the EAR in Oligodendrocytes
Protein was harvested from OPCs (A-B) or Mature Oligodendrocytes (C-D) 16 hours following 2.5 µM
tBHP treatment. Cell lysates were immunoblotted for target proteins upregulated upon activation of the
endogenous antioxidant response: HO-1 (A and C) and NQO1 (B and D). Representative Western blot
images are shown, with quantification of band intensities normalized to GAPDH loading controls revealing
no change between untreated and tBHP treated conditions. Data are presented as mean ± SEM from 4
separate cultures (n= 4). Student’s t-test determined statistical significance.
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Figure 5.3: Oxidative Insult Inhibits Oligodendrocyte Differentiation
Primary mouse OPCs were put into differentiation medium (DM) and treated with 2.5 µM tBHP. After 72
hours, cells were stained for stage-specific markers or RNA or protein was extracted to evaluate levels of
myelin components.
A)

Cells on coverslips were stained with DAPI (blue) for total cell nuclei and with antibody to GalC

(green) and MBP (red). Representative images are shown for untreated and tBHP treated conditions, with
merged images in the rightmost column. Scale bar indicates 25 µm. Epifluorescent images were captured,
with 10 fields on three coverslips per condition, from n=4 independently prepared cultures. Immature
oligodendrocytes (GalC+ cells), mature oligodendrocytes (MBP+ cells), and total cell number (DAPI+
nuclei) were counted using ImageJ software, represented as percentage normalized to untreated. Data are
presented as mean ±SEM. Student’s t-test determined statistical significance. Significance compared with
control (##= p< .01, #= p< 0.05).
B)

RNA was extracted 72hours following addition of DM and tBHP treatment. cDNA conversion,

qPCR, and analysis were performed as in Table 2. Expression of the gene for MBP was probed. ΔΔCT
±SEM are presented from 3 independent biological replicates (n = 3). Student’s t-test determined statistical
significance. A significant increase was found when precursor cells were compared with untreateddifferentiated cells (#= p< 0.05), however tBHP treatment did not significantly alter MBP mRNA
compared with untreated (ns).
C)

Protein was harvested from oligodendrocytes at 72 hours post-treatment. Cell lysates were

immunoblotted for MBP. Representative Western blot images are shown, with quantification of band
intensities normalized to GAPDH loading controls. Data are presented as mean ± SEM from 4 separate
cultures (n= 4). Student’s t-test determined statistical significance. A significant increase in MBP was
found when OPCs were compared with untreated-differentiated cultures (###= p< 0.001). A significant
reduction in MBP was observed when tBHP treated cultures were compared with untreated cultures (#= p<
0.05).
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Figure 5.4: MMF reduces ROS accumulation induced by various oxidant compounds
OPCs were pre-treated with 10 µM monomethyl fumarate (MMF) for 6 hrs. Cultures were then treated with
2.5 µM tBHP (A), 100 µM hydrogen peroxide (B), or 100 µM buthionine sulfoximine (BSO) (C) for an
additional 2 hours. DHE staining, imaging and analysis was performed as in Figure 1. Representative
experiments shown, values are presented as mean ± SEM, n= 2. Student’s t-test determined significance for
direct comparisons (#= p< 0.05, ###= p< 0.001). Significant accumulation of reactive oxygen species was
observed with each compound, and in treatment condition MMF pre-treatment significantly reduced this
effect.
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Figure 5.5: MMF fails to rescue differentiation defect caused by oxidative insult
OPCs plated on coverslips were pre-treated with 10 µM MMF for 24 hrs. Cells were then switched into
DM, supplemented with MMF and/or treated with tBHP, hydrogen peroxide, or BSO. MMF was
replenished at 24 and 48 hrs. After 72 hrs, cells were fixed and stained for GalC and DAPI, and were
imaged and analyzed as in Figure 4. Data are presented as mean ± SEM, from 3 separate cultures (n= 3).
Student’s t-test determined significance for direct comparisons compared to untreated and MMF Vehicle
(#= p< 0.05, ##= p< 0.01, ###= p< 0.001).
A) GalC+ cell number was significantly reduced with tBHP, hydrogen peroxide, and BSO. No rescue
was observed with concomitant MMF treatment.
B) MBP+ cell number was significantly reduced with tBHP and hydrogen peroxide. No significant
alterations in MBP cell number occurred with MMF co-treatment.
C) Total cell number was significantly reduced with hydrogen peroxide. Simultaneous MMF
treatment did not rescue this cell loss.
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Figure 5.6: The EAR is not upregulated by MMF in maturing oligodendrocytes
OPCs were treated with 10 µM MMF at the time of differentiation and harvested for protein analysis along
a timecourse at the following intervals: 0hr, 2hr, 6hr 12hr and 24hr. Cell lysates were immunoblotted for
HO-1 (A) and NQO1 (B), target proteins upregulated following activation of the endogenous antioxidant
response. Representative Western blot images shown, with quantification of band intensities normalized to
GAPDH loading controls revealing no change at any timepoint. Data are presented as mean ± SEM from 2
separate cultures (n= 2). One-way ANOVA followed by post-hoc Dunnett’s multiple comparison
determined statistical significance.
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CHAPTER 6
Discussion

6.1 OVERVIEW
Approximately half of HIV-positive individuals continue to suffer from some level of neurocognitive
impairment within the spectrum of HIV-Associated Neurocognitive Disorders (HAND), despite effective
suppression of viral replication through antiretroviral therapy (ART) to titers below the limits of detection
(Gray, 2003, Brew, 2004, Heaton, 2010, 2011). Rigorous studies have demonstrated that dendritic pruning
and synaptodendritic damage remain prevalent in patients (Masliah et al., 1997, Everall et al., 1999, Zheng
et al., 2001, Langford et al., 2003, Everall et al., 2005, Ellis et al., 2007, Everall et al., 2009). Additionally,
perturbations in white matter have been consistently demonstrated through evidence of disruption of myelin
integrity, thinning of the corpus callosum, reduction of blood flow, and loss of volume in white matter
structures (Pomara et al., 2001, Ragin et al., 2004, Gongvatana et al., 2009, Wohlschlaeger et al., 2009,
Hoare et al., 2010, Tate et al., 2011, Kelly et al., 2014). Reproducible evidence of these pathologies in
patients with well-controlled viral replication in the periphery suggests that within the CNS compartment,
effects from inflammation, antiretroviral drugs, and viral reservoirs may all play roles in contributing to the
persistence of HAND.

Effects of antiretroviral compounds on cells of the CNS have not been well characterized, despite potential
implications for the persistence of HAND in light of well-known peripheral toxicities (Carr, 1998, Dalakas,
2001, Cohen, 2005, Parker, 2005, Ellis et al., 2008, Vidal et al., 2010). Activation of several cellular stress
signaling pathways have been identified in peripheral cells in response to antiretroviral compounds, and are
likely to also similarly affect cellular lineages exclusive to the brain, which may contribute to cognitive,
behavioral, and motor deficits observed in HAND (Parker, 2005, Zhou, 2005, 2006, Gupta et al., 2007). In
particular, even with the implementation of ART, studies indicate that oxidative stress is pervasive and
abundant in HAND patients (Reviewed in Chapter 2). In addition to oxidative stress generated by the
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presence of viral proteins and inflammatory responses of infected cells, antiretroviral compounds
themselves had been previously shown to be capable of generating reactive oxygen species (ROS) in
peripheral cell populations, macrophages, and astrocytes (Reviewed in Chapter 2). From this accumulated
evidence, we hypothesized that ART compounds could activate cellular stress response pathways in
neuroglial cells leading to cellular dysfunction, and that by counteracting the activation of these pathways
the negative ART-induced effects could be ameliorated. Through our investigations exploring this
hypothesis, we have contributed significant evidence to the effects of antiretroviral compounds on various
neuroglial cell populations. Our findings, as discussed in the remainder of this chapter, have notable
implications for the persistence of HAND in the ART era. 	
  

We began by assessing the effects of antiretrovirals on neurons, through in vivo and in vitro models
(Chapter 3). Similar to reports from human patients, we observed synaptodendritic damage in the brains of
SIV-infected ART-treated pigtail macaques (Masliah et al., 1997, Everall et al., 1999, Zheng et al., 2001).
Through an administration model in rats, we also demonstrated that this damage can occur in vivo due to
ART compounds alone, in the absence of virus. In vitro studies determined that in neurons, exposure to
antiretrovirals resulted in accumulation of ROS and slight EAR activation, yet culminated in cell death.
Independent cultures of enriched neurons or astrocytes revealed that ROS accumulation occurred solely in
neurons, with astrocytes neither accumulating ROS nor activating the antioxidant response. In our
combined neuroglial cultures, monomethyl fumarate (MMF) potently activated the EAR, causing
upregulation of antioxidant genes. In the context of antiretroviral exposure, this prevented ROS
accumulation and subsequent neuronal death, suggesting that oxidative stress is a major contributor to
ART-induced neuronal toxicity.

Our next line of inquiry was to explore potential effects of ART compounds on oligodendrocyte survival,
maturation, and myelin maintenance (Chapter 4). While not directly toxic at physiological doses, we
definitively established that drugs from the PI class halt oligodendrocyte differentiation in a dosedependent, but reversible manner. Following antiretroviral exposure ROS accumulated, but unlike the
rescue of neuronal toxicity observed in our previous study, co-administered MMF was unable to restore
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oligodendrocyte maturation deficits. Through an in vivo ART administration model performed in mice,
Ritonavir treatment led to reduction in myelin protein levels in frontal cortex following two weeks of
repeated exposure. Similarly, through an evaluation of human patient prefrontal cortex samples, we
concluded that HIV-positive individuals with HAND who were ART-medicated displayed significant
alterations in myelin proteins compared with both ART-naïve HAND individuals and seronegative
controls.

Finally, we decided to delve deeper into the activity of the endogenous antioxidant response (EAR) in
oligodendrocytes, pursuing our finding that MMF failed to rescue oligodendrocyte maturation despite
potently activating this pathway and providing protection from oxidant insults in neurons (Chapter 5).
Oxidant application led to robust ROS accumulation in both OPCs and mature oligodendrocytes in vitro,
yet expression of EAR target genes was not enhanced. This treatment also led to a reduction in cells
progressing in differentiation from precursor cell to more mature lineage stages. MMF co-administration
reduced the ROS accumulation induced by several oxidant compounds but did not activate the EAR or
rescue the maturation deficits.

Together our results provide some of the first evidence that antiretroviral compounds could be a major
contributing factor to the persistence of HAND. In summary, we have shown that: 1) ART induces
neuronal toxicity in vivo and in vitro, 2) Neuronal toxicity is primarily a result of oxidative stress, which
can be rectified by an antioxidant promoting EAR activity, 3) PIs prevent oligodendrocyte maturation, 4)
ART causes loss of myelin integrity in vivo, and 5) The EAR is not activated in oligodendrocytes under
conditions which stimulate this pathway in other cell types. These findings advance our basic
understanding of the neuronal and oligodendroglial responses to antiretroviral compounds and oxidative
stress, and have important clinical implications for the treatment of HIV. These topics are considered in
detail in this chapter.
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6.2 ANTIRETROVIRAL COMPOUNDS GENERATE OXIDATIVE STRESS AND INVOKE
NEURONAL TOXICITY
In many neurodegenerative diseases, including HAND, a hallmark indicator of neuronal damage and
dysfunction is evidence of synaptic injury (Gupta et al., 2010). Reduction in synaptic density as indicated
by dendritic pruning is a major pathological feature in HAND patients in the ART-era (Masliah et al., 1997,
Everall et al., 1999, Zheng et al., 2001, Langford et al., 2003, Everall et al., 2005, Ellis et al., 2007, Everall
et al., 2009, Xu and Ikezu, 2009). Elevated markers of oxidative stress such as lipid and protein oxidation,
oxidative modifications to DNA, and depletion of the key antioxidant glutathione are still detectable in the
brains of ART-treated patients despite effective control of viral replication (Reviewed in Chapter 2).
Despite these findings, the small number of reported studies regarding antiretroviral compound
pharmacokinetics and effects in the CNS did not examine pathological readouts of neuronal damage
(Huisman et al., 2003, Anthonypillai et al., 2004, Anthonypillai et al., 2006).

Through our work presented in Chapter 3, we have provided evidence for ART-induced synaptic injury in
two

animal

models.

In

the

first,

adult

rats

received

an

NRTI-boosted

PI

ART-regimen

(AZT+Saquinavir+Ritonavir) over the course of one week. Even in this short time span, analysis of brain
sections derived from hippocampus revealed that repeated ART exposure led to significant reductions in
synaptophysin, an essential component of synapses, and microtubule associated protein 2 (MAP2), a
neuronal protein that stabilizes microtubules and which is used commonly as an indicator of neuronal
processes. Our second in vivo model extended our findings to non-human primates, through an evaluation
of brains from SIV-infected juvenile pigtail macaques. We observed decreased levels of synaptophysin in
SIV-infected ART-treated animals, compared with either uninfected animals or infected animals receiving
a placebo regimen. We acknowledge the caveat in the design of this study, that there is a lack of uninfected
animals receiving ART. This prevented a strict determination of the effects of ART in the absence of viral
infection, which is a topic of future investigation that will be addressed further in Section 6.5. Despite this,
we did observe a definitive contribution of ART to neuronal damage, as SIV-infected ART-treated
macaques had significantly less synaptophysin staining than their SIV-infected untreated counterparts.
These studies demonstrating evidence of ART-associated synaptic damage in vivo warrant future
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investigations into specific effects of individual drug classes, as well as the mechanisms through which
neuronal damage occurs.

Until recently, ART-induced toxicity had only been explored in cell lines, however Robertson and
colleagues have now provided the first evidence for such toxicity in primary rat neurons (Cui et al., 1997,
Robertson et al., 2012). Within our current study we have shown that the PIs Ritonavir and Saquinavir
induce oxidative stress followed by subsequent neuronal damage/death in primary cultures at clinically
relevant doses. We have also provided evidence that through activation of the EAR by MMF, we were able
to prevent the generation of oxidative stress and neuronal toxicity induced by these antiretroviral
compounds. Interestingly, application of the NRTI compounds AZT or stavudine (d4T) did not cause
neuronal toxicity in our experimental paradigm. In agreement with these observations, a previous study in
PC-12 neuron-like cells found that following extended exposure to either AZT or d4T no inhibition of cell
growth or neurite regeneration were observed (Cui et al., 1997).

We have demonstrated that ART-induced effects can be successfully blocked by MMF-mediated activation
of the EAR. Only moderate activation of this pathway by ART compounds alone was seen through
increased levels of both mRNA and protein of EAR target genes HO-1 and NQO1. Pre-treatment with
MMF resulted in further increases in HO-1 protein and provided protection against ART-induced toxicity.
We confirmed that this protection was the result of increased HO-1 activity by co-applying a heme
oxygenase inhibitor at the time of MMF pre-treatment. With this inhibition, the protection provided by
MMF was negated. We conclude that despite activation of the EAR in response to antiretroviral
compounds, this response is either insufficient or too delayed to protect neurons from ART-mediated
damage and death. In support of this interpretation, enhanced MMF-mediated activation of the EAR was
strongly protective against the neurotoxic antiretroviral effects. Future studies utilizing this in vitro model
could be very informative to determine if other clinically utilized ART combinations result in
neurotoxicity, as well as to screen additional candidate compounds for potential use as adjunctive
therapeutics prior to testing in in vivo models. The success of MMF in prevention of ART-induced neuronal
toxicity in vitro is of particular interest for the potential of translation of our findings to the clinical setting.
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MMF as a candidate for adjunctive therapy in patients with HAND will be discussed in detail in Section 6.6
“Clinical Implications”.

In our acute model of ART application in vitro, enriched astrocytes did not show evidence of ROS
accumulation or EAR activation. Astrocytes have high levels of glutathione and antioxidant enzymes, and
it is likely that our finding is reflective of efficient cellular buffering of the ROS produced by antiretroviral
compounds so that no accumulation occurs and no upregulation of antioxidant proteins are required (Sagara
et al., 1993, Bolanos et al., 1996). In SIV-infected macaques, we found that the astrogliosis normally
present after infection was resolved in ART-treated animals. While these findings suggest that astrocytes
may not be robustly impacted by ART compounds, the effects of long-term exposure cannot be predicted.
Astrocytes have been well characterized in their ability to provide trophic support and stress buffering
capabilities to neurons, including oxidative stress, and alterations in this capacity can precipitate damage in
the already susceptible neuronal population (Sagara et al., 1993, Bolanos et al., 1996, Fernandez-Fernandez
et al., 2012). In our in vitro model, enriched neuronal cultures succumb to antiretroviral-mediated toxicity
in less than 6 hours. In neuroglial culture however, which contains approximately 95% neurons and 5%
astrocytes, viability was sustained until mitochondrial depolarization and subsequent neuronal
damage/death was observed at 48 hours post-treatment. These results indicate that while astrocytes do not
themselves upregulate EAR proteins in response to antiretroviral agents, even when present in small
numbers they are capable of buffering neuronal susceptibility to the oxidative stress generated by these
compounds, at least for a time. Ultimately however, these neuroglial cultures do succumb to antiretroviralmediated toxic effects. Together, our data suggest that sustained oxidative stress and ROS accumulation
due to extended ART exposure may lead to ART-induced neuronal injury in the CNS, leading to the
persistence of clinically observed synaptodendritic damage in HIV patients in the ART-era.

The persistence of HAND despite effective viral control outside of the CNS is accompanyied by a shift in
pathology from severe dementia to more subtle neurocognitive impairments, implying a continuation of
neuronal damage, albeit in a milder form. Through our results presented here, we propose that the
mechanism of continued synaptic damage may be a combination of viral proteins and soluble factors
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released from CNS reservoirs, as well as direct damage caused by ART compounds. Comprehensive
studies have detailed neuronal and synaptic damage mediated by viral proteins and factors released from
infected cells, by several direct as well as indirect mechanisms involving multiple cell types, including
astrocytes (Gonzalez-Scarano, 2005). Our data suggest that additional synaptic damage may be caused by
direct ART-mediated effects in neurons, through mechanisms involving oxidative stress. It is likely that
longitudinal exposure to ART regimens including compounds which invoke this syanptic damage
contribute to a slower, yet persistent alteration of neuronal function which contributes to the chronic course
of progressive neurocognitive impairment observed in HAND patients in the ART-era.

6.3:

OLIGODENDROCYTE

MATURATON

AND

MYELINATION

ARE

NEGATIVELY

AFFECTED IN THE CONTEXT OF HIV AND ART
Through our results presented in Chapter 4, we have been the first to evaluate oligodendrocyte maturation
in the context of antiretroviral drug exposure. We have rigorously demonstrated that PIs produce significant
deficits in the differentiation of cells from OPC to maturing oligodendrocytes, which is independent of the
oxidative stress induced by ART compounds, despite ROS being produced. We were fortunate to be able to
examine a human cohort containing HIV-positive individuals with and without antiretroviral drug
experience, and measured a significant reduction in myelin basic protein and a significant increase in
CNPase in the HAND patients who had been ART-medicated compared to seronegative controls and
HAND patients who were ART-naïve. These data have enabled us to add cellular evidence of myelin
protein perturbation to the persistence of white matter pathologies in ART-treated HAND patients, which
corroborates previous reports utilizing non-invasive imaging studies (Pomara et al., 2001, Ragin et al.,
2004, Gongvatana et al., 2009, Wohlschlaeger et al., 2009, Hoare et al., 2010, Tate et al., 2011, Kelly et al.,
2014). Our data are also in accordance with the single transcriptome analysis study performed in patients to
define genes altered in HIV infection that remained dysregulated following suppression of viral replication
by antiretroviral therapy, which found that mRNA for myelin specific genes: myelin-associated
oligodendrocyte basic protein and myelin basic protein (MBP) were reduced (Borjabad et al., 2011).
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Given these findings, we propose the following model for the effects of antiretrovirals on the maturation of
oligodendrocytes. Oligodendrocyte precursors treated with antiretroviral compounds enter into
differentiation and proceed with transcription factor alterations and upregulation of myelin component
mRNAs as has been well documented (Miller, 2002). During this progression, cells begin to extend actin
filaments and adopt the morphology of mature, elaborated oligodendrocytes. A majority of myelin
component proteins are translated in the perinuclear endoplasmic reticulum and are trafficked through the
secretory pathway via the Golgi apparatus to be inserted into the forming myelin membrane (Colman et al.,
1982). An exception to this is MBP, in which mRNA is instead trafficked along microfilaments to sites
proximal to the myelin membrane. Once in this vicinity, protein is translated from the mRNA on freeribosomes and is rapidly inserted into the neighboring membrane (Colman et al., 1982, Ainger et al., 1997).

In the case of treatment with PIs we propose that either the translation or trafficking of myelin proteins is
affected. The rapid rescue of maturation deficits suggest that required components are already present
within treated cells, and that alleviation of cellular stress by drug removal allows for renewed translation
and/or proper trafficking of myelin components. All myelin proteins examined, both those traversing the
secretory pathway as well as MBP, are diminished at the cell surface. The most straightforward explanation
for this result would be that PI treatment decreases protein synthesis. When this blockade is removed, rapid
translation, trafficking, and membrane insertion can ensue. The caveat to this proposition is that protein
levels remain normal as assessed by western blotting under most conditions where a deficit in membrane
positivity already exists. This is particularly evident in the highest Ritonavir dose where no decreases are
detected at the protein level, yet drastic decreases are seen by immunocytochemistry. While this finding is
unusual, it is not unprecedented in oligodendrocytes and has been similarly reported by two independent
laboratories (Maier et al., 2009, Wahl et al., 2014). Reduction in cholesterol levels can result in decreased
surface expression of proteolipid protein (PLP) while maintaining normal protein level as assessed by
western blotting (Maier et al., 2009). Similarly, investigations into the role of mammalian target of
rapamycin in differentiation revealed a reduction in number of maturing oligodendrocytes yet maintenance
of normal myelin protein levels (Wahl et al., 2014). Based on our findings and supporting evidence from
these previous works, it is therefore more likely that a trafficking/membrane insertion problem exists for
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myelin proteins which have already been synthesized.

Alternatively, normal protein levels observed with Ritonavir at all concentrations and most doses of
Lopinavir may indicate a failure of protein degradation under conditions which would normally promote
destruction of myelin proteins which were synthesized but could not effectively be inserted into the
membrane. PIs have been shown in non-CNS cells to have the off-target effect of inhibiting proteasomal
degradation and activating the unfolded protein response (UPR) (Andre, 1998, Zhou, 2005, 2006). The
UPR potently suppresses global protein translation while upregulating specific stress-response proteins
(Brown and Naidoo, 2012). While we have provided evidence that the UPR is not activated in
oligodendrocytes following antiretroviral application at timepoints where such activation was evident in
neuroglial culture, we have not yet addressed potential effects on translational efficacy or inhibition of
degradation machinery. Following this line of reasoning, the mechanism behind lower protein levels with
highest dose Lopinavir would need to be explained, particularly if the proteasome is inhibited.

Notable differences were observed in the effects of the two PIs Ritonavir and Lopinavir, which are likely
the result of dissimilar metabolism and intracellular actions resulting from the unique properties of their
chemical structures. There have been several previously reported instances where different effects are noted
in the same cell population following exposure to independent PI compounds. Adipocyte differentiation
was inhibited with Nelfinavir and Indinavir but not with Amprenavir (Caron et al., 2003). Additionally in
astrocytes, ROS production, glutathione export, and toxicity differed dramatically following Nelfinavir
versus Indinavir application (Brandmann et al., 2012). In spite of differing subcellular effects invoked by
Ritonavir and Lopinavir, it is clear that exposure to either PI even at low concentrations would not result in
the formation of a properly functioning myelin membrane based on reduced myelin protein localization to
the cell surface and our observed deficit in myelin membrane elaboration.

We have demonstrated that several antiretrovirals induce ROS, mitochondrial depolarization and
neurotoxicity in astrocyte-supported neuronal culture (Chapter 3) and that oxidative stress hinders the
process of oligodendrocyte differentiation (French et al., 2009, Reid et al., 2012). While both NRTI AZT
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and PI Ritonavir induce robust ROS accumulation, this is not a universal feature of antiretrovirals, as
Lopinavir did not produce ROS accumulation even at greatly extended timepoints in oligodendrocytes.
When we probed whether the EAR, which is triggered by cellular redox homeostasis imbalance, was
activated in oligodendrocytes following antiretroviral exposure, no biologically relevant increases in
pathway gene mRNAs or in target proteins HO-1 or NQO1 were detected (Li, 2009). Furthermore,
scavenging of ROS through EAR upregulation via MMF did not rescue PI-induced decreases in
oligodendrocyte differentiation despite previously demonstrated neuroprotection (Chapter 3). Thus, while
PIs have been previously shown in other cell populations to induce oxidative stress and the UPR, we
provide evidence that in oligodendrocytes PIs act through an alternate mechanism to affect maturation. An
intriguing possibility is the potential for PIs to cause dyslipidemia, which has been demonstrated in patients
and in non-CNS cell types (Carr, 1998, Haughey et al., 2004, Zhou, 2006). An effective myelin membrane
is crucially dependent on proper lipid balance to ensure appropriate organization of myelin component
proteins (Maier et al., 2009, Chrast et al., 2011, Lee et al., 2014). As was mentioned previously, reduction
in cholesterol levels can result in decreased PLP at the surface of the myelin membrane with minimal
reduction at the protein level, which mirrors our finding with MBP under conditions of Ritonavir treatment
(Maier et al., 2009). Furthermore, PIs have been linked to altered regulation and localization of the master
transcription factor of lipid metabolism sterol regulatory-element binding protein 1 (SREBP1), which may
be involved in our differentiation phenotype (Zhou, 2006, Goulbourne and Vaux, 2010). In summary, while
previous studies have implicated oxidative stress and activation of the UPR as cellular responses to
antiretroviral compounds, in oligodendrocytes PIs do not seem to be acting through these pathways to
induce a differentiation deficit and alternative mechanisms should be considered.

Further investigation is needed to define the mechanism by which myelin proteins are dysregulated and
prevented from reaching the myelin membrane following PI application. Several potential avenues of
inquiry have been suggested by our results, including analysis of translational efficiency and protein
turnover by the proteasome. In order to ascertain translational efficiency of myelin proteins in the presence
or absence of PIs, pulse-chase experiments can be performed with radiolabeled methionine over a brief
time interval in the context of proteasomal inhibition using the compound MG-132 to prevent breakdown
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of newly synthesized proteins. At the endpoint of labeling, the myelin proteins would be pulled down using
immunoprecipitation, and following gel electrophoresis the amount of newly synthesized protein could be
quantified according to the amount of radioactive probe incorporated. To determine if proteasomal function
is inhibited as a side effect of PI application in oligodendrocytes, cells can be treated and proteasomes
specifically isolated through centrifugation in a glycerol gradient (Orino et al., 1991). Activity can then be
assayed by measuring fluorescent emission of a synthesized probe engineered to emit 440-460 nm waves
following specific proteasomal cleavage, allowing for comparisons under normal and treated conditions, as
well as under MG-132 proteasomal inhibition. Secretory pathway function can also be assessed in our in
vitro culture model. Isolation of individual cellular organelles by subcellular fractionation followed by
western blotting will determine if myelin component proteins such as CNP and PLP are properly
transitioning from the ER to the Golgi apparatus, or if unusual accumulations are occurring in these
compartments. Immunocytochemistry followed by confocal imaging will address this question using a
different approach, by co-staining with organelle markers in addition to one of the myelin proteins.
Quantification of myelin proteins in each subcellular fraction will allow comparison of myelin protein
localization to each cellular compartment under normal and PI-treated conditions. Finally, the lipid
composition of the forming myelin membrane should be evaluated to determine if an imbalance or
dysregulation of lipid rather than protein is preventing correct presentation of myelin proteins to the cell
surface. Studies within the laboratory have begun to explore these possibilities, through mass spectrometry
analysis of cellular lipid compositions during differentiation in the presence or absence of PIs, along with
assessment of the activities and levels of the transcription factor SREBP1 and its downstream gene targets
involved in lipid metabolism.

Another area crucially in need of investigation is an exploration of the potential consequences of HIVinfection on oligodendrocytes. In a recent publication, a model using inducible Tat-transgene expression in
astrocytes began to address this important question. Following 3 months of Tat-expression, animals
displayed significant abnormalities in myelin integrity, with aberrant morphology evident in the corpus
callosum, anterior commissure, caudate-putamen, and striatum (Zou et al., 2015). Furthermore, application
of exogenous Tat protein to oligodendrocytes in vitro culminated in reduced viability of immature
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oligodendrocytes and significant reductions in oligodendrocyte maturation (Zou et al., 2015). While this
foundational study has provided initial evidence that viral proteins can affect oligodendrocyte survival and
extent of myelination, it is of upmost importance to understand the effects of HIV-infection on
oligodendrocytes in the context of the entire virus and cell populations that undergo productive infection in
vivo. Evidence has shown that in addition to factors secreted by infected cells, inflammatory activation of
neighboring, uninfected macrophages, microglia, and astrocytes also contributes to release of cytotoxic
factors into the cellular milieu. Therefore, we have begun to formulate studies using a model of HIVinfection of isolated human monocyte-derived macrophages. Following infection with a CNS-isolated
strain of HIV-1, supernatants will be collected at the peak of viral infection. These supernatants have been
previously demonstrated to invoke neurotoxicity, at least in part through high levels of glutamate that
promote N-methyl-D-aspartate receptor (NMDA) receptor-mediated excitotoxicity (O'Donnell et al., 2006).
The oligodendrocyte study mentioned above from the Knapp laboratory also demonstrated a NMDA
receptor-dependent mechanism of Tat-induced effects in their model, suggesting that in the context of full
virus, high levels of extracellular glutamate may be negatively impacting oligodendrocytes as well as
neurons. On the basis of these preliminary findings, it is expected that oligodendrocyte survival and
maturation will be affected in the context of viral infection. Results investigating this possibility, in
addition to the effects of antiretroviral compounds, will have great clinical and therapeutic implications.

Through our work in Chapter 4 we have pioneered the investigation of the effects of antiretrovirals
compounds on oligodendrocytes in vivo, through use of a rodent model as well as human patient samples.
In mice, myelin alterations were evident in as little as two weeks of repeated exposure, with significant
reductions observed in both CNPase and MOG. We also performed the first reported evaluation of myelin
protein levels in individuals with HAND. None of the proteins MBP, CNP, MAG, or MOG were
significantly altered when individuals were stratified solely into HIV-negative and HIV-positive groups.
However, when only individuals with confirmed diagnosis of HAND were assessed, and were placed into
categories based on whether they had received ART, a significant reduction in MBP was observed in
patients with HAND who had been ART-medicated, when compared with either the untreated HAND
individuals or the HIV-negative controls. Our findings reinforce the transcriptome analysis performed by
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the Volsky group, which identified genes required for oligodendrocyte maturation including MBP as
dysregulated in patients with HAND, even under effective suppression of viral replication (Borjabad et al.,
2011). While this could potentially be interpreted that synaptodendritic damage in HAND occurs with a
subsequent loss of myelin, our results indicate that this is an insufficient explanation for all of our observed
effects at the protein level. Our examination of patient samples also yielded an unexpected significant
increase in CNPase in the HIV-positive ART-medicated group, over both the HIV-negative and HIVpositive ART-naïve groups regardless of neurocognitive status. This observation could be indicative of an
attempted cellular remyelination response that has been unsuccessful in restoring MBP levels, as CNPase is
one of the earliest myelin proteins to be expressed during maturation from precursor cell to mature
oligodendrocyte (Scherer et al., 1994). Together with our in vitro evidence, these results indicate that
disruption of myelin in the ART era may occur as a direct effect of ART compounds on oligodendrocytes,
rather than as a secondary consequence of neuronal damage. Our data suggests that in a reversal of roles,
damage to myelin, coupled with oligodendrocyte precursors that cannot successfully remyelinate affected
areas, may in turn lead to secondary synaptodendritic neuronal damage.

Based on the evidence from our investigations and those previously performed, we have formulated the
following model for the effects of HIV and antiretroviral compounds on oligodendrocytes in pediatric and
adult settings (Figure 6.1). In children (A), throughout adolescence productive myelination occurs which
allows for the ensheathment of neurons, axon potential conductivity, and plasticity of signaling networks
throughout development. HIV-infection with concomitant suppressive ART and inflammation culminates
in widespread neurological deficits including encephalopathy, leukoencephalopathy, cerebrovascular
complications, neurocognitive deficits and developmental delays. These pathologies are likely a combined
effect of reduction in effective myelin formation and disruption of myelin integrity of forming white matter
tracts. In the adult (B), myelin is essential for the facilitation of action potentials, axonal maintenance, and
neurotrophic support. Additionally, new myelin formation and plasticity/maintenance of formed myelin is
crucial for maintained biological homeostatic function and for motor learning in adulthood. HIV-infection
with persistent inflammation and treatment with lifelong ART together can result in HAND in patients.
Pathologies including dendritic pruning, astrogliosis, loss of white matter volume and integrity, and
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reduction in mRNA and protein for myelin components are evident in these individuals. Through the
findings resulting from our our study, we propose that the myelin pathologies observed in patients are
likely a combination of perturbed maintenance of formed myelin as well as an impairment of remyelination
capability.

6. 4 THE ENDOGENOUS ANTIOXIDANT RESPONSE IN OLIGODENDROCYTES
It was quite intriguing that the EAR was not activated in oligodendrocytes in our investigations of effects of
antiretroviral compounds despite robust oxidative stress, or following application of MMF which was
known to upregulate this pathway in other cell populations. We decided to pursue this line of investigation,
to examine the activity of the EAR in oligodendrocytes in Chapter 5.

In contrast to the well-characterized pathway function of the EAR in many other cell types, very little is
known about this pathway in oligodendrocytes. The sole reported study, using primary rat oligodendrocytes
demonstrated upregulation of HO-1 by immunoblotting following exposure to hydrogen peroxide, however
this insult culminated in loss of mitochondrial function and apoptosis, suggesting that the protein
upregulation resulting from EAR pathway activity was not sufficient to protect the cells (Goldbaum and
Richter-Landsberg, 2001). In our work, we provide compelling evidence that exposure to sub-toxic levels
of oxidants produced ROS accumulation in both OPCs as well as mature oligodendrocytes in vitro.
However, unlike other CNS cell types, in both the OPCs and mature oligodendrocytes this failed to elicit
activation of the EAR. As a possible result of this failure, oxidant exposure at the time of differentiation
prevented OPCs from progressing in differentiation to the more mature oligodendrocyte stages, and
prevented appropriate levels of myelin protein expression for insertion into the cell membrane.

In an attempt to better understand the unrectified level of oxidative stress in oligodendrocytes, we turned
our focus to a demyelinating disease in which oxidative stress is a hallmark of disease and antioxidant
treatment has benefited patients: Multiple Sclerosis (MS). Symptoms of MS arise from disruption of the
integrity of myelin in white matter tracts in the brain, with cellular pathology including destruction of
myelin sheaths and death of oligodendrocytes, as well as axonal damage and neuronal death (Criste et al.,
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2014, Mallucci et al., 2015). While initial steps leading to the autoimmune targeting of myelin are not well
understood, it is evident in MS that once initiated; chronic inflammation and oxidative stress drive ongoing
pathology (Friese et al., 2014, Mahad et al., 2015). Currently, therapies aimed at reducing relapse rates and
restoring quality of life in patients have focused on attenuating these two persistently elevated forms of
stress (Friese et al., 2014, Mahad et al., 2015). The drug Tecfidera effectively reduces relapse rates in MS
patients (Fox et al., 2014, Dubey et al., 2015). This compound is suspected to act as an antioxidant, yet the
mechanism by which it is effective has not been elucidated. Tecfidera is composed of the fumaric acid ester
dimethyl fumarate (DMF), which is rapidly metabolized to MMF following ingestion (Litjens et al., 2004,
Schmidt et al., 2007, Limmroth, 2013, Fox et al., 2014). Within minutes of administration, DMF is no
longer detectable and MMF is the primary physiological metabolite (Schmidt et al., 2007). We and others
have demonstrated antioxidant properties of MMF in neurons and macrophages through Nrf2-mediated
EAR activation and upregulation of target genes (Chapter 3) (Cross et al., 2011, Albrecht et al., 2012,
Scannevin et al., 2012). Remarkably, MMF effects on signaling pathways in oligodendrocytes have not
been explored, despite the pivotal role these cells play in MS pathology.

Within our in vitro model, we attempted to exogenously activate the EAR by treatment with MMF in
oligodendrocyte lineage cells. Pre-treatment with MMF successfully attenuated ROS accumulation caused
by various oxidant compounds in both OPCs and mature oligodendrocytes as anticipated. However, MMF
did not upregulate Nrf2-mediated EAR target genes HO1 or NQO-1 at any point during an extended 24hour timecourse in oligodendrocytes, and was unsuccessful at rescuing the oxidant-induced maturation
deficit in developing OPCs. Our finding is in line with that of the Stangel laboratory, in which animals
were fed the copper chelator cuprizone to induce a specific, reversible demyelinating lesion in the corpus
callosum. During the period of remyelination in this experimental model of MS, animals were given either
DMF or MMF, yet only minor effects on remyelination were noted and the fumarate compounds did not
protect against cell death (Moharregh-Khiabani et al., 2010). Additionally, while this group did not
examine in vitro differentiation, they demonstrated that pre-application of either DMF or MMF failed to
rescue an oligodendrocyte-like cell line from oxidative stress-induced toxicity following hydrogen peroxide
treatment (Moharregh-Khiabani et al., 2010).
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One possible explanation for the absence of EAR pathway activity in oligodendrocytes involves the
regulation of glutathione synthesis and recycling. All of the oxidants utilized within our study impact
cellular glutathione: tert-butyl hydroperoxide depletes levels of cellular glutathione, buthionine sulfoximine
selectively inhibits glutathione synthesis, and hydrogen peroxide generates highly reactive hydroxyl
radicals which interact with cellular proteins, lipids, and reducing agents such as glutathione (Meister,
1992, Sies, 1993, Back et al., 1998, Zhao et al., 2005, French et al., 2009). MMF was unable to rescue
maturation deficits induced following exposure to any of these oxidants. Glutathione s-transferase (GST) is
the enzyme responsible for glutathione conjugation to electrophilic compounds. The isoform of GST
expressed in oligodendrocytes is GST-pi, which within the brain is unique to this cell lineage and has been
used as a marker for mature oligodendrocytes in vivo (Cammer et al., 1989, Cammer and Zhang, 1992,
Girolamo et al., 2011, Li et al., 2013). Immunofluorescent studies have demonstrated that GST-pi is nuclear
in OPCs and attains a cytoplasmic distribution during differentiation, which may account for some of the
oxidative stress sensitivity of oligodendrocytes during early lineage stages (Tamura et al., 2007). It may be
that in oligodendrocytes, the glutathione system for monitoring redox homeostasis operates differently than
other CNS cell populations, such that if glutathione levels are depleted the EAR is not effectively activated,
particularly in OPCs and maturing cells when components of this system are confined to the nucleus.

Interestingly, both DMF and MMF have been reported to lower cellular glutathione levels in astrocytes and
could potentially do the same in oligodendrocytes (Schmidt and Dringen, 2010). However in contrast to
this idea, DMF has been recently reported to increase glutathione levels in a human oligodendrocyte cell
line (Huang et al., 2015). Future investigation is certainly needed to resolve these conflicting theories, and
will hopefully determine mechanistically how fumarate compounds affect glutathione regulation in primary
oligodendrocytes. In addition to the fumarates, it will be important to determine if EAR upregulation occurs
in oligodendrocytes using alternative oxidants and antioxidants which impact cellular redox sensors other
than glutathione, or if this canonical pathway is truly not utilized in this cell lineage.

Another possibility is that rather than the Nrf2 pathway playing the primary role in regulating redox
homeostasis in oligodendrocytes, the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-
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κB) pathway may take the forefront in this cell population. These two pathways are extensively
interconnected and normally antagonize each other (Li et al., 2008). It would not be surprising if a cell
lineage which lacks activity in one pathway to have overly robust activity in the other in response to
pathway initiation. This could be potentially harmful to oligodendrocytes, as NF-κB pathway activation
leads to a pro-inflammatory state (Tobon-Velasco et al., 2014). Recent evidence from the Massa laboratory
may help to support this theory. This group previously found that null mutation of Src homology 2 domaincontaining protein tyrosine phosphatase 1 (SHP-1) in mice resulted in reduced myelin gene expression and
hypomyelination in the CNS (Massa et al., 2004). SHP-1 modulates ROS production by negatively
regulating the NADPH oxidase complex (Krotz et al., 2005), which is inducible and toxic to
oligodendrocytes (Johnstone et al., 2013). In their present study, SHP-1 deficient mice display a permanent
shift away from redox homeostasis, with Nrf2 nuclear localization and upregulated HO-1 expression, but
this is accompanied by irreversible protein damage both in vitro and in vivo, suggesting that the observed
EAR pathway responses are insufficient to resolve the enhanced intracellular levels of ROS (Gruber et al.,
2015). Importantly, SHP-1 normally negatively regulates the activity of NF-κB (Mandal et al., 2010,
Mariappan et al., 2010). This report also demonstrated that silencing of SHP-1 led to enhancement of
downstream NF-κB pathway targets (Gruber et al., 2015). Investigating activity of this crucial protein
which has the potential to impact both oxidative and inflammatory cellular states in oligodendrocytes could
be very informative in regards to MS, where both of these stresses are key drivers of pathology. With these
results in mind, future studies aimed at downregulating NF-κB pathway activity may be a more effective
therapeutic approach than attempting to upregulate EAR activity.

Overall, our results suggest that the source of selective vulnerability of oligodendrocytes to oxidative stress
is two-fold. This cell lineage begins with endogenously low levels of antioxidant and detoxifying enzymes
(Halliwell, 1992, Back et al., 1998, Fern and Moller, 2000, Baud et al., 2004), and this deficit in oxidant
buffering capacity may be exacerbated by an inability to appropriately activate the supposedly ubiquitous
EAR pathway under conditions of redox imbalance. Our results indicate that in vivo, oligodendrocytes
likely rely on neighboring cells for protection from oxidative stresses, in much the same way that neuronal
protection occurs via astrocyte involvement (Fernandez-Fernandez et al., 2012). In light of our findings, it
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is not likely that Tecfidera reduces MS relapse rates through a direct effect on oligodendrocytes. Rather, it
is more probable that secondary effects from EAR upregulation in neurons, macrophages, and possibly
astrocytes play a role in conferring protection to the oligodendrocytes (Chapter 3 and (Cross et al., 2011,
Scannevin et al., 2012)). While not examined in our present study, in addition to reducing overall levels of
oxidative stress, Tecfidera may also be influencing levels of CNS inflammation through modulation of
secreted cytokines and inhibition of the NF-κB pathway (Lehmann et al., 2007, Albrecht et al., 2012,
Gillard et al., 2015). Functional recovery of patients with demyelination, as seen in MS and HAND, will be
reliant on resilient reduction of oxidative stress. Our study has provided the foundational evidence that in
order for this to succeed, the concerted efforts of multiple CNS cell populations will be required to provide
an oxidative stress free environment, so that the susceptible oligodendrocyte population can effectively
survive, mature, and re-myelinate affected areas.

6.5 ANTIRETROVIRAL STUDIES GOING FORWARD
The in vitro and in vivo models used throughout our studies have enabled great advances in the
understanding of antiretroviral effects on CNS cell populations. Continuing forward in this line of
investigation, it will be advantageous to consider: additional exploration of NRTI-based effects and initial
investigation of the nNRTI and integrase inhibitor drug classees, responses to ART drugs on the whole-cell
level, and advanced tools for evaluating CNS effects of ART compounds.

6.5a Further Investigation of Antiretroviral Drug Classes
In our detailed studies of the impacts of antiretroviral drugs in invoking neuronal toxicity and deficits in
oligodendrocyte maturation, the candidate compound tested from the NRTI class, AZT, produced ROS
accumulation but did not negatively impact the cellular functions that we assessed. NRTIs have been
unequivocally implicated in peripheral neuropathy through mechanisms of mitochondrial dysfunction and
oxidative stress, which made our negative findings rather unexpected (Dalakas, 2001, Ellis, 2008). NRTIs
are formulated as pro-drugs, and must be tri-phosphorylated by thymidine kinases in vivo in order to
effectively halt HIV replication. Expression of these enzymes is cell cycle-dependent, and while
oligodendrocytes and OPCs possess the particular kinase required for NRTI phosphorylation, post-mitotic
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neurons most likely do not (Nygard et al., 2003, Bazzoli et al., 2010). Therefore, it is highly likely that in
our model used to study neurons, AZT is not converted to its active form. We did not test whether OPCs
effectively phosphorylated AZT. Given our results, synthesized versions of tri-phosphorylated AZT and
other NRTIs should be obtained and tested to see if our current results truly are representative of the drug
class, or if antiretroviral-induced repercussions in neurons and oligodendrocytes would be different in the
context of NRTIs which had been effectively activated by other CNS cell populations.

Additionally, while we have evaluated cellular effects following application of representative candidate
compounds from the NRTI and PI classes, we have not yet explored potential consequences of drugs from
the nNRTI or Integrase Inhibitor families. Similar to the NRTI compounds, the efficacy of nNRTIs is based
on prevention of viral reverse transcription from RNA to DNA (Pau and George, 2014). However, unlike
the nucleoside/nucleotide analogs which compete as substrates for the reverse transcriptase enzyme, the
nNRTI compounds directly bind to the catalytic domain of the enzyme to prevent its activity (de Bethune,
2010, Pau and George, 2014). As the nNRTIs do not compete for endogenous cellular DNA or
mitochondrial DNA synthesis, mitochondrial dysfunction may not be observed with this class. However,
despite this differing mechanism of action, Efavirenz has been linked to the production of superoxide,
glutathione depletion, and disruption of mitochondrial membrane potential and function in a human cell
line (Apostolova et al., 2010). Furthermore, due to negative neurocognitive performance associated with
use of Efavirenz, it has been removed from treatment recommendations (Decloedt and Maartens, 2013).
Testing of Nevirapine and Rilpivirine in neuroglial cell populations is therefore imperative, as it remains to
be seen if the other commonly prescribed nNRTIs have similar effects to Efavirenz.

Another novel category of antiretroviral compounds, the integrase strand transfer inhibitors (INSTIs), has
come to the forefront in treatment regimens following the introduction of Raltegravir in 2007 and
subsequent approval of Dolutegravir and Elvitegravir (Pau and George, 2014, AIDSInfo, 2015). This drug
class halts the HIV integrase enzyme from forming covalent bonds between host-cell and viral DNA, which
prevents effective incorporation of the viral DNA into the host chromosome. Thus far, these drugs have
been associated with less peripheral toxicities than other classes, which could translate to less neuroglial
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toxicity. However preliminary evidence from our laboratory suggests that a dose-dependent reduction in
oligodendrocyte maturation may occur with Raltegravir, a finding that should be verified and expanded
upon.

Antiretroviral regimens are constantly evolving, with new compounds and drug classes being introduced
while others are eliminated. It is vital to screen these compounds in efficient ways to determine whether
CNS toxicities occur, particularly with a continued focus on higher brain penetrance to eliminate viral
reservoirs. Our current studies have demonstrated pronounced neuroglial effects following exposure to
various antiretroviral compounds, with PIs having marked deleterious effects on neurons and
oligodendrocytes. Future studies using the active form of NRTIs as well as initial examination of the
nNRTIs and INSTIs, are necessary to more thoroughly understand the full range of effects of ART in
patients who are exposed to regimens with a mix of these various classes.

6.5b Cellular responses to Antiretroviral Compounds
Through the combined efforts of many laboratories, oxidative stress, unfolded protein response activation,
proteasome inhibition, lipid dysregulation, and release of cytokines have been well documented following
exposure to antiretrovirals. These pathways have been implicated in various cell populations through
clinical observations in patients, animal and cell culture models, and have been validated through a
candidate pathway testing approach. The direct assessment of protein and mRNA changes in brain-resident
cell populations in response to antiretroviral compounds of different classes is still crucially needed.
Through DNA-microarray and RNA-Seq methods, specific pathways altered following antiretroviral
exposure can be identified. This will greatly assist in informing which regimens would have the least
negative impact on CNS-cells, and would allow for better targeting of deleterious side-effects through
specific adjunctive therapies.

6.5c Advanced Tools for Evaluating CNS Effects of Antiretroviral Compounds
Primary isolated cortical cell populations have been our principal system for analyzing the effects of
antiretroviral compounds. While we have gained much knowledge through evaluating effects on specific
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cell lineages in isolation, the full extent of functional implications to cellular changes cannot be
extrapolated by this method. An ex vivo method has been developed, where organotypic slice cultures can
be isolated from brain regions of young rodents and maintained for several weeks (Gahwiler et al., 1997,
Opitz-Araya and Barria, 2011). Performing ART studies on these cultures will allow for extension of
current studies to include evaluation of synaptic transmission, as well as functional assessment of the
formation and maintenance of myelin segments. Using this physiological model will enable normal cellular
interplay between CNS-resident cell populations, and allow for high throughput screening of ART
compounds for potential neuroglial effects, as well as potential adjunctive compounds prior to testing in a
full-scale animal model.

Our striking findings regarding the effects of PIs on oligodendrocyte maturation and myelin maintenance
have prompted consideration for additional rodent models in which to study the effects of ART compounds
in the absence of viral infection. The first of these would investigate the effects of ART on the process of
remyelination in the adult animal. Our laboratory has experience performing the cuprizone model, which
induces a specific demyelinated lesion in the corpus callosum that remyelinates in the weeks following
cessation of cuprizone ingestion (Torkildsen et al., 2008). In a procedural advancement since our jugular
vein administration model, animals could be outfitted with osmotic pumps to continually deliver specific
ART drugs at a constant dosing during the remyelination period. Evaluation of remyelination will
determine if PIs also prevent oligodendrocyte differentiation in vivo. This is an important question to
resolve, as it would validate our conclusion that PIs produce loss of myelin integrity as well as prevent
effective remyelination of the damaged areas in the adult. Furthermore, this procedure could also be
merged with candidate adjunctive therapy studies to determine if ART-effects can be attenuated. At
present, even less is known about viral and ART effects in children than in adults, with neurocognitive
outcomes being unpredictable as they are the first generation to survive infection long-term. With our
striking evidence for PI-based oligodendrocyte differentiation deficits, we would like to establish a model
of pediatric ART administration in young mice. While current technology may limit when osmotic pumps
may be installed, it is of critical importance to understand the effects of ART compounds on the developing
brain. Treatment of pediatric animals with ART drugs of various classes followed by cognitive and
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behavioral testing as well as pathological analysis will further aid in guiding treatment regimens and
understanding ART-mediated effects in HIV-infected children.

One of the most challenging aspects of HIV research is that animal models have been extremely limited
due to the lack of membrane surface receptors required for HIV cellular entry in rodents. However, the
well-developed model of SIV-infection in macaques as was described and utilized in Chapter 3 is a
remarkable tool for researchers, as the disease course and outcomes mirror that of human patients (Dinoso,
2009, Zink, 2010, Graham, 2011). While such studies are a large financial burden, well-designed
experimental plans can allow for maximum data collection and translational relevance. Future studies in
these animals with SIV-positive, SIV-positive/ART-treated, and SIV-negative/ART-treated groups will be
instrumental in determining the independent contributions of virus versus therapy to synaptic damage,
inflammation, and loss of myelin integrity. Additionally, studies in these animals can be performed over a
longer duration than the available rodent ART-administration models, and will more faithfully report the
longitudinal effects of viral and ART exposure in a primate. A final possibility to consider with this model
is the potential for development of pre-clinical screening of adjunctive therapies, as neurocognitive
function and post-mortem pathological assessment can determine efficacy in a more expedient manner than
human clinical trials.

6.6 CLINICAL IMPLICATIONS
The studies contained within this body of work have unequivocally demonstrated that antiretroviral
compounds, specifically those of the PI class, invoke neuronal toxicity through oxidative stress, halt
oligodendrocyte differentiation, produce synaptodendritic damage, and lead to loss of myelin integrity.
These findings necessitate crucial reconsiderations of recommended treatment regimens, as well as provide
impetus to develop effective adjunctive therapies to attenuate these effects.

In order to prolong anticipated lifespan and prevent viral effects, the World Health Organization urges that
all children under the age of 5 receive ART, regardless of their CD4 counts (WHO, 2013). Of paramount
concern is that the currently recommended first-line regimen for all children under 3 years of age is
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Lopinavir/ritonavir (WHO, 2013). Increasing documentation has revealed that treated pediatric patients are
developing neurocognitive deficits and developmental delays, as well as motor, cognitive, and behavioral
deficits reminiscent of the hallmarks of HAND seen in adults (Crowell et al., 2014, Whitehead et al., 2014,
Wilmshurst et al., 2014). With the currently suggested treatment guidelines, these young children are being
exposed to the specific ART-compounds that we have shown propagate neuronal toxicity and prevent
oligodendrocyte differentiation during the peak period of neuronal development and cortical myelination in
humans (Miller et al., 2012). As these children will already have the lifelong burden of effects stemming
from infection and therapy, we hope our findings will be noted by clinicians responsible for amending ART
guidelines and alter the drug class of first-line pediatric therapy away from the PI-based regimens.

Additionally, our studies have illuminated synaptodendritic damage and disruption of myelin integrity with
PI compounds in rodent models, as well as with combination regimens given to SIV-infected macaques and
HIV-infected human patients. These findings highlight that while effective at reducing viral replication,
ART compounds can directly negatively affect the health and function of CNS cell populations. The
persistence of viral reservoirs necessitates continued ART adherence, despite deleterious side-effects
(Chun, 1997, Finzi, 1997, Wong, 1997, Persidsky, 2006). It is therefore of upmost importance to develop
adjunctive therapies to ameliorate the damage caused by ART, viral enclaves, and lingering inflammation.

We have demonstrated that MMF provides effective neuronal protection against ART-induced toxicity
through Nrf2-mediated induction of the EAR. Importantly, in a study by one of our collaborators, the
Kolson laboratory has shown that both MMF and DMF suppress HIV replication in macrophages, in
addition to activating the EAR, potently upregulating HO-1 protein, and preventing neurotoxin release
(Cross et al., 2011). The specific upregulation of HO-1 responsible for the protective effects of MMF in
both our neuronal and their macrophage models may be a key element in attenuating the damage induced
by chronic oxidative stress found in HAND patients. Preliminary evidence from our laboratory showed
elevated cytoplasmic levels of Nrf2 in HIV-infected ART-treated patients with HAND compared with
those patients who remained neurocognitively normal. This increase in cytoplasmic Nrf2 could indicate a
failure of pathway activation, as nuclear localization indicates a proper stress-mediated response. To bolster
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this finding, HO-1 deficiency has been recently reported in HAND patients (Gill et al., 2014). Additionally,
it will be crucial to determine if MMF is capable of reducing oxidative stress in the brain as a whole, in the
context of viral infection and ART medication. Unfortunately, based on our findings in oligodendrocytes,
unless chronic oxidative stress is eliminated from the CNS compartment, neuronal pathology caused by
myelin disruption would remain. In this setting, neurons may initially be protected by direct antioxidant
effects of MMF, but unless oxidative stress levels are lowered to beyond the point of preventing
oligodendrocyte damage and promoting remyelination, axonal and synaptodendritic damage would
continue to persist. Together, these data also suggest that the drug Tecfidera which is currently approved
for MS treatment may also be a promising adjunctive therapy for use in HAND and should be tested in
animal models to determine if it would be efficacious in vivo. Going forward, the effects of antiretroviral
compounds on neurons and oligodendrocytes have highlighted the need for future adjunctive therapies
designed not only to alleviate neuronal damage, but also to preserve myelin integrity and remyelination
capacity of oligodendrocytes in order to attenuate and potentially reverse the neuropathologic and
neurocognitive deficits still observed in HIV-positive individuals in the ART-era.

6.7 SUMMARY AND CLOSING REMARKS
Taken together, the cumulative results from our studies indicate that specific antiretroviral compounds
invoke drastic negative cellular consequences in multiple CNS cell populations, independent of virus
infection. We demonstrated in rodent models of drug administration that synaptodendritic damage and
myelin proteins are rapidly altered following repeated exposure in the absence of virus. Extending this
finding to a non-human primate model, synaptodendritic damage was also observed in SIV-infected ARTtreated macaques. Furthermore, myelin proteins were significantly altered in human patients diagnosed
with HAND who had received ART compared to those with HAND but who were ART-naïve, and control
subjects without infection. No direct effect on myelin levels were noted when infected versus uninfected
subjects were compared, suggesting a potential correlation to alterations of myelin proteins as a
consequence of solely the antiretroviral drug exposure.
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Through neuronal cultures in vitro, we established that antiretrovirals led to ROS accumulation,
mitochondrial depolarization, and ultimately apoptotic cell death. Moderate activation of the EAR was
noted by antiretrovirals alone, and when this response was boosted by supplementation with the fumaric
acid ester MMF, neuronal toxicity was prevented. In addition to investigating cellular stress response
signaling pathways and survival in response to antiretroviral exposure, studies in oligodendrocytes also
extended our findings to the consequences of these compounds on cellular maturation. Antiretrovirals of
the PI but not the NRTI class lead to dose-dependent, reversible reductions in oligodendrocyte
differentiation that are independent of oxidative stress-mediated effects. Neither the UPR or EAR are
activated in the maturing cells following antiretroviral application, in contrast to previous findings in
neurons and peripheral cell types. According to cytoskeletal markers and rapid reversal of effects, we have
concluded that oligodendrocytes are normally primed for maturation and enter into differentiation, but
myelin proteins cannot effectively be trafficked and/or inserted into the forming myelin membrane in the
presence of the antiretrovirals.

Quite surprisingly, oligodendrocytes do not activate the EAR under conditions of oxidative stress induced
by antiretroviral drugs, oxidants, or following stimulation with MMF. This may underlie the particular
susceptibility of oligodendrocytes to oxidative stress-mediated toxicity and could help to explain the
mechanism of action for therapeutics designed to alleviate oxidative stress in Multiple Sclerosis. The
cellular milieu of the brain is an intricately interconnected system, where cell populations are critically
dependent on one-another. Our results indicate that like neurons, which rely on neighboring cells such as
astrocytes and macrophages for protection from oxidative stresses, oligodendrocytes likely behave in much
the same way. It is also important to consider that while MMF is successful at rescuing ART-induced
neuronal toxicity, it did not rescue the oligodendrocyte differentiation deficit. Even though the EAR was
not upregulated, MMF did attenuate ROS in oligodendrocytes, suggesting that PI-based inhibition of
maturation is through an independent mechanism. Future investigations will hopefully isolate the
mechanism leading to this dysfunction, in order to effectively prevent the halt in differentiation.
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We have discovered that PIs in particular have profound effects in perturbing oligodendrocyte maturation
and invoking neuronal toxicity. We sincerely hope that our findings are used to inform decisions on the
suggested pediatric ART-regimens, substituting Lopinavir/ritonavir with less toxic agents as frontline
treatment during the critical period of development and myelination in children.

Much work is still needed to facilitate a better understanding of the effects of antiretroviral compounds in
CNS cell populations. Once cellular consequences to antiretroviral drug exposure are more thoroughly
defined, appropriately targeted adjunctive therapies will be more likely to succeed in attenuating
neurological complications and reducing the severity and prevalence of HAND in HIV-infected
individuals.
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Figure 6.1: Model of Antiretroviral Effects on Myelin in Humans
A) Schematic of pediatric myelination and the negative consequences of HIV-infection & treatment
B) Schematic of adult myelin maintenance and the negative consequences of HIV-infection & treatment

Highlighted in red are hypothesized concepts supported through data within the Chapter 4 manuscript.
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A1.1 EXPERIMENTAL RATIONALE
In light of our findings regarding direct neuronal toxicity and altered oligodendrocyte function following
antiretroviral drug exposure, we also wished to extend our findings to the possible indirect effects that
secreted factors from astrocytes may have in each of these scenarios. To do this, enriched astrocytes and
neurons were grown in vitro as described in Chapters 3, with oligodendrocytes generated from Sprague
Dawley rat pups instead of mice following the same protocol as in Chapter 4 to maintain the same species
throughout all experiments. Primary astrocyte cultures were then treated with a panel of antiretroviral
compounds in a timecourse of 6, 12, and 24 hours (n=3 independent biological replicates). At each
endpoint, supernatants were collected to determine potential effects on neurons and oligodendrocytes. The
following antiretrovirals were tested: NRTIs AZT (25 µM), d4T (25 µM), ddC (25 µM); and Protease
Inhibitors Ritonavir (10 µM), Saquinavir (1.0 µM), and Indinavir (25 µM). Thapsigargin at 1.0 µM served
as a positive control, as release of ER-calcium stores should invoke the release of factors from astrocytes
which may harm neurons.

To begin, these supernatants were applied to 14DIV enriched neuronal cultures for 48 hours at a 1:20
dilution. Following this period a MAP2 ELISA assay was performed to assess neuronal damage/death as
described in Chapter 3. As can be seen in Figure A1.1, none of the supernatants from antiretroviral treated
astrocytes at any point during the timecourse produced an effect on neuronal viability (n=3 biological
replicates of neurons, each treated with the triplicate astrocytes derived samples). The only treatment which
caused a significant decrease in MAP2 fluorescence was the sample group from 6 hour Thapsigargin
treated-astrocytes (p <0.001), however this effect is resolved if samples are not taken until 12 or 24 hours
suggesting that at later timepoints the astrocytes have successfully dealt with the ER-stress.

To assess potential contributions to oligodendrocyte maturation and survival, astrocyte derived
supernatants were also applied at the start of differentiation at a 1:20 dilution. After 72 hours in
differentiation medium, maturation was assessed by immunofluorescence as in Chapter 4. Similar to the
findings on neurons, no effects on oligodendrocyte differentiation or cell number were observed following
exposure to supernatants from antiretroviral treated astrocytes at any point during the timecourse (n=3
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biological replicates of oligodendrocytes, each treated with the triplicate astrocytes derived samples).
Thapsigargin again produced a significant effect, with a reduction in cells progressing to express either
immature (GalC) or mature (MBP) markers. This effect is found in oligodendrocytes treated with
supernatants collected from all antiretroviral exposure times for the astrocytes. There is also a trend
towards a significant decrease in total cell number, suggesting a potential toxic effect in addition to a halt in
differentiation (Figure A1.2).

A1.2 MATERIALS AND METHODS
Chemicals and reagents. AIDS Research and Reference Reagent Program, Division of AIDS, NIAID,
NIH: antiretroviral reagents. Covance (Princeton, NJ): mouse monoclonal microtubule-associated protein 2
(MAP2) antibody (SMI-52). Life Technologies (Carlsbad, CA): B27 supplement, Dulbecco’s Modified
Eagle’s Medium (DMEM), goat anti-mouse beta-lactamase TEM-1 conjugate, fluorocillin green substrate,
L-glutamine,

Ham’s

F12,

Hank’s

Balanced

Salt

Solution

(HBSS),

Neurobasal

media,

Penicillin/Streptomycin. Jackson Immunoresearch Laboratories (West Grove, PA): FITC-conjugated goat
anti-mouse IgG3, Rhodamine-conjugated goat anti-rat IgG. Peprotech (Rocky Hill, NJ): neurotrophin-3
(NT-3). Peptide International (Louisville, KY): poly-L-lysine, poly-D-lysine. R&D Systems (Minneapolis,
MN): basic fibroblast growth factor (bFGF), platelet-derived growth factor -AA (PDGF-AA). Sigma
Aldrich (St. Louis, MO): cytosine arabinoside (Ara-C), fetal bovine serum (FBS), progesterone, putrescine,
thyroxine (T4), transferrin. Tocris Bioscience (Ellisville, MO): thapsigargin. Vector Laboratories
(Burlingame, CA): Vectashield with DAPI.

Additional antibodies: anti-galactocerebroside mouse hybridoma supernatant (GalC H8H9), anti-myelin
basic protein rat hybridoma supernatant (MBP, gift of Virginia Lee, University of Pennsylvania).

Primary Cortical Neuroglial Cultures. All experiments were performed in accordance with guidelines set
forth by The University of Pennsylvania Institutional Animal Care and Use Committees (IACUC). Primary
rat cortical neuroglial cultures were isolated from embryonic day 17 Sprague Dawley rat pups, as
previously described (Chapter 3). Cortical cell suspensions isolated from pups were plated on poly-L-lysine
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coated T25 tissue culture flasks (2 x 106 cells/flask) or 96-well tissue culture plates (0.5 x 105 cells/well).
To attain pure astrocytic cultures, the cortical cell suspensions were initially plated in 10% fetal bovine
serum (FBS) in DMEM and maintained at 37°C with 5% CO2 for 7-12 days. At this stage the cultures are
confluent and astrocytes constitutes approximately 90% of cells. Cells were harvested from these cultures
and re-plated onto poly-L-lysine coated 60mm dishes, with experiments conducted once cells had achieved
75% confluency. Neuronal cultures were maintained in Neurobasal media with B27 supplement at 37°C
with 5% CO2, with 10µM Ara-C added 24 hours after plating to establish pure neuronal cultures. Half of the
media was replaced with fresh media every 7 days, with experiments conducted at 14 DIV.

Primary Cortical Oligodendrocyte Cultures
All experiments were performed in accordance with the guidelines set forth by The Children's Hospital of
Philadelphia and The University of Pennsylvania Institutional Animal Care and Use Committees (IACUC).
Primary rat oligodendrocyte precursor cell (OPC) cultures were isolated from postnatal day 4 Sprague
Dawley rat pups obtained from Charles River Laboratories, as previously described in Chapter 4 for mouse
oligodendrocyte isolation. Cortical cell suspensions isolated from rat pups using standard protocols were
plated on poly-D-lysine coated 10-cm dishes in Neurobasal medium with B27 supplement at 37°C with 5%
CO2. Cultures were switched to growth medium consisting of Neurobasal medium with B27, which
contained 10 ng/ml bFGF, 2 ng/ml PDGF-AA, and 1 ng/ml NT-3 24 hours after initial plating. Following a
week of growth, confluent cells were purified to 90-95% OPCs and 5-15% astrocytes using a gentle washdown procedure (Feigenson et al., 2009), and sub-cultured onto poly-lysine-coated coverslips. For
differentiation, growth medium was replaced with differentiation medium, consisting of 50% DMEM, 50%
Ham’s F12, Pen/Strep and 2 mM glutamine with 50 µg/ml transferrin, 5 µg/ml putrescine, 3 ng/ml
progesterone, 2.6 ng/ml selenium, 12.5 µg/ml insulin, 0.4 µg/ml T4, 0.3% glucose, and 10 ng/ml biotin.

MAP2 Cell-Based ELISA
To quantify neuronal damage/death, a MAP2 cell-based ELISA was performed as previously described
(Chapter 3). At the end of treatments, neuronal cultures in 96-well plates were fixed with 4%
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paraformaldehyde and 4% sucrose for 30 minutes. Following blocking for 1 hour in PBS+5% normal goat
serum, plates were incubated with MAP2 antibody overnight at 4°C. Plates were washed with PBS+0.1%
Tween-20 (PBS-T), then incubated with goat anti-mouse secondary antibody conjugated to beta-lactamase
TEM-1 for 30 minutes. Following subsequent PBS-T washes, the plate was incubated with fluorocillin
green substrate for 1 hour in the dark. Fluorescence intensity was measured using a Fluoroskan Ascent
plate reader (Thermo Electron, Waltham, MA) with excitation at 485 nm and emission at 527 nm.

Immunofluorescence
Oligodendrocytes were processed for detection of specific antigens as described in Chapter 4. Live cells
were labeled for cell surface marker detection anti-GalC (mouse hybridoma supernatant, undiluted). For
detection of internal antigens following acid alcohol fixation and permeabilization, anti-MBP (rat
hybridoma supernatant, 1:2 dilution) was used. Secondary antibodies (1:100 dilution) were Rhodamine or
Fluorescein conjugated. Vectashield with DAPI was used to mount coverslips and to stain all nuclei.
Antigen-positive and DAPI-positive cells were counted in 10 fields in each of 3 coverslips using a Leica
DM6000B fluorescence microscope at 40x magnification. A total of approximately 2000 cells were
counted per condition.
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Figure A1.1 Indirect Neuronal Toxicity Does Not Occur Following Incubation with Conditioned
Medium from Antiretroviral-Treated Astrocytes
Primary rat enriched neuronal cultures aged 14 days in vitro (DIV) on coverslips were exposed for 48 hours
to a 1:20 dilution of supernatants derived from astrocytes which had been treated for 6 hours (A), 12 hours
(B), or 24 hours (C) with Vehicle, AZT, Ritonavir, Saquinavir, Indinavir, ddC, d4T, or Thapsigargin. A
MAP2 cell-based ELISA was performed to assess neuronal damage/death (n=3, vehicle: 0.02% DMSO,
###p<0.001, One-Way ANOVA with post-hoc Newman-Keuls determined statistical significance).
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Figure A1.2 Conditioned Medium from Antiretroviral-Treated Astrocytes Does Not Alter
Oligodendrocyte Differentiation
Primary rat oligodendrocyte cultures were exposed to a 1:20 dilution of supernatants derived from
astrocytes which had been treated for 6 hours (A), 12 hours (B), or 24 hours (C) with Vehicle, AZT,
Ritonavir, Saquinavir, Indinavir, ddC, d4T, or Thapsigargin during the 72 hour course of differentiation.
Cells were fixed and stained with antibody to GalC, and MBP, with DAPI for total cell nuclei.
Epifluorescent images were captured, with 10 fields on three coverslips per condition. Immature
oligodendrocytes (GalC+ cells, left-hand column), mature oligodendrocytes (MBP+ cells, middle column),
and total cell number (right-hand column) were counted using ImageJ software, represented as percentage
normalized to untreated. Data are presented as mean ±SEM. (n=3, vehicle: 0.02% DMSO, ###p<0.001,
##p<0.01, One-Way ANOVA with post-hoc Newman-Keuls determined statistical significance).
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